{
  "questions": [
    {
      "body": "Does smoking increase risk for glioblastoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21742680", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20487573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19494549", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19107440", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19022673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17372252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15685439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2319291"
      ], 
      "type": "yesno", 
      "id": "550e7d6aa103b7801600000e", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Glioma risk has consistently been inversely associated with allergy history but not with smoking history despite putative biologic plausibility.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1159, 
          "offsetInEndSection": 1380, 
          "text": "No relation was observed between glioma risk and smoking (odds ratio = 0.92, 95% confidence interval: 0.77, 1.10; P = 0.37), and there were no interactions for glioma risk of smoking history with any of the risk alleles. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21742680", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1654, 
          "offsetInEndSection": 1926, 
          "text": "Non-smokers with G/A and A/A genotype showed increased glioma risk compared with G/G genotype (adjusted OR = 1.72, 95%CI: 1.29-2.30, p = 0.0002 and adjusted OR = 1.81, 95%CI: 1.10-2.99, p = 0.020, respectively). This association was not found in ever- or current-smokers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20487573", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1256, 
          "offsetInEndSection": 1363, 
          "text": "There was no significant association between glioma and alcohol consumption, smoking and mobile phone use. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19494549", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1145, 
          "offsetInEndSection": 1565, 
          "text": "RESULTS: We found no associations between the GSTM3, GSTP1, NQO1, CYP1A1, GSTM1, or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C (Val-Ala) GSTP1 105/114 haplotype and glioma [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54, 0.99], nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17372252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 825, 
          "offsetInEndSection": 1029, 
          "text": "We did not find any evidence for an association with life-style characteristics such as cigarette smoking, alcohol consumption, use of drugs of any kind, or dietary intake of cured or smoked meat or fish.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2319291", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does helicobacter pylori infection increase risk for ischemic stroke?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22713083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22688569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21775946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21669114", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21060340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19355997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18988408", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18706211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18665936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18346651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18249521", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17669100", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16466297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16386288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16230797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16004850", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15694938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15166387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14500942", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12725602", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12388919", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12147540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12063957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11588309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11412864", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11253332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11157171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11155465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9805426", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9436737"
      ], 
      "type": "summary", 
      "id": "551c2cd26b348bb82c00000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 393, 
          "text": "Helicobacter pylori (H. pylori) infection is reported to be associated with many extragastrointestinal manifestations, such as hematological diseases [idiopathic thrombocytopenic purpura (ITP) and unexplained iron deficiency anemia (IDA)], cardiovascular diseases (ischemic heart diseases), neurological disorders (stroke, Parkinson's disease, Alzheimer's disease), obesity and skin disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22713083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22688569", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1701, 
          "offsetInEndSection": 1859, 
          "text": "This meta-analysis indicated that chronic H. pylori infection was significantly associated with an increased risk of IS, especially for non-cardioembolic IS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22688569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "In the last years, a considerable number of studies have been performed on the relationship between infection from Helicobacter Pylori and atherosclerotic diseases, like stroke and ischemic heart disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21775946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 112, 
          "offsetInEndSection": 249, 
          "text": "However, there are conflicting results on the relevance of chronic infection by Helicobacter pylori as a risk factor for ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21669114", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2123, 
          "offsetInEndSection": 2266, 
          "text": "CONCLUSIONS: This case-control study does not reveal any strong association between chronic Helicobacter pylori infection and ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21669114", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 738, 
          "offsetInEndSection": 1106, 
          "text": "Case-control and prospective studies indicate that chronic infections, such as periodontitis, chronic bronchitis and infection with Helicobacter pylori, Chlamydia pneumoniae or Cytomegalovirus, might increase stroke risk, although considerable variation exists in the results of these studies, and methodological issues regarding serological results remain unresolved.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060340", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1040, 
          "offsetInEndSection": 1208, 
          "text": "Chronic infections, presently discussed as stroke risk factors mainly include periodontitis and infections with Helicobacter pylori (Hp) and Chlamydia pneumoniae (Cp). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19355997", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 805, 
          "offsetInEndSection": 901, 
          "text": "CONCLUSION: H. Pylori gastritis is not independently associated with increased risk for stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18988408", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1309, 
          "offsetInEndSection": 1495, 
          "text": "CONCLUSIONS: Our results support the hypothesis that CagA-seropositive strains infection is significantly associated with susceptibility to ischemic strokes and coronary heart diseases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706211", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "BACKGROUND: Previous studies suggested an association between CagA-positive H. pylori strains and ischemic stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18665936", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1070, 
          "offsetInEndSection": 1199, 
          "text": "CONCLUSIONS: Our findings suggest that CagA-positive strains of H. pylori are significantly associated to atherosclerotic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18665936", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1304, 
          "offsetInEndSection": 1452, 
          "text": "We concluded that H pylori infection is common in DM and seems to be linked to the presence of atherosclerosis and ischemic cerebrovascular stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18346651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 651, 
          "offsetInEndSection": 897, 
          "text": "Interesting results show that H. pylori infection affects atherosclerosis and is weakly associated with ischemic heart disease and stroke. Moreover, CagA-positive H. pylori strains may play a role in the natural history of atherosclerotic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18249521", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 284, 
          "text": "Interestingly, the majority of the extradigestive-related literature is focused on two vascular manifestations: stroke and ischemic heart disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17669100", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 490, 
          "text": "Chronic infectious diseases that may increase the risk of stroke include periodontitis, chronic bronchitis and infections with microbial antigens, such as Helicobacter pylori and Chlamydia pneumoniae. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16466297", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1315, 
          "offsetInEndSection": 1446, 
          "text": "CONCLUSIONS: These results suggest that H. pylori infection is a risk factor for ischemic stroke and that CD14 polymorphism is not.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16386288", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1453, 
          "offsetInEndSection": 1653, 
          "text": " CONCLUSIONS: Our case-control study provides evidence of an association between the immune response to H. pylori , a marker of prior infection with this organism and noncardioembolic ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16230797", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 320, 
          "text": "Case-control studies and a few prospective studies have indicated that chronic infections may add to the risk of stroke and that acute infections may act as trigger factors for stroke. Such chronic infections include periodontal disease, infection with Chlamydia pneumoniae or Helicobacter pylori, and chronic bronchitis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16004850", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1267, 
          "offsetInEndSection": 1602, 
          "text": "Chronic H. pylori infection still showed an overall association with ischemic stroke (odds ratio for all subtypes combined: 2.57; 95% CI: 1.09-6.08) after adjusting for major cardiovascular risk factors. These results suggest that chronic H. pylori infection may be a triggering factor that increases the risk of acute ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15694938", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "BACKGROUND AND PURPOSE: Studies on Helicobacter pylori infection and risk of ischemic stroke yielded variable results. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15166387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1208, 
          "offsetInEndSection": 1357, 
          "text": "CONCLUSIONS: Our results support the hypothesis of an association between infection with CagA-positive H. pylori strains and acute cerebral ischemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15166387", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1315, 
          "text": " Chronic infections (eg, infection with Chlamydia pneumoniae or Helicobacter pylori) were found to increase the risk of stroke; however, study results are at variance, residual confounding is not excluded, and causality is not established at present. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500942", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1182, 
          "offsetInEndSection": 1395, 
          "text": "CONCLUSIONS: Infection with Helicobacter pylori is associated with an increased risk of stroke and increased fibrinogen levels but these findings can be attributed to a confounding effect of socio-economic status.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12725602", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1532, 
          "offsetInEndSection": 1698, 
          "text": " CONCLUSIONS: Hp infection represents risk factor of ischemic stoke via an interaction of Hp cytotoxins or cytokines with atherosclerotic plaques in carotic arteries.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388919", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1415, 
          "offsetInEndSection": 1608, 
          "text": "CONCLUSIONS: The association between H pylori and acute cerebrovascular disease seems to be due to a higher prevalence of more virulent H pylori strains in patients with atherosclerotic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12147540", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1748, 
          "offsetInEndSection": 1891, 
          "text": "CONCLUSIONS: H. pylori infection appears to be significantly more frequent in middle-aged patients with acute ischemic stroke than in controls.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12063957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 995, 
          "offsetInEndSection": 1353, 
          "text": "Chronic H pylori infection was associated with a higher risk of stroke caused by small-artery occlusion (adjusted odds ratio, 3.31; 95% CI, 1.15 to 9.56) and a lower risk of cardioembolic stroke (adjusted odds ratio, 0.21; 95% CI, 0.06 to 0.71). Overall, elevated H pylori as well as elevated C pneumoniae antibodies were not associated with ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11588309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 188, 
          "text": "Presently, it is insufficiently established whether Helicobacter pylori infection represents a risk factor for ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11412864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1003, 
          "offsetInEndSection": 1101, 
          "text": " H. pylori seropositivity may be an independent risk factor for stroke of atherothrombotic origin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11412864", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1199, 
          "offsetInEndSection": 1452, 
          "text": "Appropriately randomized studies employing an antibiotic treatment for patients affected by ischemic vascular disease will answer the question of whether H. pylori has a causal role in the pathogenesis of acute myocardial infarction and ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11253332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 424, 
          "offsetInEndSection": 579, 
          "text": "Results on the association between this bacterium and acute myocardial infarction or stroke are controversial, due to the degree of studies heterogeneity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11155465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 736, 
          "offsetInEndSection": 1010, 
          "text": "Interventional randomized studies employing an antibiotic treatment for patients affected by ischemic vascular diseases will rapidly answer the question of wheather Helicobacter pylori has a causal role in the pathogenesis of acute myocardial infarction and ischemic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11155465", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1415, 
          "offsetInEndSection": 1584, 
          "text": " CONCLUSION: Chronic H pylori infection is an independent risk factor for ischaemic cerebrovascular disease and may act, at least in part, by increasing atherosclerosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9436737", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which clotting factor is inhibited by betrixaban?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23964817", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23876036", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23683607", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23557519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23547865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23487517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23394539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23298923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23086101", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22742650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22680641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22655676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22564122", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22371104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21892216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21144965", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21047577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20520539"
      ], 
      "type": "factoid", 
      "id": "55200c606b348bb82c000013", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "Evaluation of the oral direct factor Xa inhibitor - betrixaban.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964817", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 552, 
          "text": "Betrixaban , an orally administered direct factor Xa inhibitor, is entering a Phase III trial and undergoing investigation for similar indications as apixaban, dabigatran and rivaroxaban. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964817", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 379, 
          "offsetInEndSection": 565, 
          "text": "Following the success of the direct thrombin and FXa inhibitors already in the market, new agents are being tested. These include AZD0837, betrixaban, letaxaban, darexaban, and LY517717.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23876036", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 686, 
          "offsetInEndSection": 842, 
          "text": "Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23557519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 486, 
          "offsetInEndSection": 628, 
          "text": "They must be modified and standardized for the measurement of direct FXa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban and others). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23547865", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 78, 
          "offsetInEndSection": 224, 
          "text": "Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23487517", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 160, 
          "offsetInEndSection": 735, 
          "text": " These newer agents directly target specific steps in coagulation cascade and include newer low molecular weight heparins (adomiparin), ultra low molecular weight heparins (semuloparin, RO-14), inhibitors of activated factor II (dabigatran, AZD0837), X (rivaroxaban, apixaban, edoxaban, betrixaban), IX (REG1,2), XI (antisense oligonucleotides, BMS 262084, clavatadine A), VII/tissue factor (tifacogin, PCI 274836, and BMS 593214), V (recomodulin, solulin), VIII (TB402), dual thrombin/factor X inhibitors (EP21709, tanogitran), and newer vitamin K antagonists (tecarfarin). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 711, 
          "offsetInEndSection": 842, 
          "text": "Apixaban, rivaroxaban, endoxaban, and betrixaban are specific direct inhibitors of factor Xa, while dabigatran inhibits factor IIa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086101", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 402, 
          "text": "The majority of the drugs in development belong to the class of direct factor Xa inhibitors (the -xabans). These include betrixaban, letaxaban, darexaban, eribaxaban, and LY517717.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22742650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 884, 
          "offsetInEndSection": 992, 
          "text": "Examples of direct factor Xa inhibitors include apixaban, rivaroxaban, otamixaban, betrixaban and edoxaban. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22680641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1260, 
          "offsetInEndSection": 1411, 
          "text": "EXPERT OPINION: A large body of Phase II and Phase III data is now available for FXa inhibitors such as rivaroxaban, apixaban, edoxaban and betrixaban.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22655676", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1228, 
          "offsetInEndSection": 1433, 
          "text": "Another factor Xa inhibitor, edoxaban, is under evaluation in an ongoing phase III clinical trial and others such as AZD0837, betrixaban and darexaban are still in safety and tolerability phase II studies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564122", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 502, 
          "offsetInEndSection": 658, 
          "text": "Apixaban, betrixaban, edoxaban, and rivaroxaban are small-molecule, selective inhibitors that directly and reversibly bind to the active site of factor Xa. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371104", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 684, 
          "text": "Novel oral anticoagulant drugs, the direct thrombin antagonist dabigatran and factor Xa inhibitors such as rivaroxaban, apixaban, edoxaban, and betrixaban are more predictable and convenient anticoagulants in comparison with warfarin, mainly because of the non-requirement of regular laboratory monitoring and dose adjustments.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892216", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 445, 
          "offsetInEndSection": 615, 
          "text": "Recently developed anticoagulants include direct thrombin antagonists such as dabigatran or factor Xa inhibitors such as rivaroxaban, apixaban, betrixaban, and edoxaban. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21144965", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 525, 
          "offsetInEndSection": 755, 
          "text": "Direct factor Xa inhibitors include rivaroxiban, which has shown promising results for VTE prophylaxis and is being studied for VTE treatment, as well as apixaban and betrixaban, which are at earlier stages of clinical validation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1086, 
          "offsetInEndSection": 1350, 
          "text": "Two direct factor Xa inhibitors are emerging from phase II trials (betrixaban and YM150) and three are being evaluated in phase III trials (apixaban, edoxaban, and rivaroxaban) for the prevention of stroke and systemic emboli in patients with atrial fibrillation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20520539", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which receptors can be evaluated with the [18F]altanserin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23456885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23390031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23137806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21996132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21750562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21473029", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21473027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21098981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20641567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19959344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19353726", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19162492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19007894", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18828013", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17541696", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17241616"
      ], 
      "type": "factoid", 
      "id": "55242d512c8b63434a000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 268, 
          "text": "PURPOSE: While the selective 5-hydroxytryptamine type 2a receptor (5-HT2AR) radiotracer [18F]altanserin is well established in humans, the present study evaluated its suitability for quantifying cerebral 5-HT2ARs with positron emission tomography (PET) in albino rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1021, 
          "offsetInEndSection": 1138, 
          "text": "CONCLUSION: [18F]Altanserin PET is a reliable tool for in vivo quantification of 5-HT2AR availability in albino rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "Imaging the cerebral serotonin 2A (5-HT2A ) receptors with positron emission tomography (PET) has been carried out in humans with [(11) C]MDL 100907 and [(18) F]altanserin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1185, 
          "offsetInEndSection": 1348, 
          "text": "The cortical binding of [(18) F]MH.MZ and [(18) F]altanserin was blocked by ketanserin supporting that both radioligands bind to 5-HT2A receptors in the pig brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 246, 
          "offsetInEndSection": 494, 
          "text": "We investigated 94 healthy individuals (60 men, mean age 47.0\u00b118.7, range 23-86) to determine if trait aggression and trait impulsivity were related to frontal cortex 5-HT2A receptor binding (5-HT2AR) as measured with [18F]-altanserin PET imaging. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23137806", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 634, 
          "offsetInEndSection": 802, 
          "text": "Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21996132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1679, 
          "offsetInEndSection": 1921, 
          "text": "These data suggest that the combination of a dexfenfluramine-induced 5-HT release and subsequent assessment of 5-HT(2A) receptor availability with [(18)F]altanserin PET is suitable to measure cortical 5-HT release capacity in the human brain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21996132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "The 5-hydroxytryptamine type 2a (5-HT(2A)) selective radiotracer [(18)F]altanserin has been subjected to a quantitative micro-positron emission tomography study in Lister Hooded rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 697, 
          "offsetInEndSection": 788, 
          "text": "[(18)F]altanserin is suitable for quantification of 5-HT(2A) receptor availability in rats.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2262, 
          "offsetInEndSection": 2662, 
          "text": "Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent antagonist of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (9, 10). This led to the development of 3-{2-[4-(4-[(18)F]fluorobenzoyl)-1-piperidyl]ethyl}-2-sulfanyl-3H-quinazolin-4-one ([(18)F]altanserin) as a useful tool for 5-HT2A receptor PET imaging in vivo (11). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473029", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2262, 
          "offsetInEndSection": 2936, 
          "text": "Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent antagonist of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (9, 10). This led to the development of 3-{2-[4-(4-[(18)F]fluorobenzoyl)-1-piperidyl]ethyl}-2-sulfanyl-3H-quinazolin-4-one ([(18)F]altanserin) as a useful tool for 5-HT2A receptor PET imaging in vivo (11). 5-HT2A antagonists bind to the total pool of receptors, whereas 5-HT2A agonists bind only to the high-affinity functional state of the receptor but may be more important in disease states because the high affinity sites are the ones that transmit the intracellular signals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 478, 
          "text": "Baseline and follow-up partial volume corrected levels of 5-HT2A in four neocortical lobes and the posterior cingulate gyrus were investigated using [18F]altanserin positron emission tomography with a bolus-infusion approach.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21098981", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2240, 
          "offsetInEndSection": 2637, 
          "text": "Altanserin, a fluorobenzoyl derivative related to ketanserin, was reported to be a potent inhibitor of 5-HT2A receptors with >100-fold selectivity over D2/3 receptors, 5-HT1A, 5-HT6, and 5-HT7 (8, 9). This led to the development of 3-[2-[4-(4-[(18)F]fluorobenzoyl)-1-piperidyl]ethyl]-2-sulfanyl-3H-quinazolin-4-one ([(18)F]altanserin) as a useful tool for 5-HT2A receptor PET imaging in vivo (10).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20641567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 196, 
          "offsetInEndSection": 381, 
          "text": "We investigated the relationships of gender, mood, impulsivity, aggression and temperament to 5HT(2A) receptor binding in 21 healthy subjects using [18F]altanserin and PET neuroimaging.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19959344", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 247, 
          "offsetInEndSection": 458, 
          "text": "We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19353726", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "[(18)F]altanserin is the preferred radiotracer for in-vivo labeling of serotonin 2A receptors by positron emission tomography (PET). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19162492", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 349, 
          "offsetInEndSection": 448, 
          "text": "Twenty-one healthy subjects underwent PET scanning with the 5-HT(2A) antagonist, [(18)F]altanserin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007894", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 525, 
          "text": "METHODS: [(18)F]-Altanserin PET was used to quantify 5-HT(2A) receptors in 12 healthy elderly individuals at baseline and at 2 years in six volumes of interest. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18828013", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 583, 
          "text": "The aim of this feasibility study was to examine whether acute ketamine-induced 5-HT release interferes with the binding of the 5-HT(2A) receptor (5-HT(2A)R) radioligand [(18)F]altanserin and positron emission tomography (PET)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17541696", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 302, 
          "offsetInEndSection": 557, 
          "text": "METHODS: Fifteen women ill with AN (ILL AN) were compared with 29 healthy control women (CW); PET and [11C]WAY100635 were used to assess binding potential (BP) of the 5-HT1A receptor, and [18F]altanserin was used to assess postsynaptic 5-HT2A receptor BP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241616", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is CD56 useful in Ewing sarcoma prognosis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21467162"
      ], 
      "type": "yesno", 
      "id": "552fa32fbc4f83e828000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 804, 
          "offsetInEndSection": 986, 
          "text": "There was a highly significant correlation between CD56 expression and progression-free survival (PFS; 69% in low/negative expression versus 30% in high expression groups, P = 0.024)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 988, 
          "offsetInEndSection": 1132, 
          "text": "In patients with localized nonpelvic disease, those expressing low/negative CD56 had 100% PFS versus 40% in the high expressing group (P = 0.02)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1162, 
          "offsetInEndSection": 1305, 
          "text": "CD56 was found to be an independent prognostic marker with an 11-fold increased risk for relapse in patients with localized disease (P = 0.006)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1459, 
          "offsetInEndSection": 1654, 
          "text": "CD56 expression could be used to reveal ES patients with excellent prognosis or patients predisposed to relapse, thus improving treatment stratification and implementation of personalized therapy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is peripheral neuroepithelioma related to Ewing sarcoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10968707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9825003", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7595741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7771924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8204006"
      ], 
      "type": "yesno", 
      "id": "552fa6f5bc4f83e828000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 784, 
          "text": "The term \"small round-cell tumor\" describes a group of highly aggressive malignant tumors composed of relatively small and monotonous undifferentiated cells with high nuclear to cytoplasmic ratios. This group includes Ewing's sarcoma (ES), peripheral neuroepithelioma (aka, primitive neuroectodermal tumor or extraskeletal ES), peripheral neuroblastoma (\"classic-type\"), rhabdomyosarcoma, desmoplastic small round-cell tumor, lymphoma, leukemia, small-cell osteosarcoma, small-cell carcinoma (either undifferentiated or neuroendocrine), olfactory neuroblastoma, cutaneous neuroendocrine carcinoma (aka, Merkel-cell carcinoma), small-cell melanoma, and mesenchymal chondrosarcoma. Their clinical presentations often overlap, thus making a definitive diagnosis problematic in some cases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10968707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 318, 
          "text": "AIMS: To retrospectively study the DNA content in a series of childhood Ewing Family Tumors (EFT), and to investigate its prognostic value. METHODS: The study was performed on a series of 27 EFTs (osseous Ewing's sarcoma, 18 cases; extraosseous Ewing's sarcoma, 2; peripheral neuroepithelioma, 4; Askin Rosai tumors, 3", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9825003", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 172, 
          "text": "To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's sarcoma)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7595741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 389, 
          "text": "Large group of small-round-cell tumours of soft tissues and bone represents a complex diagnostic problem for the pathologists. Neuronal nature of many tumours from this group is proven by means of new methods--immunophenotypic analysis, tissue culture, cytogenetics. Peripheral neuroepithelioma, Ewing tumour, primitive neuroectodermal tumour (PNET), Askin tumour belong to these neoplasms", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7771924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 415, 
          "text": "Ewing's sarcoma of bone (ESB) and peripheral neuroepithelioma (PN) are frequently considered to be different tumors. Some researchers have suggested that PN is morphologically a neuroectodermal Ewing's sarcoma. We sought to determine the extent of neuroectodermal features in conventional ESB on direct patient material (25 cases) and to compare these tumors with a similar group of readily diagnosed PNs (10 cases)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 664, 
          "offsetInEndSection": 827, 
          "text": "Neuroectodermal antigens (neuron-specific enolase, Leu-7 [HNK-1], neurofilament 200 kd, and S100) were found in nine of 10 cases of PN and in 17 of 25 cases of ESB", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1074, 
          "offsetInEndSection": 1265, 
          "text": "These data support the concept that ESB and PN are both peripheral primitive neuroectodermal neoplasms, differing only in extent of neuroectodermal phenotype and morphological differentiation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the genes thought to be regulated by EWS/FLI?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23527175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19920188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19718047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17114343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16697960", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15492248"
      ], 
      "type": "list", 
      "id": "552faa43bc4f83e828000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23527175", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 123, 
          "offsetInEndSection": 549, 
          "text": "EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes. The expression levels of thousands of genes are affected in Ewing sarcoma, however, it is unknown which of these genes contribute to the transformed phenotype. Here we characterize BCL11B as an up-regulated EWS/FLI target that is necessary for the maintenance of transformation in patient derived Ewing sarcoma cells lines", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23527175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 551, 
          "offsetInEndSection": 705, 
          "text": "BCL11B, a zinc finger transcription factor, acts as a transcriptional repressor in Ewing's sarcoma and contributes to the EWS/FLI repressed gene signature", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23527175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 539, 
          "text": "EWS/FLI functions as an aberrant transcription factor to regulate genes that mediate the oncogenic phenotype of Ewing's sarcoma. One of these regulated genes, NR0B1, encodes a corepressor protein, and likely plays a transcriptional role in tumorigenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19718047", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 407, 
          "text": "We recently showed that EWS/FLI regulates one of its key targets, NR0B1, through a GGAA-microsatellite in its promoter", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19718047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 723, 
          "offsetInEndSection": 856, 
          "text": "We found that EWS/FLI directly binds the GSTM4 promoter, and regulates GSTM4 expression through a GGAA-microsatellite in its promoter", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19718047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1023, 
          "offsetInEndSection": 1092, 
          "text": "The gene that was most reproducibly up-regulated by EWS/FLI was NR0B1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17114343", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1203, 
          "offsetInEndSection": 1313, 
          "text": "We validated NR0B1 as an EWS/FLI-dysregulated gene and confirmed its expression in primary human tumor samples", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17114343", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16697960", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 523, 
          "offsetInEndSection": 653, 
          "text": "Functional analysis revealed that NKX2.2 is an EWS/FLI-regulated gene that is necessary for oncogenic transformation in this tumor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16697960", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 857, 
          "offsetInEndSection": 989, 
          "text": "Neuroblastoma-Ews/Fli-1 infectant cell lines showed marked increases in p53 protein expression without transcriptional up-regulation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15492248", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1529, 
          "offsetInEndSection": 1804, 
          "text": "We then tested the p53 response pathway and observed that the neuroblastoma parent cells responded to genotoxic stress, whereas the neuroblastoma-Ews/Fli-1 infectants did not. These results suggest that Ews/Fli-1 can directly abrogate the p53 pathway to promote tumorigenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15492248", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which translocation is the hallmark of Ewing sarcoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24124617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23145994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22742646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22266186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22240531"
      ], 
      "type": "factoid", 
      "id": "552faababc4f83e828000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "Tumours defined as Ewing sarcoma (ES) constitute a group of highly malignant neoplasms that most often affect children and young adults in the first 2 decades of life. The EWS/Fli-1 fusion gene, a product of the translocation t(11;22) (q24; 12), is detected in 95% of ES patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24124617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 199, 
          "text": "Ewing's sarcoma is a malignancy characterized by a specific 11:22 chromosomal translocation which generates a novel EWS-FLI1 fusion protein functioning as an aberrant transcription factor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23145994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "The hallmark of Ewing's sarcoma (EWS) is a translocation--t(11;22)(q24;q12)--that most frequently results in the EWS/FLI1 aberrant chimeric gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22742646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "The chromosomal translocation t(11;22)(q24;q12) yields the EWS-Fli1 fusion gene, which contributes to the development of Ewing Family Tumors (EFTs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 82, 
          "text": "Ewing sarcoma is extremely rare in people from East and Southeast Asia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22240531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1064, 
          "offsetInEndSection": 1141, 
          "text": "The t(11;22)(q24:q12) translocation was present in all patients in our series", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22240531", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1155, 
          "offsetInEndSection": 1318, 
          "text": "We confirmed that distant metastases is highly predictive of a poor outcome, and that the t(11;22)(q24:q12) translocation was present in all patients in our series", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22240531", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which fusion protein is involved in the development of Ewing sarcoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23750284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17453169", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17250957", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22723308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16206264"
      ], 
      "type": "factoid", 
      "id": "552fac4fbc4f83e828000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 266, 
          "text": "Ewing sarcoma is the second most common bone malignancy in children and young adults. It is driven by oncogenic fusion proteins (i.e. EWS/FLI1) acting as aberrant transcription factors that upregulate and downregulate target genes, leading to cellular transformation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23750284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17453169", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "Ewing sarcoma/primitive neuroectodermal tumors (EWS/PNET) are characterized by specific chromosomal translocations most often generating a chimeric EWS/FLI-1 gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17453169", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 912, 
          "text": "The resulting EWS-FLI-1 fusion protein is believed to behave as an aberrant transcriptional activator that contributes to ESFT development by altering the expression of its target genes in a permissive cellular environment", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17250957", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 284, 
          "offsetInEndSection": 590, 
          "text": "Herein, we show that the DNA repair protein and transcriptional cofactor, EYA3, is highly expressed in Ewing sarcoma tumor samples and cell lines compared with mesenchymal stem cells, the presumed cell-of-origin of Ewing sarcoma, and that it is regulated by the EWS/FLI1 fusion protein transcription factor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723308", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16206264", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 553, 
          "text": "The Ewing family of tumors harbors chromosomal translocations that join the N-terminal region of the EWS gene with the C-terminal region of several transcription factors of the ETS family, mainly FLI1, resulting in chimeric transcription factors that play a pivotal role in the pathogenesis of Ewing tumors. To identify downstream targets of the EWS/FLI1 fusion protein, we established 293 cells expressing constitutively either the chimeric EWS/FLI1 or wild type FLI1 proteins and used cDNA arrays to identify genes differentially regulated by EWS/FLI1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16206264", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1400, 
          "offsetInEndSection": 1616, 
          "text": "The high levels of DAX1 found in Ewing tumors and its potent transcriptional repressor activity suggest that the oncogenic effect of EWS/FLI1 may be mediated, at least in part, by the up-regulation of DAX1 expression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16206264", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which technique is used for detection of EWS/FLI1 fusion transcripts?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20231617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10379685"
      ], 
      "type": "factoid", 
      "id": "553653a5bc4f83e828000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 520, 
          "text": "We evaluated the feasibility and usefulness of reverse transcriptase-polymerase chain reaction (RT-PCR) on fine-needle aspirates for categorization of small blue round cell tumors (SBRCTs). A total of 51 cases, including 25 Ewing sarcoma/peripheral primitive neuroectodermal tumors (PNETs), 11 rhabdomyosarcomas, 13 neuroblastomas, and 2 desmoplastic small round cell tumors (DSRCTs) were analyzed. The detection of the EWS-FLI1 (20/25) and EWS-ERG (4/25) fusion transcripts resolved 24 of 25 cases of Ewing sarcoma/PNET", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20231617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Molecular detection of EWS-FLI1 chimeric transcripts in Ewing family tumors by nested reverse transcription-polymerase chain reaction", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10379685", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 374, 
          "offsetInEndSection": 1042, 
          "text": "To assess the feasibility and reliability of the molecular detection of the transcript originating from the chimeric gene in paraffin-embedded tumor specimens, we performed a nested reverse transcription-polymerase chain reaction (RT-PCR)-based assay to detect the EWS-FLI1 chimeric message in a series of Ewing family tumors. Of 24 paraffin-embedded tumor specimens from 23 cases analyzed, the chimeric message was detectable in 20 (83%) specimens from 20 cases (87%) by this nested RT-PCR assay, whereas none of 7 small round cell tumors not from this family (3 alveolar rhabdomyosarcomas, 2 neuroblastomas, 2 malignant lymphomas) showed detectable chimeric messages", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10379685", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Between which probes does the recurrent translocation breakpoint on chromosome 22 of neuroepithelioma lie?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2303258"
      ], 
      "type": "list", 
      "id": "5536554abc4f83e828000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The recurrent translocation breakpoint on chromosome 22 of neuroepithelioma has been localized between two probes, D22S1 and D22S15, by both in situ hybridization and somatic cell hybrids", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2303258", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which translocation is harbored in the Askin tumor cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23674776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17009618", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9213191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7571088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1333942"
      ], 
      "type": "factoid", 
      "id": "553656c4bc4f83e828000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "The Ewing sarcoma family of tumors includes osseous Ewing sarcoma, extraskeletal Ewing sarcoma, primitive neuroectodermal tumor, and Askin tumor. They share a karyotype abnormality with translocation involving chromosomes 11 and 22", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23674776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 259, 
          "text": "Ewing tumor family consists of Ewing tumor of bone, extraosseous Ewing tumor, primitive neurectodermal tumor and Askin tumor. All of them share genetic abnormality, reciprocal translocation (11; 22) (q24; q12), and originate from the same primordial stem cell", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17009618", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 410, 
          "offsetInEndSection": 551, 
          "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Malignant small cell tumor of the thoracopulmonary region (MSCT) was first described in 1979 and has been referred to as the Askin tumor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7571088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1331, 
          "offsetInEndSection": 1454, 
          "text": "MSCT and PPNET have a common reciprocal cytogenetic translocation [t(11;22)q(24;q12)], which is shared with Ewing's sarcoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7571088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 241, 
          "text": "The Askin tumor, a primitive malignant small-cell tumor of the chest wall, is mostly seen among children and adolescents. It is closely related to Ewing's sarcoma of the same location, both tumors showing a chromosomal translocation t(11;22)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1333942", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which biomarker is widely used in the diagnosis of Ewing sarcoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12783138"
      ], 
      "type": "factoid", 
      "id": "55376663bc4f83e82800000a", 
      "snippets": [
        {
          "offsetInBeginSection": 218, 
          "offsetInEndSection": 463, 
          "text": "half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is CD99 encoded by MIC2 gene?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24322504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24158076", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23644663", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22020966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21063743"
      ], 
      "type": "yesno", 
      "id": "55376b37bc4f83e82800000b", 
      "snippets": [
        {
          "offsetInBeginSection": 285, 
          "offsetInEndSection": 488, 
          "text": "We report 2 unusual cytogenetic findings in a pediatric Ewing sarcoma, an insertion of the MIC2 gene encoding CD99 from Xp to 10p and a submicroscopic deletion of the well-known tumor supressor gene KLF6", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 405, 
          "offsetInEndSection": 609, 
          "text": "We obtained the final diagnosis of ES/PNET by immunohistochemical molecular study with positive staining for the MIC2 gene product (CD99) and a Ewing sarcoma breakpoint region 1 (EWSR1) gene rearrangement", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24158076", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644663", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "CD99 is a 32-kDa transmembrane glycoprotein that is encoded by the MIC2 gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22020966", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 445, 
          "text": "The surgical specimens showed small round cell tumor with positive staining for MIC2 gene product (CD99)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21063743", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the most common type of pediatric cerebellar tumor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21681603", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6502196"
      ], 
      "type": "factoid", 
      "id": "55376f19bc4f83e82800000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Medulloblastoma (MDB) is the most common malignant cerebellar tumor in children", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21681603", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "Medulloblastoma is a malignant cerebellar tumor seen primarily in the pediatric age group that has a known ability to metastasize extraneurally", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6502196", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the characteristics of the Meier-Gorlin syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23023959", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14564153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11477602"
      ], 
      "type": "summary", 
      "id": "5537766dbc4f83e82800000d", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 146, 
          "text": "Meier-Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized by primordial dwarfism, microtia, and patellar aplasia/hypoplasia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23023959", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "The Meier-Gorlin syndrome (MGS) is a rare autosomal recessive disorder, characterized by bilateral microtia, aplasia or hypoplasia of the patellae, and severe intrauterine and post-natal growth retardation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14564153", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 259, 
          "text": "The Meier-Gorlin syndrome or ear, patella, short stature syndrome (MIM 224690) is a rare autosomal recessive disorder, characterized by the association of bilateral microtia, aplasia/hypoplasia of the patellae, and severe pre- and postnatal growth retardation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11477602", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which genes are thought to be involved in medulloblastoma development?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24252690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21597995", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20717685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19048113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15705863", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14688019", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10738305"
      ], 
      "type": "list", 
      "id": "5539029cbc4f83e828000012", 
      "snippets": [
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 436, 
          "text": "Medulloblastomas, the most frequent malignant brain tumours affecting children, comprise at least 4 distinct clinicogenetic subgroups. Aberrant sonic hedgehog (SHH) signalling is observed in approximately 25% of tumours and defines one subgroup. Although alterations in SHH pathway genes (e.g. PTCH1, SUFU) are observed in many of these tumours, high throughput genomic analyses have identified few other recurring mutations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 645, 
          "offsetInEndSection": 1156, 
          "text": "Mutagenesis significantly increased medulloblastoma frequency and identified 17 candidate cancer genes, including orthologs of genes somatically mutated (PTEN, CREBBP) or associated with poor outcome (PTEN, MYT1L) in the human disease. Strikingly, these candidate genes were enriched for transcription factors (p=2x10-5), the majority of which (6/7; Crebbp, Myt1L, Nfia, Nfib, Tead1 and Tgif2) were linked within a single regulatory network enriched for genes associated with a differentiated neuronal phenotype", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1363, 
          "offsetInEndSection": 1497, 
          "text": "Igf2, previously implicated in medulloblastoma, was the most differentially expressed gene in murine tumours with network perturbation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 63, 
          "text": "PCDH10 is a candidate tumour suppressor gene in medulloblastoma", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21597995", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 145, 
          "text": "The aim of this study was to investigate the genetic and epigenetic mechanisms contributing to PCDH10 down-regulation in medulloblastoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21597995", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 914, 
          "offsetInEndSection": 1174, 
          "text": "We report a very focal homozygous deletion on chromosome 4q28.3 harbouring the PCDH10 gene. We demonstrate that PCDH10 transcription is down-regulated in 19/26 (73%) of medulloblastomas suggesting that other mechanisms also could be involved in gene repression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21597995", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1470, 
          "offsetInEndSection": 1732, 
          "text": "Our findings suggest that genetic and epigenetic deregulation of PCDH10 occurs in a significant portion of medulloblastoma patients. Failure to express PCDH10 may result in loss of inhibition of cell migration, thereby contributing to medulloblastoma progression", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21597995", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 950, 
          "offsetInEndSection": 1078, 
          "text": "We found that the higher expression levels of BMI1 and PCGF2 genes were associated with significantly decreased patient survival", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20717685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1266, 
          "offsetInEndSection": 1384, 
          "text": "Our analysis showed correlation between BMI1 and PCGF2 gene's expression and survival in children with medulloblastoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20717685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048113", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1446, 
          "offsetInEndSection": 1773, 
          "text": "These data provide the first demonstration that Bmi1 is required for spontaneous de novo development of a solid tumor arising in the brain, suggest a crucial role for Bmi1-dependent, nestin-expressing progenitor cells in medulloblastoma expansion, and implicate Bmi1 as a key factor required for Hh pathway-driven tumorigenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19048113", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 70, 
          "text": "Genomic amplification of orthodenticle homologue 2 in medulloblastomas", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15705863", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 459, 
          "offsetInEndSection": 900, 
          "text": "Genomic alterations normally associated with medulloblastomas, including MYC amplification and isochromosome 17q, were easily detected. Surprisingly, analysis of only five genomes revealed novel amplicons on chromosome 14q, one of which contained the orthodenticle homologue 2 (OTX2) homeobox gene. DNA copy number analysis showed that OTX2 had undergone genomic amplification in 2 of 11 medulloblastoma cell lines and 8 of 42 primary tumors", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15705863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1300, 
          "offsetInEndSection": 1487, 
          "text": "Serial analysis of gene expression of 240 different human tumors or normal tissues revealed that 96% of all 783 OTX2 transcripts sequenced were in medulloblastomas or embryonic stem cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15705863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1489, 
          "offsetInEndSection": 1691, 
          "text": "OTX2 functions to specify the fate of neuroectoderm in various regions of the developing brain. This developmental role is consistent with the evidence suggesting that OTX2 is a medulloblastoma oncogene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15705863", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 627, 
          "offsetInEndSection": 793, 
          "text": "Extensive hypermethylation of RASSF1A was detected frequently in medulloblastomas but not in the normal cerebellum (41/44 primary tumours versus 0/5 normal cerebella)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14688019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 795, 
          "offsetInEndSection": 984, 
          "text": "In contrast, complete methylation of HIC1 and CASP8 in a subset of primary tumours (17/44 and 14/39) occurred against a consistent background of partial methylation in the normal cerebellum", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14688019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 986, 
          "offsetInEndSection": 1115, 
          "text": "These data therefore indicate that extensive methylation of RASSF1A, HIC1 and CASP8 are tumour-specific events in medulloblastoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14688019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1885, 
          "offsetInEndSection": 2061, 
          "text": "We conclude that epigenetic TSG inactivation is a significant feature of medulloblastoma, and identify RASSF1A, HIC1 and CASP8 as potentially critical genes in its pathogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14688019", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 101, 
          "text": "Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 173, 
          "offsetInEndSection": 370, 
          "text": "Seventy-nine % (27 of 34) of primary tumors and 100% (8 of 8) of medulloblastoma cell lines displayed extensive tumor-specific DNA hypermethylation across the RASSF1A promoter-associated CpG island", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 372, 
          "offsetInEndSection": 616, 
          "text": "Hypermethylation was associated with epigenetic silencing of RASSF1A transcription in medulloblastoma cell lines, and RASSF1A expression in these lines was restored after treatment with the DNA-methyltransferase inhibitor 5-aza-2'-deoxycytidine", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 879, 
          "offsetInEndSection": 1023, 
          "text": "Epigenetic inactivation by biallelic hypermethylation therefore represents the primary mechanism of RASSF1A gene inactivation in medulloblastoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1038, 
          "offsetInEndSection": 1237, 
          "text": "RASSF1A hypermethylation is a frequent event in medulloblastoma tumorigenesis detectable in adult (5 of 7) and pediatric patients (22 of 27) and in all histological variants and age and sex groupings", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12384556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 171, 
          "offsetInEndSection": 330, 
          "text": "Medulloblastoma, a brain tumor, develops in about 3% of NBCCS patients, and mutations in PTCH have also been described in a subset of sporadic medulloblastomas", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10738305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 459, 
          "offsetInEndSection": 652, 
          "text": "Recently, a transgenic mouse hemizygous for the Ptch gene was generated by homologous recombination. Medulloblastomas were found in about 19% of these mice within the first 25 weeks after birth", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10738305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1228, 
          "offsetInEndSection": 1714, 
          "text": "We also examined the mRNA expression levels for the remaining Ptch allele, as well as for Gli1, a gene known to be transcriptionally activated by Ptch inactivation. Blot analysis of RNA from the 13 tumors shows that Ptch mRNA of appropriate size is expressed in all tumors at varying levels. Expression of Gli1 was increased in tumors compared to normal cerebellum. These results suggest that deletion of one copy of Ptch may be sufficient to promote medulloblastoma development in mice", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10738305", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the implication of histone lysine methylation in medulloblastoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23184418", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19270706"
      ], 
      "type": "summary", 
      "id": "5539062dbc4f83e828000013", 
      "snippets": [
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 1148, 
          "text": "Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 923, 
          "text": "we identified previously unknown amplifications and homozygous deletions, including recurrent, mutually exclusive, highly focal genetic events in genes targeting histone lysine methylation, particularly that of histone 3, lysine 9 (H3K9). Post-translational modification of histone proteins is critical for regulation of gene expression, can participate in determination of stem cell fates and has been implicated in carcinogenesis. Consistent with our genetic data, restoration of expression of genes controlling H3K9 methylation greatly diminishes proliferation of medulloblastoma in vitro", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the effects of homozygosity of EDNRB mutations in addition to Hirschsprung disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16237557", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12939697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11891690", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11324313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9885824"
      ], 
      "type": "summary", 
      "id": "55391825bc4f83e828000016", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "Homozygous mutations of EDNRB in human have been reported to result in Waardenburg-Hirschsprung disease (WS4), while mutated heterozygotes manifested isolated Hirschsprung disease in lower penetrance", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16237557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 367, 
          "offsetInEndSection": 1143, 
          "text": "The index patient, who was born to a family with no history of Hirschsprung disease, presented total colonic aganglionosis with small bowel extension, sensorineural hearing loss and generalized cutaneous pigmentary defects. Interestingly, both irides were normally black. The study detected a homozygous missense mutation at codon 196 in exon 2 (Ser196Asn), which has not been reported. Both parents and four in six siblings harbored heterozygous mutation without any clinical manifestation. Our findings were consistent with previous observations that full spectrum of WS4 occurred to the mutate homozygotes. Moreover, the non-penetrance of heterozygotes in our pedigree, which differs from other reports, demonstrates the high pleiotropic effect of EDNRB mutations in human.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16237557", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 631, 
          "offsetInEndSection": 864, 
          "text": "Our own studies could show that, whereas a homozygous mutation of EDNRB causes long-segment HSCR, a heterozygous EDNRB deficiency leads to alterations of the ENS resembling the histopathology observed in intestinal neuronal dysplasia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12939697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 741, 
          "text": "ABCD syndrome is an autosomal recessive syndrome characterized by albinism, black lock, cell migration disorder of the neurocytes of the gut (Hirschsprung disease [HSCR]), and deafness. This phenotype clearly overlaps with the features of the Shah-Waardenburg syndrome, comprising sensorineural deafness; hypopigmentation of skin, hair, and irides; and HSCR. Therefore, we screened DNA of the index patient of the ABCD syndrome family for mutations in the endothelin B receptor (EDNRB) gene, a gene known to be involved in Shah-Waardenburg syndrome. A homozygous nonsense mutation in exon 3 (R201X) of the EDNRB gene was found. We therefore suggest that ABCD syndrome is not a separate entity, but an expression of Shah-Waardenburg syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891690", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 627, 
          "text": "Three susceptibility genes have been recently identified in HSCR, namely the RET proto-oncogene, the endothelin B receptor (EDNRB) gene, and the endothelin 3 (EDN3) gene. RET gene mutations were found in significant proportions of familial (50%) and sporadic (15-20%) HSCR, while homozygosity for EDNRB or EDN3 mutations accounted for the rare HSCR-Waardenburg syndrome (WS) association. More recently, heterozygous EDNRB an EDN3 missense mutations have been reported in isolated HSCR patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11324313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 134, 
          "offsetInEndSection": 628, 
          "text": "Three susceptibility genes have been recently identified in HSCR, namely the RET proto-oncogene, the endothelin B receptor (EDNRB) gene, and the endothelin 3 (EDN3) gene. RET gene mutations were found in significant proportions of familial (50%) and sporadic (15-20%) HSCR, while homozygosity for EDNRB or EDN3 mutations accounted for the rare HSCR-Waardenburg syndrome (WS) association. More recently, heterozygous EDNRB and EDN3 missense mutations have been reported in isolated HSCR patients", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885824", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the involvement of PDGFRB in metastatic medulloblastoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19417143"
      ], 
      "type": "summary", 
      "id": "55391b2cbc4f83e828000017", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 200, 
          "text": "Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "Platelet-derived growth factor (PDGF) receptor (PDGFR) expression correlates with metastatic medulloblastoma. PDGF stimulation of medulloblastoma cells phosphorylates extracellular signal-regulated kinase (ERK) and promotes migration", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1004, 
          "offsetInEndSection": 1900, 
          "text": "Imatinib (1 \u03bcmol/L) treatment of DAOY and D556 cells inhibited PDGF-BB- and serum-mediated migration and invasion at 24 and 48 h, respectively, and concomitantly inhibited PDGF-BB activation of PDGFRB, Akt, and ERK but increased PTEN expression and activity. Imatinib treatment also induced DAOY cell apoptosis at 72 h and inhibited DAOY and D556 cell proliferation at 48 h. siRNA silencing of PDGFRB similarly inhibited signaling, migration, and survival and both siRNA and imatinib treatment inhibited PDGF-BB-mediated EGFR transactivation, indicating that the effects of imatinib treatment are specific to PDGFRB target inhibition. These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which signaling pathways have been associated with medulloblastoma formation and growth?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21679342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20232424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18651559", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9973222"
      ], 
      "type": "list", 
      "id": "55391ce8bc4f83e828000018", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 285, 
          "text": "Hedgehog (Hh) signaling is an important factor in growth and patterning during embryonic development. A mutation in Patched, Smoothened or Gli1, which regulate the Hh signaling pathway, might lead to the onset of glioblastoma, basal cell carcinoma, medulloblastoma and rhabdomyosarcoma", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21679342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1376, 
          "offsetInEndSection": 1546, 
          "text": "These data indicate that inhibition of Aurora Kinase A inhibits cell growth in medulloblastoma through inhibition of pro-proliferative signaling pathways Wnt, Myc, and RB", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20232424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 324, 
          "text": "Multiple signaling pathways have been associated with medulloblastoma formation and growth. These include the developmental pathways Hedgehog, (Hh) Notch, and Wnt as well as the receptor tyrosine kinases (RTK) c-Met, erbB2, IGF-R and TrkC, and the oncoprotein Myc", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18651559", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973222", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Elevated expression of the neurotrophin-3 (NT-3) receptor TrkC by childhood medulloblastomas is associated with favorable clinical outcome", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973222", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 759, 
          "offsetInEndSection": 961, 
          "text": "Considered collectively, these results support the conclusion that the biological actions of TrkC activation affect medulloblastoma outcome by inhibiting tumor growth through the promotion of apoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973222", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is protein Fbw7 a SCF type of E3 ubiquitin ligase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18094723", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23820376", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23776410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23507969", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22665065", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22608923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22124735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21827743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21349854", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21282377"
      ], 
      "type": "yesno", 
      "id": "550ae16bc2af5d5b70000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "FBW7 (F-box and WD repeat domain-containing 7) is the substrate recognition component of an evolutionary conserved SCF (complex of SKP1, CUL1 and F-box protein)-type ubiquitin ligase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18094723", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 359, 
          "offsetInEndSection": 700, 
          "text": "However, very few E3 ubiquitin ligases are known to target G-CSFR for ubiquitin-proteasome pathway. Here we identified F-box and WD repeat domain-containing 7 (Fbw7), a substrate recognizing component of Skp-Cullin-F box (SCF) E3 ubiquitin Ligase physically associates with G-CSFR and promotes its ubiquitin-mediated proteasomal degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23820376", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "FBW7 is a crucial component of an SCF-type E3 ubiquitin ligase, which mediates degradation of an array of different target proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776410", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "F-box and WD repeat domain-containing 7 (FBW7), the substrate-binding subunit of E3 ubiquitin ligase SCF(FBW7) (a complex of SKP1, cullin-1 and FBW7), plays important roles in various physiological and pathological processes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23507969", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "The tumor suppressor Fbxw7 (also known as Sel-10, hCdc4, hAgo, or Fbw7) is an F-box protein that functions as the substrate-recognition subunit of an SCF ubiquitin ligase complex and targets a group of oncoproteins for degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665065", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 191, 
          "text": "Fbw7 is the substrate recognition component of the Skp1-Cullin-F-box (SCF)-type E3 ligase complex and a well-characterized tumor suppressor that targets numerous oncoproteins for destruction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22608923", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Fbw7 is a member of F-box family proteins, which constitute one subunit of Skp1, Cul1, and F-box protein (SCF) ubiquitin ligase complex.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22124735", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 274, 
          "text": "The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase. SCF(Fbw7) facilitates polyubiquitination and subsequent degradation of various proteins such as Notch, cyclin E, c-Myc and c-Jun.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827743", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 485, 
          "text": "Fbxw7 (also known as Fbw7, SEL-10, hCdc4, or hAgo) is the F-box protein subunit of an Skp1-Cul1-F-box protein (SCF)-type ubiquitin ligase complex that plays a central role in the degradation of Notch family members.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21349854", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 314, 
          "text": "The Fbxw7 (F-box/WD repeat-containing protein 7; also called CDC4, Sel10, Ago, and Fbw7) component of the SCF (Skp1/Cullin/F-box protein) E3 ubiquitin ligase complex acts as a tumor suppressor in several tissues and targets multiple transcriptional activators and protooncogenes for ubiquitin-mediated degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282377", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the protein product of the cylindromatosis gene (CYLD) a deubiquitinating enzyme?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23066153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22406061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21931165", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21573132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21283724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21109933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20227366", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19893491", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19412431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18643924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18497946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17765686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17495026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17392286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16900776"
      ], 
      "type": "yesno", 
      "id": "550aef0ec2af5d5b7000000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 365, 
          "text": "CYLD was originally identified as a tumor suppressor gene mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple benign neoplasms of the skin known as cylindromas. The CYLD protein is a deubiquitinating enzyme that acts as a negative regulator of NF-\u03baB and JNK signaling through its interaction with NEMO and TNFR-associated factor 2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23066153", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "CYLD, a deubiquitinating enzyme (DUB), is a critical regulator of diverse cellular processes, ranging from proliferation and differentiation to inflammatory responses, via regulating multiple key signaling cascades such as nuclear factor kappa B (NF-\u03baB) pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406061", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 82, 
          "text": "CYLD is a lysine 63-deubiquitinating enzyme that inhibits NF-\u03baB and JNK signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21931165", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "Tumor suppressor gene CYLD is a deubiquitinating enzyme which negatively regulates various signaling pathways by removing the lysine 63-linked polyubiquitin chains from several specific substrates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21573132", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "The cylindromatosis tumor suppressor (CYLD) is a deubiquitinating enzyme that has been implicated in various aspects of adaptive and innate immune responses. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21283724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 426, 
          "text": "The cylindromatosis gene (CYLD) was identified as a tumor suppressor gene, which is mutated in familial cylindromatosis (Brooke-Spiegler syndrome), an autosomal-dominant predisposition to multiple tumors of the skin appendages. CYLD is a deubiquitinating enzyme acting as a negative regulator of the nuclear factor \u03baB (NF-\u03baB) signaling pathway by removing lysine-63-linked polyubiquitin chains from NF-\u03baB activating proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109933", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 293, 
          "offsetInEndSection": 470, 
          "text": "Here, we identify the deubiquitinating enzyme CYLD, the familial cylindromatosis tumor suppressor gene, as a negative regulator of proximal events in Wnt/beta-catenin signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20227366", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 293, 
          "text": "CYLD is a tumour-suppressor gene that is mutated in a benign skin tumour syndrome called cylindromatosis. The CYLD gene product is a deubiquitinating enzyme that was shown to regulate cell proliferation, cell survival and inflammatory responses, mainly through inhibiting NF-kappaB signalling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19893491", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Cyld encodes a 956-amino acid deubiquitinating enzyme (CYLD), which is a negative regulator of nuclear factor kappaB and mitogen-activated protein kinase pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 402, 
          "offsetInEndSection": 498, 
          "text": "The deubiquitinating enzyme CYLD has been identified as a key negative regulator for NF-kappaB. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18643924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 424, 
          "text": "CYLD, a tumor suppressor gene, has deubiquitinating enzyme activity and inhibits the activation of transcription factor NF-kappaB. Loss of the deubiquitinating activity of CYLD is correlated with tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18497946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 645, 
          "offsetInEndSection": 794, 
          "text": "We show that dCYLD encodes a deubiquitinating enzyme that deubiquitinates dTRAF2 and prevents dTRAF2 from ubiquitin-mediated proteolytic degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17765686", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 113, 
          "offsetInEndSection": 298, 
          "text": "The CYLD gene encodes a deubiquitinating enzyme that removes Lys-63-linked ubiquitin chains from I kappa B kinase signaling components and thereby inhibits NF-kappaB pathway activation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17495026", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 415, 
          "text": "Deubiquitinating enzymes (DUB) form a family of cysteine proteases that digests ubiquitin chains and reverses the process of protein ubiquitination. Despite the identification of a large number of DUBs, their physiological functions remain poorly defined. Here we provide genetic evidence that CYLD, a recently identified DUB, plays a crucial role in regulating the peripheral development and activation of B cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17392286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 398, 
          "text": "The cylindromatosis (CYLD) gene was originally identified as a tumor suppressor that is mutated in familial cylindromatosis, an autosomal dominant condition that confers a predisposition to multiple tumors of the skin appendages. CYLD has deubiquitinating enzyme activity and inhibits the activation of transcription factor NF-kappaB. Therefore, loss of CYLD function correlates with tumorigenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16900776", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the E3 ubiquitin ligase which ubiquitinates IkB leading to its proteasomal degradation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22435548", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20028970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17001349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16778892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10837071"
      ], 
      "type": "factoid", 
      "id": "550af222c2af5d5b7000000b", 
      "snippets": [
        {
          "offsetInBeginSection": 600, 
          "offsetInEndSection": 1200, 
          "text": "IKK activation and I\u03baB degradation involve different ubiquitination modes; the latter is mediated by a specific E3 ubiquitin ligase SCF(\u03b2-TrCP) . The F-box component of this E3, \u03b2-TrCP, recognizes the I\u03baB degron formed following phosphorylation by IKK and thus couples I\u03baB phosphorylation to ubiquitination. SCF(\u03b2-TrCP) -mediated I\u03baB ubiquitination and degradation is a very efficient process, often resulting in complete degradation of the key inhibitor I\u03baB\u03b1 within a few minutes of cell stimulation. In vivo ablation of \u03b2-TrCP results in accumulation of all the I\u03baBs and complete NF-\u03baB inhibition. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22435548", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 514, 
          "offsetInEndSection": 710, 
          "text": "Sequence comparison analysis showed sequence motif identity between CLU and beta-transducin repeat-containing protein (beta-TrCP), a main E3 ubiquitin ligase involved in IkappaB-alpha degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20028970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 379, 
          "offsetInEndSection": 548, 
          "text": "IkappaB degradation is dependent upon its phosphorylation by the IkappaB kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17001349", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 508, 
          "offsetInEndSection": 1100, 
          "text": "Here we show that beta-catenin stabilizes the mRNA encoding the F-box protein betaTrCP1, and identify the RNA-binding protein CRD-BP (coding region determinant-binding protein) as a previously unknown target of beta-catenin/Tcf transcription factor. CRD-BP binds to the coding region of betaTrCP1 mRNA. Overexpression of CRD-BP stabilizes betaTrCP1 mRNA and elevates betaTrCP1 levels (both in cells and in vivo), resulting in the activation of the Skp1-Cullin1-F-box protein (SCF)(betaTrCP) E3 ubiquitin ligase and in accelerated turnover of its substrates including IkappaB and beta-catenin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1479, 
          "offsetInEndSection": 2122, 
          "text": " The multisubunit IkappaB kinase (IKK) responsible for inducible IkappaB phosphorylation is the point of convergence for most NF-kappaB-activating stimuli. IKK contains two catalytic subunits, IKKalpha and IKKbeta, both of which are able to correctly phosphorylate IkappaB. Gene knockout studies have shed light on the very different physiological functions of IKKalpha and IKKbeta. After phosphorylation, the IKK phosphoacceptor sites on IkappaB serve as an essential part of a specific recognition site for E3RS(IkappaB/beta-TrCP), an SCF-type E3 ubiquitin ligase, thereby explaining how IKK controls IkappaB ubiquitination and degradation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10837071", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Magnetic beads has been used in numerous applications. List some coatings used.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24291643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24148457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23971905", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23934803", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23928048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23877419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23850993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23845492", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23746403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23598134", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23540244", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23501439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23401153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23378340", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23326761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23257838", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23176741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23174509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23149231", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23143268", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23021809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22903707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22841112", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22796092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24224000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23411631"
      ], 
      "type": "list", 
      "id": "550b0408c2af5d5b7000000c", 
      "snippets": [
        {
          "offsetInBeginSection": 539, 
          "offsetInEndSection": 580, 
          "text": "aptamer-based magnetic separation system ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291643", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 93, 
          "text": "enzymes coated to magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148457", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 317, 
          "offsetInEndSection": 430, 
          "text": " Aptamers are short, single-stranded (ss) oligonucleotidesable to recognize target molecules with high affinity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971905", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 578, 
          "offsetInEndSection": 669, 
          "text": " Recent developments involve immobilization of tagged enzymes onto magnetic nanoparticles. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23934803", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 329, 
          "text": "Using magnetic beads to immobilize DNAs containing various types of structures, we evaluated the in vitro binding activities of two well-characterized DNA repair proteins, Escherichia coli MutS and human p53.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "An affinity capture involved enzymatic assay for thrombin by using peptide aptamers as affinity ligands on magnetic beads", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877419", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 265, 
          "text": "During phage selection the biotinylated antigens are bound to streptavidin coupled magnetic beads, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23850993", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 69, 
          "offsetInEndSection": 108, 
          "text": " aptamer-functionalized magnetic beads ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845492", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 985, 
          "offsetInEndSection": 1030, 
          "text": "native antibody immobilized to magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22796092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Plasma membrane isolation using immobilized concanavalin A magnetic beads.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903707", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 991, 
          "offsetInEndSection": 1018, 
          "text": "streptavidin magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22903707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 351, 
          "offsetInEndSection": 420, 
          "text": " Digoxin was coated onto the surface of streptavidin magnetic beads. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23021809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 582, 
          "text": "covalent immobilization of the antigen onto carboxylic-modified magnetic beads (HOOC-MBs) activated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS), and further incubation in a mixture solution containing variable concentrations of the antigen and a fixed concentration of an HRP-labeled detection antibody. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 386, 
          "offsetInEndSection": 441, 
          "text": "Aptamers against HNE were immobilized on magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23598134", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 194, 
          "offsetInEndSection": 269, 
          "text": "The high specificity was obtained by using the magnetic beads and aptamers,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23540244", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 389, 
          "offsetInEndSection": 620, 
          "text": "Multiple targets (maltase, invertase, lipase) were immobilized on the magnetic beads by covalent linkage using 1-(3-dimethyl-aminopropyl)-3-ethyl-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) as reaction reagents, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23501439", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 629, 
          "text": "TiO2 -coated magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401153", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 19, 
          "offsetInEndSection": 51, 
          "text": "antibody-targeted magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378340", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 381, 
          "offsetInEndSection": 478, 
          "text": "A special SELEX library was constructed with the aim to immobilize this library on magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326761", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 408, 
          "offsetInEndSection": 443, 
          "text": "streptavidin-coupled magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23257838", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 450, 
          "offsetInEndSection": 488, 
          "text": "aptamers loaded on the magnetic beads ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 391, 
          "offsetInEndSection": 418, 
          "text": "His-affinity magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174509", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 382, 
          "offsetInEndSection": 415, 
          "text": "treptavidin-coated magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23149231", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 505, 
          "offsetInEndSection": 549, 
          "text": ", synthesized DNA is bound to magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143268", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 143, 
          "offsetInEndSection": 185, 
          "text": "streptavidin-modified magnetic microbeads ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841112", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 424, 
          "offsetInEndSection": 448, 
          "text": "oligo(dT) magnetic beads", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411631", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is cystatin C or cystatin 3 used as a biomarker of kidney function?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24321840", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24300829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24262510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24178972", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24114579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24001705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23910705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23866593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23813702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23797027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23744636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23701892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23698027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23669156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23577724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23574755", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23571811"
      ], 
      "type": "yesno", 
      "id": "550bf315c2af5d5b7000000e", 
      "snippets": [
        {
          "offsetInBeginSection": 23, 
          "offsetInEndSection": 202, 
          "text": "to explore the effect of ageing on renal function with cystatin C as the marker of glomerular filtration rate (GFR) in the general population without vascular disease or diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321840", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1224, 
          "offsetInEndSection": 1315, 
          "text": "Cystatin C, a more specific kidney function biomarker, was also elevated at 24 h after CLP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300829", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 227, 
          "offsetInEndSection": 454, 
          "text": "This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24262510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 764, 
          "offsetInEndSection": 856, 
          "text": "he primary predictor was estimated GFR (eGFR) calculated using serum cystatin C (eGFR(cys)).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24178972", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 169, 
          "text": "A number of recent reports have suggested that the cystatin C/creatinine (CysC/Cr) ratio might be a useful biomarker of renal function in pediatric patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1653, 
          "offsetInEndSection": 1784, 
          "text": "The CKD-EPI equation using cystatin C was the most precise method of renal function evaluation in patients with neurogenic bladder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 73, 
          "offsetInEndSection": 140, 
          "text": "Serum cystatin C (CysC) is an endogenous marker of kidney function.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23910705", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1560, 
          "offsetInEndSection": 1684, 
          "text": "The urinary content of CysC reflects tubular epithelial dysfunction whereas that of NGAL also characterizes tubular atrophy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23866593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 52, 
          "text": "Estimated kidney function based on serum cystatin C ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23813702", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 15, 
          "offsetInEndSection": 144, 
          "text": ": Several formulas for glomerular filtration rate (GFR) estimation, based on serum creatinine or cystatin C, have been proposed. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23797027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 839, 
          "offsetInEndSection": 946, 
          "text": "he highest and lowest eGFR levels corresponded to the cystatin C-based and MDRD-4 equations, respectively. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23797027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 336, 
          "text": "The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently proposed an equation to estimate GFR in subjects without cirrhosis using both serum creatinine and cystatin C levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23744636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 368, 
          "text": "Emerging evidence has shown that cystatin C may improve classification of glomerular filtration rate for defining chronic kidney disease in certain clinical populations and assist in understanding the complications of chronic kidney disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701892", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 99, 
          "text": "Beta-trace protein (BTP) and cystatin C (CysC) are novel biomarkers of renal function. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698027", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 132, 
          "text": "Cystatin C could improve chronic kidney disease (CKD) classification in HIV-infected women relative to serum creatinine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23669156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1564, 
          "offsetInEndSection": 1725, 
          "text": " Iohexol clearance and cystatin C formulae identify a greater proportion of patients with a GFR <60 mL/min/1.73 m(2), which also predicts the development of AKI.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23577724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 90, 
          "offsetInEndSection": 249, 
          "text": " Cystatin C was recently reported to be an endogenous surrogate of kidney function, and a high level of cystatin C is reported to be a strong predictor of CVD;", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574755", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 327, 
          "offsetInEndSection": 509, 
          "text": "Studies that have simultaneously compared measured GFR and estimated GFR (using endogenous filtration markers such as creatinine, or newer ones such as cystatin C or \u03b2-trace protein)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23571811", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is selenium deficiency involved in autoimmune thyroid disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23565426", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23448365", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22009156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20810577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15132715"
      ], 
      "type": "yesno", 
      "id": "550c1ca3a103b78016000003", 
      "snippets": [
        {
          "offsetInBeginSection": 14, 
          "offsetInEndSection": 205, 
          "text": "In areas with severe selenium deficiency higher incidence of thyroiditis has been reported due to a decreased activity of selenium-dependent glutathione peroxidase enzyme within thyroid cells", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565426", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1028, 
          "offsetInEndSection": 1355, 
          "text": "Of 30 patients in the selenium treated group, 6 patients were overtly hypothyroid, 15 were subclinical hypothyroid, 6 were euthyroid, and 3 were subclinical hyperthyroid. The mean TPOAb concentration decreased significantly by 49.5% (P < 0.013) in the selenium treated group versus 10.1% (P < 0.95) in the placebo-treated group", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565426", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1369, 
          "offsetInEndSection": 1479, 
          "text": "Selenium substitution has a significant impact on inflammatory activity in thyroid-specific autoimmune disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565426", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 56, 
          "text": "Serum selenium is low in newly diagnosed Graves' disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448365", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 678, 
          "offsetInEndSection": 801, 
          "text": "S-Se was lower in patients with GD than in controls (mean (SD), GD: 89\u00b79\u00a0\u03bcg/l (18\u00b74); controls: 98\u00b78\u00a0\u03bcg/l (19\u00b77), P\u00a0<\u00a00\u00b701)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448365", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1371, 
          "offsetInEndSection": 1603, 
          "text": "Patients with newly diagnosed GD and AIH had significantly lower s-Se compared with random controls. Our observation supports the postulated link between inadequate selenium supply and overt autoimmune thyroid disease, especially GD", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448365", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1618, 
          "offsetInEndSection": 1852, 
          "text": "Selenium deficiency is likely to constitute a risk factor for a feedforward derangement of the immune system-thyroid interaction, while selenium supplementation appears to dampen the self-amplifying nature of this derailed interaction", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22009156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 437, 
          "text": "The recent recognition that the essential trace element selenium is incorporated as selenocysteine in all three deiodinases has decisively confirmed the clear-cut link between selenium and thyroid function. It has additionally been established that the thyroid contains more selenium than any other tissue and that selenium deficiency aggravates the manifestation of endemic myxedematous cretinism and autoimmune thyroid disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1669, 
          "offsetInEndSection": 1834, 
          "text": "Maintenance of \"selenostasis\" via optimal intake not only aids preservation of general health but also contributes substantially to the prevention of thyroid disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 520, 
          "offsetInEndSection": 844, 
          "text": "Low birth weight, iodine excess and deficiency, selenium deficiency, parity, oral contraceptive use, reproductive span, fetal microchimerism, stress, seasonal variation, allergy, smoking, radiation damage to the thyroid gland, viral and bacterial infections all play a role in the development of autoimmune thyroid disorders", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15132715", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23979994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23587141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23531432", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23281786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23225525"
      ], 
      "type": "factoid", 
      "id": "550c3754a103b78016000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 266, 
          "text": "Parkinson's disease (PD) is one of the most common degenerative disorders of the central nervous system that produces motor and non-motor symptoms. The majority of cases are idiopathic and characterized by the presence of Lewy bodies containing fibrillar \u03b1-synuclein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Parkinson's disease is characterized by \u03b1-synuclein pathology in the form of Lewy bodies and Lewy neurites", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23587141", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Parkinson's disease is characterized by neuronal death in the substantia nigra and the presence of intracellular inclusions of \u03b1-synuclein in the Lewy bodies", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531432", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 286, 
          "text": "Parkinson's disease, also known as paralysis agitans, is a progressive degenerative disorder of the central nervous system, with onset usually between the ages of 50 and 65 years, and is associated with loss of dopaminergic neurons in the subsantia nigra and the presence of Lewy bodies", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23281786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 961, 
          "offsetInEndSection": 1118, 
          "text": "The protein \u03b1-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the main component of the Lewy bodies?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23562579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23384565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23382946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23300799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23295909"
      ], 
      "type": "factoid", 
      "id": "550c3d45a103b78016000008", 
      "snippets": [
        {
          "offsetInBeginSection": 350, 
          "offsetInEndSection": 443, 
          "text": "\u03b1-syn is the main component of Lewy bodies in Parkinson's disease (PD) and Lewy body dementia", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein, the main component of Lewy bodies, plays a central role in the PD pathogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23384565", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 365, 
          "text": "Parkinson's disease (PD) is characterized by the progressive degeneration of substantia nigra pars compacta (SNpc) dopaminergic neurones and the formation of Lewy bodies (LB) in a proportion of the remaining neurones. \u03b1-synuclein is the main component of LB, but the pathological mechanisms that lead to neurodegeneration associated with LB formation remain unclear", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382946", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 122, 
          "text": "\u03b1-Synuclein is the main component of Lewy bodies, the intraneuronal inclusion bodies characteristic of Parkinson's disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300799", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 409, 
          "text": "Parkinson's disease (PD) is the second most common neurodegenerative disease. The majority of PD cases are sporadic, for which genetic causes and underlying molecular mechanisms remain largely unclear. Autophagy, a highly conserved cellular process that governs the breakdown of long-lived proteins and organelles, has been involved in the degradation of \u03b1-synuclein (\u03b1-Syn), the main component of Lewy bodies", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295909", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23567651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23314528", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15834418"
      ], 
      "type": "factoid", 
      "id": "550c4011a103b78016000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodies", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 294, 
          "offsetInEndSection": 649, 
          "text": "Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314528", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is PLK2 involved in alpha-synuclein phosphorylation in the nervous system?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19004816"
      ], 
      "type": "yesno", 
      "id": "550c44d1a103b7801600000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 293, 
          "offsetInEndSection": 476, 
          "text": "Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to alpha-synuclein phosphorylation at Ser-129 in neurons", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 566, 
          "text": "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 568, 
          "offsetInEndSection": 701, 
          "text": "Inhibitors of PLK kinases inhibited alpha-synuclein phosphorylation both in primary cortical cell cultures and in mouse brain in vivo", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 712, 
          "offsetInEndSection": 857, 
          "text": "specific knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 975, 
          "text": "These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has the fungus Ashbya gossypii got many nuclei that share cytoplasm?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17158735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17122387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16899511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16449188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16023404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11181180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24094857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23771903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23015595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22267774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21737675", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21642510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20844079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20053682", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19910487"
      ], 
      "type": "yesno", 
      "id": "550e6688a103b7801600000d", 
      "snippets": [
        {
          "offsetInBeginSection": 81, 
          "offsetInEndSection": 118, 
          "text": "multinucleated Ashbya gossypii cells.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158735", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 60, 
          "offsetInEndSection": 103, 
          "text": "multinucleated Ashbya gossypii fungal cells", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17122387", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Nuclei in the filamentous, multinucleated fungus Ashbya gossypii divide asynchronously. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 72, 
          "offsetInEndSection": 108, 
          "text": "multinucleated Ashbya gossypii cells", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16899511", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 168, 
          "text": "We analyzed a unique asynchronous nuclear division cycle in a multinucleated filamentous fungus, Ashbya gossypii.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16449188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 61, 
          "offsetInEndSection": 103, 
          "text": " multinucleated hyphae in Ashbya gossypii.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16023404", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "We have followed the migration of GFP-labelled nuclei in multinucleate hyphae of Ashbya gossypii", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181180", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 283, 
          "offsetInEndSection": 319, 
          "text": "multinucleate fungus Ashbya gossypii", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094857", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Ashbya gossypii grows as multinucleated and constantly elongating hyphae", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771903", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 55, 
          "offsetInEndSection": 96, 
          "text": "multinucleated hyphae of Ashbya gossypii.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23015595", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "We report the mechanistic basis guiding the migration pattern of multiple nuclei in hyphae of Ashbya gossypii. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23015595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 113, 
          "offsetInEndSection": 139, 
          "text": "multinucleate fungal cells", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22267774", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 35, 
          "offsetInEndSection": 107, 
          "text": "multinucleate Ashbya gossypii cells relies on a minimal network of genes", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737675", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 158, 
          "text": "Clustering of nuclei in multinucleated hyphae is prevented by dynein-driven bidirectional nuclear movements and microtubule growth control in Ashbya gossypii.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21642510", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "In the multinucleate fungus Ashbya gossypii, cytoplasmic microtubules (cMTs) emerge from the spindle pole body outer plaque (OP) in perpendicular and tangential directions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20053682", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 84, 
          "offsetInEndSection": 125, 
          "text": "multinucleated hyphae of Ashbya gossypii.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19910487", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 53, 
          "text": "multiple nuclei in Ashbya gossypii hyphae", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20844079", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Ashbya gossypii has a budding yeast-like genome but grows exclusively as multinucleated hyphae.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20844079", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which molecule is targeted by the drug Gevokizumab?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24194526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23729309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23041424", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22699287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22084392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21154167", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21048425"
      ], 
      "type": "factoid", 
      "id": "550e828c71445a662f000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1\u03b2 antibody with differential receptor-modulating properties.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194526", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 533, 
          "text": "Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1575, 
          "offsetInEndSection": 1763, 
          "text": "These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1484, 
          "offsetInEndSection": 1751, 
          "text": "Most recently, rising evidence reports on the use of adalimumab, etanercept, and golimumab, while use of anti-interleukin (IL)-1 agents (anakinra, canakinumab, gevokizumab), IL-6 blockers (tocilizumab), and rituximab (depleting anti-CD20 antibody) is also increasing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1\u03b2.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041424", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 363, 
          "text": "Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 504, 
          "offsetInEndSection": 927, 
          "text": "Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1603, 
          "offsetInEndSection": 1815, 
          "text": "In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041424", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 142, 
          "offsetInEndSection": 215, 
          "text": "Gevokizumab is a novel, human-engineered monoclonal anti-IL-1\u03b2 antibody. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22699287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084392", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 131, 
          "offsetInEndSection": 341, 
          "text": "This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recombinant humanised anti-interleukin 1\u03b2 antibody, in Beh\u00e7et's disease patients with uveitis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Gevokizumab, an anti-IL-1\u03b2 mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154167", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 590, 
          "text": "XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1\u03b2, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1\u03b2 and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154167", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 587, 
          "offsetInEndSection": 771, 
          "text": "To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21048425", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Intetumumab has been tested in clinical trials for treatment of which cancers?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20145975"
      ], 
      "type": "list", 
      "id": "550e866271445a662f000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 476, 
          "text": "BACKGROUND: Intetumumab is a fully human mAb with antiangiogenic, antitumor properties which has shown potential therapeutic effect in castration-resistant prostate cancer (CRPC) patients. PATIENTS AND METHODS: In a phase 2, randomized, double-blind, multicenter study, men with metastatic CRPC without prior systemic nonhormonal therapy were randomly assigned to 75-mg/m(2) docetaxel (Taxotere) and 5-mg prednisone plus placebo (N = 65) or 10-mg/kg intetumumab (N = 66) q3w. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1605, 
          "offsetInEndSection": 1730, 
          "text": "CONCLUSION: The addition of intetumumab to docetaxel resulted in shorter PFS without additional toxicity among CRPC patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 220, 
          "offsetInEndSection": 491, 
          "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1523, 
          "offsetInEndSection": 1680, 
          "text": "CONCLUSION: With its favourable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 164, 
          "offsetInEndSection": 446, 
          "text": "METHODS: In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab (n=33), or 5 mg kg(-1) intetumumab (n=32) q3w. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 559, 
          "text": "PURPOSE: In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-\u03b1v integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. PATIENTS AND METHODS: Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to standard treatment were allocated to treatment with 10 mg/kg or 20 mg/kg intetumumab, administered once every 3 weeks for up to four cycles unless unacceptable toxicity or disease progression occurred.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1546, 
          "offsetInEndSection": 1803, 
          "text": "CONCLUSIONS: In patients with metastatic malignant melanoma and angiosarcoma in this study, intetumumab demonstrated manageable toxicity, was well tolerated, and presented approximately dose-proportional pharmacokinetics for the 10 mg/kg and 20 mg/kg doses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 251, 
          "text": "A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human \u03b1(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 449, 
          "text": "PURPOSE: We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer. Patients and methods In this phase 1, open-label, multicenter, nonrandomized study, 75 mg/m\u00b2 docetaxel was administered on Day 1 of each of nine 21-day treatment cycles and intetumumab 5 or 10 mg/kg was administered on Days 1, 8, and 15 of Cycles 2 and 3 and on Day 1 of all subsequent cycles. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which variables are included in the SPAN-100 score?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23894342", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23175723"
      ], 
      "type": "list", 
      "id": "550e9d2cb305b40c5c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 1040, 
          "offsetInEndSection": 1240, 
          "text": "Furthermore, MR-proADM levels significantly improved reclassification of patients in the prediction of outcome by the Stroke Prognostication using Age and NIHSS-100 (SPAN-100; NRI\u200a=\u200a0.175; p\u200a=\u200a0.04). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894342", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 64, 
          "text": "Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175723", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 431, 
          "offsetInEndSection": 584, 
          "text": "METHODS: We created the Stroke Prognostication using Age and NIH Stroke Scale (SPAN) index by combining age in years plus NIH Stroke Scale (NIHSS) \u2265100. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175723", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Pridopidine has been tested for treatment of which disorder?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22948856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22560595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20667452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20373247"
      ], 
      "type": "factoid", 
      "id": "550ea8f1b305b40c5c000005", 
      "snippets": [
        {
          "offsetInBeginSection": 1892, 
          "offsetInEndSection": 2083, 
          "text": "These effects of pridopidine may serve to strengthen the cortico-striatal communication and to improve motor control in Huntington's disease for which pridopidine is currently in development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington's disease, with additional evaluation of its safety and tolerability. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1304, 
          "offsetInEndSection": 1497, 
          "text": "Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450660", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "One-year safety and tolerability profile of pridopidine in patients with Huntington disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "OBJECTIVE: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1430, 
          "offsetInEndSection": 1616, 
          "text": "CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that pridopidine (\u226490 mg/day) is generally safe and well-tolerated in patients with Huntington disease for up to 1 year.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23446684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 211, 
          "text": "Pridopidine is being developed for the treatment of impaired motor function associated with Huntington's disease and belongs to a new class of compounds known as dopidines, which act as dopaminergic stabilizers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 248, 
          "offsetInEndSection": 431, 
          "text": " There is so far neither cure nor approved disease-slowing therapy for HD, though recent clinical studies have shown a beneficial long-term effect of pridopidine in patients with HD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 139, 
          "offsetInEndSection": 652, 
          "text": "Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington's disease suggested that this drug might improve voluntary motor function. We aimed to assess further the effects of pridopidine in patients with Huntington's disease. METHODS: We undertook a 6 month, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2432, 
          "offsetInEndSection": 2725, 
          "text": "INTERPRETATION: This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington's disease merits further investigation. Pridopidine up to 90 mg per day was well tolerated in patients with Huntington's disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22071279", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 221, 
          "offsetInEndSection": 748, 
          "text": "Pridopidine (ACR16) belongs to a novel class of central nervous system compounds in development for the treatment of Huntington disease. The objective of the study was to investigate the metabolic changes in patients with Huntington disease before and after pridopidine treatment. METHODS: [(18)F]Fluorodeoxyglucose positron emission tomographic imaging was used to measure the regional cerebral metabolic rate of glucose at baseline and after 14 days of open-label pridopidine treatment in 8 patients with Huntington disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1163, 
          "offsetInEndSection": 1562, 
          "text": "CONCLUSIONS: Our findings suggest that pridopidine induces metabolic changes in brain regions implicated as important for mediating compensatory mechanisms in Huntington disease. In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington disease-related metabolic activity pattern.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21586914", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1365, 
          "offsetInEndSection": 1574, 
          "text": "The putative restoration of function in cortico-subcortical circuitry by pridopidine is likely to make it useful for ameliorating several neurological and psychiatric disorders, including Huntington's disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20667452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 294, 
          "text": "OBJECTIVES: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). METHODS: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1151, 
          "offsetInEndSection": 1237, 
          "text": "CONCLUSIONS: Pridopidine shows promise as a treatment for some of the symptoms of HD. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616707", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 647, 
          "offsetInEndSection": 841, 
          "text": "Investigational drugs discussed include ALN-HTT (Alnylam Pharmaceuticals Inc/Medtronic Inc), EPI-743 (Edison Pharmaceuticals Inc), LNK-754 (Link Medicine Corp) and pridopidine (NeuroSearch A/S).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373247", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23966205", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23593020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23644600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23777630", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22892954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22798623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22718021", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22536400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21951698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21529284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21288772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21484336"
      ], 
      "type": "factoid", 
      "id": "550f0e4c6a8cde6b72000003", 
      "snippets": [
        {
          "offsetInBeginSection": 571, 
          "offsetInEndSection": 667, 
          "text": "e expression of DUX4 has been confirmed in both FSHD cells and biopsies by several laboratories.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23966205", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1341, 
          "offsetInEndSection": 1516, 
          "text": "These results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23966205", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 702, 
          "offsetInEndSection": 992, 
          "text": "DUX4, the primary candidate for FSHD pathogenesis, is upregulated over ten-fold in FSHD myoblasts and myotubes with short telomeres, and its expression is inversely proportional to telomere length. FSHD may be the first known human disease in which TPE contributes to age-related phenotype.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23644600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 128, 
          "offsetInEndSection": 319, 
          "text": "Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23777630", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 999, 
          "offsetInEndSection": 1161, 
          "text": "Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 485, 
          "text": "Recent studies have proposed that FSHD pathology is caused by the misexpression of the DUX4 (double homeobox 4) gene resulting in production of a pathogenic protein, DUX4-FL, which has been detected in FSHD, but not in unaffected control myogenic cells and muscle tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22798623", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22718021", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "Facioscapulohumeral Disease (FSHD) is a dominantly inherited progressive myopathy associated with aberrant production of the transcription factor, Double Homeobox Protein 4 (DUX4).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22536400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 250, 
          "offsetInEndSection": 379, 
          "text": " A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2021, 
          "offsetInEndSection": 2304, 
          "text": "DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21951698", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "Double homeobox 4 (DUX4) is a candidate disease gene for facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophies characterized by progressive skeletal muscle degeneration. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21529284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 648, 
          "text": "In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 464, 
          "text": "In facioscapulohumeral muscular dystrophy, recent findings implicate a stabilized DUX4 transcript within the contracted D4Z4 repeats, opening the door for an RNA interference treatment strategy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21484336", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which event results in the acetylation of S6K1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19961954"
      ], 
      "type": "summary", 
      "id": "551173c26a8cde6b72000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 73, 
          "text": "S6K1 is acetylated at lysine 516 in response to growth factor stimulation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 293, 
          "offsetInEndSection": 396, 
          "text": "In addition to phosphorylation, we have recently shown that S6K1 is also targeted by lysine acetylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 398, 
          "offsetInEndSection": 590, 
          "text": "Here, using tandem mass spectrometry we have mapped acetylation of S6K1 to lysine 516, a site close to the C-terminus of the kinase that is highly conserved amongst vertebrate S6K1 orthologues", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 592, 
          "offsetInEndSection": 738, 
          "text": "Using acetyl-specific K516 antibodies, we show that acetylation of endogenous S6K1 at this site is potently induced upon growth factor stimulation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1074, 
          "offsetInEndSection": 1215, 
          "text": "We propose that K516 acetylation may serve to modulate important kinase-independent functions of S6K1 in response to growth factor signalling", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20599721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 100, 
          "text": "Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961954", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 404, 
          "offsetInEndSection": 626, 
          "text": "Following mitogen stimulation, S6Ks interact with the p300 and p300/CBP-associated factor (PCAF) acetyltransferases. S6Ks can be acetylated by p300 and PCAF in vitro and S6K acetylation is detected in cells expressing p300", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 774, 
          "offsetInEndSection": 1033, 
          "text": "Acetylation of S6K1 and 2 is increased upon the inhibition of class I/II histone deacetylases (HDACs) by trichostatin-A, while the enhancement of S6K1 acetylation by nicotinamide suggests the additional involvement of sirtuin deacetylases in S6K deacetylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19961954", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the effect of resveratrol on mTOR activity?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20851890"
      ], 
      "type": "summary", 
      "id": "551177626a8cde6b72000005", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 88, 
          "text": "Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 359, 
          "text": "Here, we show that RSV inhibits insulin- and leucine-stimulated mTOR signaling in C2C12 fibroblasts via a Sirt1-independent mechanism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 361, 
          "offsetInEndSection": 601, 
          "text": "Treating C2C12 cells with RSV dramatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little effect on tyrosine phosphorylation of the insulin receptor and activation of the p44/42 MAPK signaling pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 603, 
          "offsetInEndSection": 790, 
          "text": "RSV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1187, 
          "offsetInEndSection": 1396, 
          "text": "Taken together, our studies reveal that RSV inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR interaction and thus uncover a novel mechanism by which RSV negatively regulates mTOR activity", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20851890", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which proteins are the different isoforms of the p38 MAP kinase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24107108", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22720195", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17855341", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17591882", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16022178", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9430721"
      ], 
      "type": "list", 
      "id": "5512c1ee6a8cde6b72000009", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 398, 
          "text": "The p38 Mitogen-Activated Protein (MAP) kinase, a serine/threonine kinase, is one of the best characterized kinases in the inflammatory process. Among the four identified p38 isoforms (p38\u03b1, p38\u03b2, p38\u03b3, and p38\u03b4), the \u03b1-form is the most fully studied and plays a central role in the biosynthesis of the proinflammatory cytokines i.e. IL-1\u03b2 and TNF-\u03b1 at the translational and transcriptional levels.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24107108", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 328, 
          "offsetInEndSection": 692, 
          "text": "The p38 mitogen-activated protein kinase (MAPK) is one of the kinase pathways that regulate the production of IL-1\u03b2 and TNF\u03b1. Importantly, small molecule inhibitors of the p38 MAPK family have been developed and show efficacy in blocking the production of IL-1\u03b2 and TNF\u03b1. The p38 family consists of at least four isoforms (p38\u03b1, \u03b2, \u03b3, \u03b4) encoded by separate genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22720195", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 130, 
          "offsetInEndSection": 257, 
          "text": "Defining the roles of the various p38 family members, specifically p38alpha and p38beta, in these processes has been difficult.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17855341", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1841, 
          "offsetInEndSection": 2070, 
          "text": " The anomalous p38 inhibitor effect on IL-1alpha induction of MMP-3 and phosphorylation of p38 delta/gamma suggests complex interactions between p38 MAP kinase isoforms and their differential uses by TNFalpha and IL-1alpha in TM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591882", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1352, 
          "offsetInEndSection": 1497, 
          "text": "Human and porcine TM cells expressed p38 alpha, beta, delta, and gamma isoforms, which migrate coincident with bands of specific phosphorylation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17591882", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 342, 
          "text": "The mitogen-activated protein kinase (MAPK) p38 is a Ser/Thr kinase, originally isolated from lipopolysaccharide-stimulated monocytes. There are four isoforms of the enzyme (p38alpha, p38beta, p38gamma and p38delta), which differ in tissue distribution, regulation of kinase activation and subsequent phosphorylation of downstream substrates.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16022178", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 266, 
          "text": "We report the molecular cloning of a novel isoform of p38 MAP kinase, p38 beta 2.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430721", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 359, 
          "offsetInEndSection": 557, 
          "text": "The p38 MAP kinase kinase MKK6 is identified as a common activator of p38 alpha, p38 beta 2, and p38 gamma MAP kinase isoforms, while MKK3 activates only p38 alpha and p38 gamma MAP kinase isoforms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430721", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are BRAF mutations common in melanoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23903755", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23900694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23893853", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23890154", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23890105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23890088", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24325952", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24309328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24298448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24295639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24291778", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24289205", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24283590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24265155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24265154", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24265153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24259661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24258979", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24258977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24258972", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24252159", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24248543", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24220097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24202393", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24201813"
      ], 
      "type": "yesno", 
      "id": "5512c91b6a8cde6b7200000b", 
      "snippets": [
        {
          "offsetInBeginSection": 125, 
          "offsetInEndSection": 160, 
          "text": "patients with BRAF-mutant melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903755", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 585, 
          "offsetInEndSection": 607, 
          "text": "BRAF-mutated melanoma ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 421, 
          "text": "The RAS/RAF/MEK/ERK pathway has been reported to be activated in over 80% of all cutaneous melanomas, making it the focus of many scientific studies in the melanoma field. Discoveries of mutations and aberrant expression of components in this cascade, in particular, BRAF and NRAS render a deeper understanding of the mechanisms responsible for oncogenesis and provide new therapeutic strategies for this deadly disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23893853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 846, 
          "offsetInEndSection": 1010, 
          "text": " BRAF-targeted therapies (e.g., vemurafenib, dabrafenib) have showed impressive results in systemic therapy for melanoma harboring activating BRAF V600E mutations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23893853", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 301, 
          "offsetInEndSection": 460, 
          "text": " An independent cohort of 91 archival MUPs was also screened for 46 hot spot mutations highly prevalent in melanoma including BRAF, NRAS, KIT, GNAQ, and GNA11.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890154", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 580, 
          "offsetInEndSection": 746, 
          "text": " a high rate of BRAF (45 of 101, 45%) and NRAS (32 of 101, 32%) mutations, collectively indicating a mutation profile consistent with cutaneous sun-exposed melanomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890154", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 100, 
          "text": "Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890105", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 84, 
          "text": "BRAF is the most prevalent oncogene and an important therapeutic target in melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890088", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 353, 
          "text": "Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway, are common in a variety of human cancers. Several small molecule BRAF inhibitors have been developed during the last years and shown promising results in clinical trials, especially for metastatic melanoma, while they have been less effective in colon cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24325952", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 92, 
          "text": "BRAF mutations have emerged as an important predictive biomarker for metastasized melanoma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 734, 
          "offsetInEndSection": 849, 
          "text": "BRAF V600 selective inhibitors have been approved for the treatment of V600 mutation positive metastatic melanoma, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24298448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 29, 
          "offsetInEndSection": 67, 
          "text": "BRAF(V600) mutation-positive melanoma ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295639", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 280, 
          "text": "Melanoma is the most aggressive form of skin cancer. The treatment of patients with advanced melanoma is rapidly evolving due to an improved understanding of molecular drivers of this disease. Somatic mutations in BRAF are the most common genetic alteration found in these tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291778", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 40, 
          "offsetInEndSection": 146, 
          "text": " genetically activated BRAF, is now commonly prescribed for metastatic melanoma harboring a BRAF mutation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289205", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "BRAF inhibitors improve melanoma patient survival, but resistance invariably develops. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283590", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant melanoma, but acquired drug resistance is almost universal. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 112, 
          "text": "Most patients with BRAF(V600)-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265153", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 695, 
          "offsetInEndSection": 900, 
          "text": "BRAF(V600E) mutation confers constitutive BRAK kinase activation in melanoma cells, promoting tumor growth. This discovery led to the development of BRAF kinase inhibitors like vemurafenib and dabrafenib. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "(V600)BRAF mutation was identified as an ideal target for clinical therapy due to its indispensable roles in supporting melanoma initiation and progression.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258979", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "The Braf(V600E) mutation has been detected in patients with metastatic melanoma, colon, thyroid, and other cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258977", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 116, 
          "offsetInEndSection": 365, 
          "text": "Since the identification of activating BRAF mutations and subsequent development of drugs targeting the mutant BRAF protein, oncologists now need to incorporate prognostic and predictive biomarkers into treatment decisions for their melanoma patient", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258972", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 138, 
          "text": "BRAF mutations occur in approximately 8% of all human cancers and approach 50% in melanoma and papillary carcinoma of thyroid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252159", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 163, 
          "text": "Vemurafenib is a selective and potent small molecule inhibitor of the V600 mutant form of the BRAF protein used in the treatment of melanoma and colorectal cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24248543", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1178, 
          "offsetInEndSection": 1290, 
          "text": "Molecular studies demonstrated that the melanoma was positive for the 1799T>A (V600E) mutation in the BRAF gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24220097", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "RAF kinase inhibitors have substantial therapeutic effects in patients with BRAF-mutant melanoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24202393", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "An activating BRAF (V600E) kinase mutation occurs in approximately half of melanomas. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201813", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is protein M3/6 a dual specificity phosphatase?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23679081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23159405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22100391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11566103", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8910287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15888437"
      ], 
      "type": "yesno", 
      "id": "5512cce26a8cde6b7200000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Involvement of the dual-specificity phosphatase M3/6 in c-Jun N-terminal kinase inactivation following cerebral ischemia in the rat hippocampus.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 453, 
          "text": "The results revealed upregulation of dual-specificity phosphatase M3/6 (DUSP8) activity at 4\u00a0h of reperfusion in rat hippocampi. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 163, 
          "offsetInEndSection": 323, 
          "text": "This study examines the molecular mechanism underlying JNK dephosphorylation and inactivation evoked by dual-specificity phosphates following cerebral ischemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 677, 
          "text": "Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 448, 
          "text": "Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22100391", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 637, 
          "offsetInEndSection": 702, 
          "text": "M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566103", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 555, 
          "text": "Here we describe two new dual specificity phosphatases of the CL100/MKP-1 family that are selective for inactivating ERK or JNK/SAPK and p38 MAP kinases when expressed in COS-7 cells. M3/6 is the first phosphatase of this family to display highly specific inactivation of JNK/SAPK and p38 MAP kinases. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8910287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 319, 
          "text": "We previously demonstrated that the dual specificity phosphatases (DSPs) MKP7 and M3/6 bind the scaffold JNK-interacting protein-1 (JIP-1) and inactivate the bound subset of JNK (1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15888437", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21332651", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18722880", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16616117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11984797", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11919388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9916508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8697423", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8656667"
      ], 
      "type": "factoid", 
      "id": "55149f156a8cde6b72000013", 
      "snippets": [
        {
          "offsetInBeginSection": 5, 
          "offsetInEndSection": 307, 
          "text": "Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) is a common cytogenetic abnormality associated with poor outcome in adults. This preliminary study, in the absence of substantial evidence, reported the prevalence of the BCR-ABL gene fusion in ALL patients by RT-PCR in Pakistan.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332651", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "The Philadelphia chromosome and its corresponding fusion gene, BCR-ABL, is one of the best-known genetic abnormalities in hematological malignancies. Major BCR-ABL translocation is much more common in chronic myelogenous leukemia (CML) and minor BCR-ABL in acute lymphoblastic leukemia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18722880", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16616117", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 198, 
          "text": "The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11984797", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 234, 
          "text": "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919388", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 187, 
          "offsetInEndSection": 761, 
          "text": "Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9916508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 263, 
          "text": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8656667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1012, 
          "offsetInEndSection": 1351, 
          "text": "There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8656667", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 532, 
          "text": "We studied two cases of chronic myelogenous leukemia (CML) with unusual variant Philadelphia (Ph) translocation (22;22)(q11;q13). Southern blot analysis showed a chromosomal break in the BCR gene within the 5.8-kilobase (kb) breakpoint cluster region (bcr), between bcr exons 2 and 3 and between bcr exons 3 and 4, respectively. Chimeric bcr-abl mRNA was detected using polymerase chain reaction (PCR) which amplified, according to the respective bcr breakpoints, bcr exon 2-abl exon II and bcr exon 3-abl exon II junction products.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2204477", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List scaffold proteins of the ERK signaling pathway.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21615688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23987506", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21829671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17052209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11940661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10769183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23788642"
      ], 
      "type": "list", 
      "id": "55152bd246478f2f2c000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 344, 
          "text": "Human disc-large homolog (hDlg), also known as synapse-associated protein 97, is a scaffold protein, a member of the membrane-associated guanylate kinase family, implicated in neuronal synapses and epithelial-epithelial cell junctions whose expression and function remains poorly characterized in most tissues, particularly in the vasculature. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615688", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 428, 
          "offsetInEndSection": 656, 
          "text": "Using the yeast two-hybrid system to screen a human aorta cDNA library, we identified mitogen-activated protein/extracellular signal-responsive kinase (ERK) kinase (MEK)2, a member of the ERK cascade, as an hDlg binding partner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615688", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1296, 
          "offsetInEndSection": 1566, 
          "text": "Taken together, these findings allow us to hypothesize that hDlg acts as a MEK2-specific scaffold protein for the ERK signaling pathway, and may improve our understanding of how scaffold proteins, such as hDlg, differentially tune MEK1/MEK2 signaling and cell responses.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615688", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 240, 
          "offsetInEndSection": 468, 
          "text": "Here, we show that two scaffold proteins, caveolin-1 and IQGAP1, are required for phosphorylation of the actin associated pool of extracellular signal regulated kinase 1 and 2 (ERK1/2) in response to protein kinase C activation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23987506", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "ERK activation is enhanced by the scaffolding proteins KSR and MP1, localized near the cell membrane and late endosomes respectively, but little is known about their dynamic interplay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21829671", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 698, 
          "offsetInEndSection": 942, 
          "text": " Originally identified in yeast, scaffold proteins are now recognized to contribute to the specificity of MEK/ERK pathways in mammalian cells. These scaffolds include KSR (kinase suppressor of Ras), beta-arrestin, MEK partner-1, Sef and IQGAP1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17052209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 428, 
          "text": "Here we analyze a potential scaffold of the Ras/mitogen-activated protein kinase (MAPK) pathway, kinase suppressor of Ras (KSR), by generating KSR-deficient mice. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11940661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 731, 
          "offsetInEndSection": 865, 
          "text": "This demonstrates that KSR is a bona fide scaffold that is not required for but enhances signaling via the Ras/MAPK signaling pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11940661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 94, 
          "offsetInEndSection": 422, 
          "text": "We reported previously that several 14-3-3 isotypes bind to protein kinase C (PKC)-zeta and facilitate coupling of PKC-zeta to Raf-1 [van der Hoeven, van der Wal, Ruurs, van Dijk and van Blitterswijk (2000) Biochem. J. 345, 297-306], an event that boosts the mitogen-activated protein kinase (ERK) pathway in Rat-1 fibroblasts. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10769183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 317, 
          "offsetInEndSection": 567, 
          "text": "In this study, IQGAP1 (IQ motif-containing GTPase-activating protein 1), a new Nrf2 interaction partner that we have published previously, was found to modulate MEK-ERK-mediated Nrf2 activation and induction of phase II detoxifying/antioxidant genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23788642", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1001, 
          "offsetInEndSection": 1118, 
          "text": "In the aggregate, these results suggest that IQGAP1 may play an important role in the MEK-ERK-Nrf2 signaling pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23788642", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the Barr body?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21416650", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23542155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16980188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15682788", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12915472", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6270519"
      ], 
      "type": "summary", 
      "id": "55152c0a46478f2f2c000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 188, 
          "text": "The Barr body is the inactive X chromosome in a female somatic cell. It is readily identified as plano-convex structure of 2-3 micron in diameter on the periphery of the nuclear membrane. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21416650", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "Human inactive X chromosome (Xi) forms a compact structure called the Barr body, which is enriched in repressive histone modifications such as trimethylation of histone H3 Lys9 (H3K9me3) and Lys27 (H3K27me3). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 352, 
          "text": "In the late 1940s, a microanatomist from London Ontario, Murray Barr, discovered a mark of sex chromosome status in bodily tissues, what came to be known as the 'Barr body'. This discovery offered an important diagnostic technology to the burgeoning clinical science community engaged with the medical interpretation and management of sexual anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 325, 
          "text": "Barr body is an inactivated X chromosome in the normal female somatic cell. Inactivation of these chromosomes is known as Lyonization. Lyonization has both genetic and clinical significance. Barr body can be easily identified with ordinary stains. It also helps in identifying the sex of an individual when used judiciously. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15682788", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 231, 
          "text": "The Barr body has long been recognized as the cytological manifestation of the inactive X chromosome (Xi) in interphase nuclei. Despite being known for over 50 years, relatively few components of the Barr body have been identified.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12915472", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 209, 
          "text": "One of the X-chromosomes by a random inactivation process condenses to form X-chromatin (Barr body) in early embryonic life. Once this occurs, it is final and fixed for that cell and all its descendants (1,2).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6270519", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 210, 
          "offsetInEndSection": 315, 
          "text": "However, numerous investigators have observed extreme variations in Barr body frequency in tumour cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6270519", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is the gene DUX4 epigenetically regulated in somatic cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23196547", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21288772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24278031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23593020", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21734574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21060811"
      ], 
      "type": "yesno", 
      "id": "55152c2946478f2f2c000005", 
      "snippets": [
        {
          "offsetInBeginSection": 590, 
          "offsetInEndSection": 853, 
          "text": "There are several genes on chromosome 4q35 region including DUX4 within D4Z4 repeats. Transcription of these genes is usually repressed by epigenetic modifications of this chromosomal region and also accumulation of transcriptional repressors to the repeat array.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196547", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 399, 
          "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "The human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 685, 
          "offsetInEndSection": 1029, 
          "text": " These mice recapitulate important epigenetic and DUX4 expression attributes seen in patients and controls, respectively, including high DUX4 expression levels in the germline, (incomplete) epigenetic repression in somatic tissue, and FSHD-specific variegated DUX4 expression in sporadic muscle nuclei associated with D4Z4 chromatin relaxation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 579, 
          "offsetInEndSection": 681, 
          "text": "DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734574", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1018, 
          "offsetInEndSection": 1625, 
          "text": "In contrast to control skeletal muscle and most other somatic tissues, full-length DUX4 transcript and protein is expressed at relatively abundant levels in human testis, most likely in the germ-line cells. Induced pluripotent (iPS) cells also express full-length DUX4 and differentiation of control iPS cells to embryoid bodies suppresses expression of full-length DUX4, whereas expression of full-length DUX4 persists in differentiated FSHD iPS cells. Together, these findings indicate that full-length DUX4 is normally expressed at specific developmental stages and is suppressed in most somatic tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060811", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the main NMD factors in Saccharomyces cerevisiae?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20675403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16043493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11238889"
      ], 
      "type": "list", 
      "id": "5516757c46478f2f2c000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 295, 
          "text": "In addition to their well-documented roles in the promotion of nonsense-mediated mRNA decay (NMD), yeast Upf proteins (Upf1, Upf2/Nmd2, and Upf3) also manifest translational regulatory functions, at least in vitro, including roles in premature translation termination and subsequent reinitiation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20675403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 377, 
          "text": "In Saccharomyces cerevisiae, nonsense-mediated mRNA decay (NMD) requires Upf1p, Upf2p, and Upf3p to accelerate the decay rate of two unique classes of transcripts: (1) nonsense mRNAs that arise through errors in gene expression, and (2) naturally occurring transcripts that lack coding errors but have built-in features that target them for accelerated decay (error-free mRNAs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16043493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 230, 
          "text": "In Saccharomyces cerevisiae, rapid degradation of nonsense-containing mRNAs requires the decapping enzyme Dcp1p, the 5'-to-3' exoribonuclease Xrn1p, and the three nonsense-mediated mRNA decay (NMD) factors, Upf1p, Nmd2p, and Upf3p", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11238889", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 401, 
          "offsetInEndSection": 641, 
          "text": "Our results indicate that Upf1p, Nmd2p, and Upf3p regulate decapping and exonucleolytic degradation of nonsense-containing mRNAs. In addition, we show that these factors also regulate the same processes in the degradation of wild-type mRNAs", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11238889", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the common feature in congenital central hypoventilation and Mowat-Wilson syndromes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17397038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16443855"
      ], 
      "type": "summary", 
      "id": "55167dec46478f2f2c00000a", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 982, 
          "text": "Hirschsprung's disease (HSCR) is a fairly frequent cause of intestinal obstruction in children. It is characterized as a sex-linked heterogonous disorder with variable severity and incomplete penetrance giving rise to a variable pattern of inheritance. Although Hirschsprung's disease occurs as an isolated phenotype in at least 70% of cases, it is not infrequently associated with a number of congenital abnormalities and associated syndromes, demonstrating a spectrum of congenital anomalies. Certain of these syndromic phenotypes have been linked to distinct genetic sites, indicating underlying genetic associations of the disease and probable gene-gene interaction, in its pathogenesis. These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 461, 
          "offsetInEndSection": 879, 
          "text": "On the other hand, about 30% of HSCR are syndromic. Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 642, 
          "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 644, 
          "offsetInEndSection": 764, 
          "text": "The RET locus was genotyped in 143 CCHS patients, among whom 44 had HSCR, and in 30 MWS patients, among whom 20 had HSCR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 976, 
          "offsetInEndSection": 1077, 
          "text": "RET was shown to act as a modifier gene for the HSCR phenotype in patients with CCHS but not with MWS", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is Dicer part of the RISC loading complex?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24303839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23550157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23511973", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23424633", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23272173", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23226452"
      ], 
      "type": "yesno", 
      "id": "5516fc8832767d0305000002", 
      "snippets": [
        {
          "offsetInBeginSection": 121, 
          "offsetInEndSection": 336, 
          "text": "Dicer is a component of the protein machinery (the RNA Induced Silencing Complex [RISC]) which is involved in catalyzing the formation of mature microRNAs from their precursors in the process of microRNA biogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24303839", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550157", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 305, 
          "text": "The cytoplasmic RNA-induced silencing complex (RISC) contains dsRNA binding proteins, including protein kinase RNA activator (PACT), transactivation response RNA binding protein (TRBP), and Dicer, that process pre-microRNAs into mature microRNAs (miRNAs) that target specific mRNA species for regulation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 414, 
          "offsetInEndSection": 761, 
          "text": " Although the major RNAi pathway proteins are found in most subcellular compartments, the miRNA- and siRNA-loaded Ago2 populations co-sediment almost exclusively with the rER membranes, together with the RISC loading complex (RLC) factors Dicer, TAR RNA binding protein (TRBP) and protein activator of the interferon-induced protein kinase (PACT).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23511973", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 104, 
          "offsetInEndSection": 307, 
          "text": "RNA interference (RNAi) is mediated by small interfering RNAs (siRNAs), which are liberated from double-stranded (ds)RNA precursors by Dicer and guide the RNA-induced silencing complex (RISC) to targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424633", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 280, 
          "offsetInEndSection": 510, 
          "text": ". Dicer, an RNase III enzyme, plays a central role in the RNAi pathway by cleaving precursors of both of these classes of RNAs to form mature siRNAs and miRNAs, which are then loaded into the RNA-induced silencing complex (RISC). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272173", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 364, 
          "offsetInEndSection": 616, 
          "text": "Canonical siRNAs are 21 nucleotides (nt) in length and are loaded to the RNA Induced Silencing Complex when introduced into the cells, while longer siRNA molecules are first processed by endogenous Dicer and thus termed Dicer-substrate siRNA (DsiRNA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23226452", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17706594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17341613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17156427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15798210", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11735129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11007777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10974562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10956665"
      ], 
      "type": "list", 
      "id": "5517f9286487737b43000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "The single genomic locus, AbetaH-J-J, encodes three functionally distinct proteins aspartyl beta-hydroxylase, junctin and junctate by alternative splicing.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17706594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "The human AbetaH-J-J locus is a genomic sequence which generates three functionally distinct proteins, the enzyme aspartyl-beta-hydroxylase (AbetaH), the structural protein of sarcoplasmic reticulum junctin, and the membrane-bound calcium binding protein junctate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17341613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 367, 
          "text": "Aspartyl (asparaginyl)-beta-hydroxylase (AAH) hydroxylates Asp and Asn residues within EGF-like domains of Notch and Jagged, which mediate cell motility and differentiation. This study examines the expression, regulation and function of AAH, and its related transcripts, Humbug and Junctin, which lack catalytic domains, using SH-Sy5y neuroblastoma cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17156427", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 271, 
          "text": "Alternative splicing of the locus AbetaH-J-J generates three functionally distinct proteins: an enzyme, AbetaH (aspartyl-beta-hydroxylase), a structural protein of the sarcoplasmic reticulum membrane (junctin), and an integral membrane calcium binding protein (junctate).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15798210", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "Junctate is a newly identified integral ER/SR membrane calcium binding protein, which is an alternative splicing form of the same gene generating aspartyl beta-hydroxylase and junctin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11735129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 185, 
          "offsetInEndSection": 374, 
          "text": "Screening a mouse heart cDNA library using canine junctin cDNA as a probe yielded three complete mouse heart cDNAs. One of the cDNAs is homologous to the previously reported human junctate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11735129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 641, 
          "text": "Screening a cDNA library from human skeletal muscle and cardiac muscle with a cDNA probe derived from junctin led to the isolation of two groups of cDNA clones. The first group displayed a deduced amino acid sequence that is 84% identical to that of dog heart junctin, whereas the second group had a single open reading frame that encoded a polypeptide with a predicted mass of 33 kDa, whose first 78 NH(2)-terminal residues are identical to junctin whereas its COOH terminus domain is identical to aspartyl beta-hydroxylase, a member of the alpha-ketoglutarate-dependent dioxygenase family. We named the latter amino acid sequence junctate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11007777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1832, 
          "offsetInEndSection": 2080, 
          "text": "Our study shows that alternative splicing of the same gene generates the following functionally distinct proteins: an enzyme (aspartyl beta-hydroxylase), a structural protein of SR (junctin), and a membrane-bound calcium binding protein (junctate).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11007777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 864, 
          "text": "Junctin is a calsequestrin binding protein detected in junctional sarcoplasmic reticulum of striated muscles. In the present study, the human cardiac junctin cDNA has been cloned by human heart cDNA library screening and RT-PCR, and the cDNA sequence has been determined. The deduced amino acid sequence of human junctin (210 aa) has 84% sequence identity to that of canine junctin identified previously. A human junctin isoform (isoform 1, 225 aa) was also identified and characterized. The isoform 1 has a 15 aa insertion at the amino acid residue 55 of the human junctin. Northern blot analysis revealed that the human junctin was present both in cardiac and skeletal muscles, and the sizes of the transcripts were approximately 3.0 and 4.2kb. Amino acid residues 6-78 of human junctin and 35-107 of human aspartyl beta-hydroxylase (hAspH) overlapped perfectly.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10974562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 610, 
          "text": "The mouse aspartyl beta-hydroxylase gene (Asph, BAH) has been cloned and characterized. The mouse BAH gene spans 200 kilobase pairs of genomic DNA and contains 24 exons. Of three major BAH-related transcripts, the two largest (6,629 and 4,419 base pairs) encode full-length protein and differ only in the use of alternative polyadenylation signals. The smallest BAH-related transcript (2,789 base pairs) uses an alternative 3' terminal exon, resulting in a protein lacking a catalytic domain. Evolutionary conservation of this noncatalytic isoform of BAH (humbug) is demonstrated in mouse, man, and Drosophila.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10956665", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the typical rash associated with gluten ?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22547981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21159258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17340026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15953332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15489956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15033190", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14632800", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12485471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12459520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11247893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9824575", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9814827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9407155", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8881298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8521118"
      ], 
      "type": "factoid", 
      "id": "55180ef46487737b43000006", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "Dermatitis herpetiformis (DH) is an autoimmunity-driven inflammatory blistering dermatosis associated with a gluten-dependent enteropathy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22547981", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Dermatitis herpetiformis is an autoimmune blistering disease that appears as a cutaneous manifestation of gluten intolerance. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 627, 
          "offsetInEndSection": 845, 
          "text": "Treatment of dermatitis herpetiformis is based on a life-long, strict gluten-free diet, which improves all clinical aspects of gluten sensitivity, and dapsone, a drug that is only effective for the skin manifestations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21159258", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Dermatitis herpetiformis and coeliac disease are gluten-sensitive diseases that share immunopathological mechanisms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17340026", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 271, 
          "offsetInEndSection": 491, 
          "text": "We report the unusual case of an 8-month-old child presenting to his general practitioner with pruritic skin lesions, subsequently proven to be dermatitis herpetiformis (DH) as the first sign of gluten-sensitive disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15953332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "Dermatitis herpetiformis (DH) is an autoimmune blistering skin disorder that is associated with gluten sensitivity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15489956", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 688, 
          "offsetInEndSection": 927, 
          "text": " These findings may relate to the fact, that dermatitis herpetiformis is associated with gluten sensitive enteropathy, coeliac disease, which is characterised by IgA type autoantibodies to a closely related enzyme, tissue transglutaminase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15033190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1175, 
          "offsetInEndSection": 1440, 
          "text": " There is growing evidence that dermatitis herpetiformis should be considered as the skin manifestation of gluten sensitivity developing in those patients with mild coeliac disease, who produce epidermal transglutaminase autoantibodies of high avidity and affinity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15033190", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "BACKGROUND: A life-long gluten-free diet is the treatment of choice for dermatitis herpetiformis, which is considered to be coeliac disease of the skin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14632800", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1434, 
          "offsetInEndSection": 1582, 
          "text": "We report long-term clinical and histological remissions in seven patients with dermatitis herpetiformis after the reintroduction of dietary gluten.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14632800", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "Gluten sensitive enteropathy has various manifestations, of which the two major forms are classical coeliac disease (cCD) and dermatitis herpetiformis (DH).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 152, 
          "offsetInEndSection": 331, 
          "text": "The major significant advances in our understanding of DH have been the demonstration that DH patients also have coeliac diseases (CD) and that the rash is also gluten dependent. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12459520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 554, 
          "offsetInEndSection": 755, 
          "text": "Despite the fact that it has been known for over fifty years that gluten causes the enteropathy of CD, and for over thirty years the rash of DH, it is still not known how gluten produces these effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12459520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "BACKGROUND: Dermatitis herpetiformis (DH) is a specific dermatological manifestation of coeliac disease and 80% of DH patients have gluten sensitive enteropathy manifested by crypt hyperplasia and villous atrophy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11247893", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 490, 
          "text": "The presence of a rash is also a sensitive indicator of gluten ingestion in dermatitis herpetiformis, and this was used to study whether patients with this disease could also tolerate oats. PATIENTS/METHODS: Eleven patients with dermatitis herpetiformis in remission on a gluten-free diet were challenged daily with 50 g oats for six months.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9824575", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Dermatitis herpetiformis (DH) is a lifelong, gluten-sensitive, blistering skin disease with pathognomonic immunoglobulin (Ig)A deposits in the papillary dermis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9814827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1460, 
          "offsetInEndSection": 1629, 
          "text": "CONCLUSIONS: Patients with dermatitis herpetiformis can include moderate amounts of oats in their gluten-free diets without deleterious effects to the skin or intestine.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9407155", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "BACKGROUND: Dermatitis herpetiformis (DH) is a chronic papulovesicular immune-mediated disorder associated with gluten-sensitive enteropathy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8881298", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 283, 
          "text": "Serum IgA class antigliadin antibodies (IgA-AGA) are increased in untreated patients with coeliac disease and dermatitis herpetiformis (DH), and it has been suggested that salivary IgA-AGA measurements could be used as a non-invasive screening test for gluten-sensitive enteropathy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8521118", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What are the breath test biomarkers of pulmonary tuberculosis", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23737604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23499413", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22366996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21219679", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20189456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19481976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16635588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16194024"
      ], 
      "type": "list", 
      "id": "55181d1e6487737b43000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 185, 
          "text": "BACKGROUND: Nitric oxide (NO), a key macrophage antimycobacterial mediator that ameliorates immunopathology, is measurable in exhaled breath in individuals with pulmonary tuberculosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1507, 
          "offsetInEndSection": 1677, 
          "text": "CONCLUSIONS: Among patients with pulmonary tuberculosis, impaired pulmonary NO bioavailability is associated with more-severe disease and delayed mycobacterial clearance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1123, 
          "offsetInEndSection": 1331, 
          "text": "Four KI windows corresponded with KI values of VOCs previously identified as biomarkers of pulmonary TB and metabolic products of M. tuberculosis, principally derivatives of naphthalene, benzene and alkanes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 93, 
          "text": "Measurement of exhaled nitric oxide as a potential screening tool for pulmonary tuberculosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219679", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1119, 
          "offsetInEndSection": 1370, 
          "text": "CONCLUSION: While eNO measurement has limited value in the direct diagnosis of pulmonary TB, it may be worth developing and evaluating as a cost-effective replacement of chest X-ray in screening algorithms of pulmonary TB where X-ray is not available.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21219679", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1434, 
          "offsetInEndSection": 1577, 
          "text": "CONCLUSIONS/SIGNIFICANCE: Urea breath testing may provide a useful diagnostic and biomarker assay for tuberculosis and for treatment response. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 773, 
          "offsetInEndSection": 1009, 
          "text": "RESULTS: Breath VOCs contained apparent biomarkers of active pulmonary tuberculosis comprising oxidative stress products (alkanes and alkane derivatives) and volatile metabolites of M. tuberculosis (cyclohexane and benzene derivatives).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20189456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "Pulmonary tuberculosis may alter volatile organic compounds (VOCs) in breath because Mycobacteria and oxidative stress resulting from Mycobacterial infection both generate distinctive VOCs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16635588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1705, 
          "offsetInEndSection": 2095, 
          "text": "We conclude that volatile biomarkers in breath were sensitive and specific for pulmonary tuberculosis: the breath test distinguished between \"sick versus well\" i.e. between normal controls and patients hospitalized for suspicion of pulmonary tuberculosis, and between infected versus non-infected patients i.e. between those whose sputum cultures were positive or negative for Mycobacteria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16635588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 532, 
          "offsetInEndSection": 782, 
          "text": "RESULTS: The concentrations of H202 and TBARs (1022.96+/-186.02 nM and 4.22+/-0. 80 microM, respectively) were significantly higher in patients with tuberculosis as compared with the controls (398.15+/-37.10 nM and 0.48+/-0.17 microM, respectively). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16194024", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List the diseases for which there are point-of-care breath tests", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24305596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24299143", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23462278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23471596", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23601567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23708532", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23772662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22771606", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22209594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22134047", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21619467", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20973886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20507559", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20495659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19717480", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19248196", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18657870", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18619827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18420865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18367951", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18045887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17868431", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16887493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16377649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16326150", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15963485", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15006940", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12877652", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12540328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11215996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10443811"
      ], 
      "type": "list", 
      "id": "551829a76487737b43000009", 
      "snippets": [
        {
          "offsetInBeginSection": 861, 
          "offsetInEndSection": 1145, 
          "text": "Additionally, we try to clarify controversial issues concerning possible experimental malpractice in the field, and propose ways to translate the basic science results as well as the mechanistic understanding to tools (sensors) that could serve as point-of-care diagnostics of cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24305596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "Point of care monitoring of hemodialysis patients with a breath ammonia measurement device based on printed polyaniline nanoparticle sensors.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299143", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 887, 
          "offsetInEndSection": 1152, 
          "text": " Excellent intraindividual correlations were demonstrated between breath ammonia and BUN (0.86 to 0.96), which demonstrates the possibility of using low cost point of care breath ammonia systems as a noninvasive means of monitoring kidney dysfunction and treatment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299143", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 321, 
          "offsetInEndSection": 452, 
          "text": "Recently, fractional exhaled nitric oxide (FeNO) has emerged as an important biomarker for the assessment and management of asthma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462278", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 137, 
          "offsetInEndSection": 374, 
          "text": "Here we discuss the potential of adapting a technology from the electronics industry, surface acoustic wave (SAW) sensors, for diagnosis of multiple markers of sepsis in real time, using non-invasive assays of exhaled breath condensate. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23471596", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1555, 
          "offsetInEndSection": 1674, 
          "text": "Together these data indicate that FeNO testing has an important role in the assessment and management of adult asthma. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23601567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "Measurement of acetone in human breath samples has been previously shown to provide significant non-invasive diagnostic insight into the control of a patient's diabetic condition. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23708532", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1374, 
          "offsetInEndSection": 1487, 
          "text": " Urea breath testing may provide a useful diagnostic and biomarker assay for tuberculosis and treatment response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22771606", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1544, 
          "offsetInEndSection": 1678, 
          "text": "These animal model results suggest that exhaled breath can be used as a point-of-care tool for the diagnosis and monitoring of sepsis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22209594", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Point-of-care breath test for biomarkers of active pulmonary tuberculosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "RATIONALE: Volatile organic compounds (VOCs) in breath provide biomarkers of tuberculosis (TB) because Mycobacterium tuberculosis manufactures VOC metabolites that are detectable in the breath of infected patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1730, 
          "offsetInEndSection": 1862, 
          "text": "CONCLUSIONS: A six-minute point-of-care breath test for volatile biomarkers accurately identified subjects with active pulmonary TB.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647661", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 252, 
          "text": "Selected ion flow tube-mass spectrometry (SIFT-MS) can measure volatile compounds in breath on-line in real time and has the potential to provide accurate breath tests for a number of inflammatory, infectious and metabolic diseases, including diabetes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1093, 
          "offsetInEndSection": 1252, 
          "text": "Breath analysis by SIFT-MS offers a rapid, reproducible and easily performed measurement of acetone concentration in ambulatory patients with type 2 diabetes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134047", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1151, 
          "offsetInEndSection": 1309, 
          "text": "IGR is a new approach for non-invasive cardiac output measurement in mechanically ventilated individuals, but requires further investigation for clinical use.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21619467", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 907, 
          "offsetInEndSection": 1203, 
          "text": "The liver metabolic breath test relies on measuring exhaled (13) C tagged methacetin, which is metabolized only by the liver. Measuring this liver-specific substrate by means of molecular correlation spectroscopy is a rapid, non-invasive method for assessing liver function at the point-of-care. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973886", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1320, 
          "offsetInEndSection": 1562, 
          "text": "Our recent findings regarding the ability of point-of-care (13) C MBT to assess the hepatic functional reserve in patients with acute and chronic liver disease are reviewed along with suggested treatment algorithms for common liver disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973886", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1434, 
          "offsetInEndSection": 1576, 
          "text": "CONCLUSIONS/SIGNIFICANCE: Urea breath testing may provide a useful diagnostic and biomarker assay for tuberculosis and for treatment response.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1341, 
          "offsetInEndSection": 1487, 
          "text": "CONCLUSIONS: The non-invasive real-time BreathID GBT reliably assesses changes in liver glucose metabolism, and the degree of insulin resistance. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20507559", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1226, 
          "offsetInEndSection": 1343, 
          "text": "DISCUSSION: The LiMAx test can validly determine liver function capacity and is feasible in every clinical situation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20495659", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1082, 
          "offsetInEndSection": 1289, 
          "text": "A P(ET,CO(2)) of >or=36 mmHg may reliably exclude PE. Accuracy is augmented by combination with Wells score. P( ET,CO(2)) should be prospectively compared to D-dimer in accuracy and simplicity to exclude PE.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19717480", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19248196", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 969, 
          "offsetInEndSection": 1108, 
          "text": "CONCLUSION: The (13)C-MBT provides a rapid, non-invasive assessment of liver function in acute severe liver disease of diverse etiologies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19248196", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 985, 
          "offsetInEndSection": 1206, 
          "text": "CONCLUSION: The determination of CO by IGR and CWD revealed a good agreement and reproducibility with a low rate of impossible measurements, suggesting that IGR and CWD can be used interchangeably in the clinical setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18657870", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 116, 
          "text": "BACKGROUND: Exhaled NO (FE(NO)) is a useful biomarker for the monitoring of asthma control and response to therapy. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18619827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1558, 
          "offsetInEndSection": 1896, 
          "text": "A high percentage of patients with different severities of asthma and regardless of their treatment with ICS and current smoking habit (current and/or ex-smokers) had highly elevated FE(NO) values, suggesting that their current therapy was possibly insufficient to control the underlying degree of airway inflammation and asthma symptoms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18619827", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 397, 
          "offsetInEndSection": 602, 
          "text": "H. pylori-positive status was defined by positivity on at least 2 tests: a commercial H. pylori stool antigen enzyme immunoassay, an immunoglobulin G antibody enzyme immunoassay, and the C-urea breath test", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367951", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "End-tidal carbon dioxide measurements in children with acute asthma.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045887", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1432, 
          "offsetInEndSection": 1539, 
          "text": "CONCLUSIONS: Noninvasive bedside measurement of EtCO2 values among children with acute asthma is feasible. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "Review article: the assessment of liver function using breath tests.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17868431", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 394, 
          "offsetInEndSection": 548, 
          "text": "The recent development of a real-time, point-of-care liver function breath test has made it straightforward to assess the metabolic function of the liver.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17868431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 723, 
          "offsetInEndSection": 985, 
          "text": "RESULTS: The (13)C-methacetin breath test enables accurate follow-up of patients with acute or chronic liver damage, where overall hepatic function is significantly suppressed by known causes of liver disorders, including acute, sub-acute or chronic conditions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17868431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1112, 
          "offsetInEndSection": 1294, 
          "text": "CONCLUSIONS: Breath testing that provides continuous quantification of methacetin metabolism may be a sensitive tool for the diagnosis and follow-up of patients with liver disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17868431", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 248, 
          "offsetInEndSection": 497, 
          "text": " A multi-center study in a multi-ethnic population compared the RAPIRUN urine antibody test with the (13)C-urea breath test (C-UBT) and a traditional serologic test, the high-molecular-weight cell-associated protein enzyme immunoassay (HM-CAP EIA). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16887493", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1400, 
          "offsetInEndSection": 1666, 
          "text": "CONCLUSION: EGA provided non-invasive, accurate, continuous, high-resolution COHb% measurements. Applying EGA to carboxyhaemoglobin dilution, we achieved RCV measurements with accuracy equivalent to that of CO-haemoximetry, with one-fifth of the COB infusion volume.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16377649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 957, 
          "offsetInEndSection": 1162, 
          "text": " These results suggest that the IR device, which is small, light-weight, and rugged may enable the foreign gas uptake method to be used in clinical, field, and point-of-care settings for Q (T) measurement.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16326150", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 156, 
          "text": "UNLABELLED: The 13C-urea breath test provides non-invasive testing for Helicobacter pylori infection with the possibility of analysis at the point of care. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15963485", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1827, 
          "offsetInEndSection": 1968, 
          "text": "CONCLUSION: Fdlate, a variable of VCap, had a statistically better diagnostic performance in suspected PE than the PaCO(2)-EtCO(2) gradient. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006940", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1451, 
          "offsetInEndSection": 1566, 
          "text": " In conclusion, the investigated rebreathing system allows for a non-invasive determination of PBF at the bedside. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12877652", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Non-invasive measurement of pulmonary blood flow during prone positioning in patients with early acute respiratory distress syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12877652", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 141, 
          "text": "The 13C-urea breath test provides accurate, noninvasive diagnosis of active Helicobacter pylori infection and can document posttherapy cure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12540328", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 223, 
          "text": "A portable Fourier transform infrared (FT-IR) multicomponent point-of-care analyzer was tested for the diagnosis of methanol intoxications. Breath analysis with FT-IR was fast and easy, and no sample preparation was needed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11215996", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 875, 
          "offsetInEndSection": 969, 
          "text": "CONCLUSIONS: The Fd(late) is a valuable tool for bedside screening of PE in surgical patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10443811", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene(s) should be genotyped in order to prescribe the drug Cetuximab (anti-EGFR)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24152305", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23671647", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23299277", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22735045", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22287728", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21851273", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21686179", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21673069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21036743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20645028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20637356", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20619739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19368524", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19367287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19343364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18810446"
      ], 
      "type": "list", 
      "id": "5518414a15fa47643f000001", 
      "snippets": [
        {
          "offsetInBeginSection": 222, 
          "offsetInEndSection": 473, 
          "text": "Treatment of metastatic colorectal cancer with targeted anti-EGFR therapeutics such as cetuximab extends survival in only 25% of patients who test wild-type for KRAS, while the majority of patients prove resistant (J Clin Oncol 28(7):1254-1261, 2010).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 657, 
          "offsetInEndSection": 973, 
          "text": ". Somatic mutation of the EGFR signalling pathway is a prevalent mechanism of resistance to cetuximab (Nature 486(7404):532-536, 2012). If the human genome harbours variants that influence susceptibility of the EGFR pathway to oncogenic mutation, such variants could also be prognostic for cetuximab responsiveness. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152305", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 111, 
          "offsetInEndSection": 271, 
          "text": "KRAS mutations are strong predictors for clinical outcomes of EGFR-targeted treatments such as cetuximab and panitumumab in metastatic colorectal cancer (mCRC).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671647", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 176, 
          "text": "KRAS mutation is widely accepted as a strong, negative predictive marker for anti-epidermal growth factor receptor antibodies, including cetuximab and panitumumab. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299277", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 279, 
          "text": "KRAS status is now a mandatory prerequisite in order to treat metastatic colorectal patients with anti-Epidermal Growth Factor Receptor (EGFR) antibodies, such as cetuximab or panitumumab. KRAS mutations are unambiguously linked to a lack of response to these targeted therapies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22735045", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1180, 
          "offsetInEndSection": 1335, 
          "text": "The EGFR-R497K polymorphism is a potential predictor for overall survival in HNSCC patients treated with cetuximab based therapy in the palliative setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287728", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 327, 
          "text": "Laboratories are increasingly required to perform molecular tests for the detection of mutations in the KRAS gene in metastatic colorectal cancers to allow better clinical management and more effective treatment for these patients. KRAS mutation status predicts a patient's likely response to the monoclonal antibody cetuximab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21851273", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 152, 
          "text": "KRAS mutation has been unambiguously identified as a marker of resistance to cetuximab-based treatment in metastatic colorectal cancer (mCRC) patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21686179", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1637, 
          "offsetInEndSection": 1848, 
          "text": " This study suggested EGF A+61G polymorphism to be a predictive marker for pCR, independent of KRAS mutation status, to cetuximab-based neoadjuvant chemoradiation of patients with locally advanced rectal cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21673069", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 1076, 
          "text": "Intratumoral gene expression levels of EGFR, VEGFR2 and NRP as well as polymorphisms in FCGR3A, CyclinD1 and EGFR could predict clinical outcome in mCRC patients enrolled in BOND2, independent of KRAS mutation status.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21036743", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 624, 
          "text": "Numerous clinical studies have shown that anti-EGFR therapies are effective only in a subset of patients with colorectal cancer. Even though mutations in the KRAS gene have been confirmed as negative predictors of the response to EGFR-targeted therapies, not all KRAS wild-type (wt-KRAS) patients will respond to treatment. Recent studies have demonstrated that additionally wild-type BRAF (wt-BRAF) genotype is required for response to panitumumab or cetuximab, suggesting that BRAF genotype criteria should be used together with KRAS genotype for selecting the patients who are about to benefit from the anti-EGFR therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20645028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1158, 
          "offsetInEndSection": 1366, 
          "text": "KRAS mutation is a dramatic example of single nucleotide polymorphism, which is able to identify a priori patients that could receive or not an anti-EGFR monoclonal antibody such as cetuximab or panitumumab. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20637356", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 3095, 
          "offsetInEndSection": 3286, 
          "text": "While confirming the negative effect of KRAS mutations on outcome after cetuximab, we show that BRAF, NRAS, and PIK3CA exon 20 mutations are significantly associated with a low response rate.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20619739", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 253, 
          "text": "Cetuximab and panitumumab, mAbs targeting EGFR, are registered for metastatic colorectal carcinoma (mCRC) patients whose tumors express EGFR as determined by immunohistochemistry. However, this method is not predictive of treatment efficacy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19368524", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1079, 
          "offsetInEndSection": 1328, 
          "text": ". This study suggests that TP53 mutations are predictive of cetuximab sensitivity, particularly in patients without KRAS mutation, and that TP53 genotyping could have a clinical interest to select patients who should benefit from cetuximab-based CT.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19367287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1250, 
          "offsetInEndSection": 1358, 
          "text": "A KRAS mutation confers resistance to cetuximab, which reduces treatment options, especially in first-line. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19343364", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 877, 
          "offsetInEndSection": 1032, 
          "text": "KRAS genotyping was recently introduced as predictive biomarker, since only tumors carrying a wildtype were found to respond to treatment with panitumumab.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18810446", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List protein gel staining methods visualizing the entire protein set.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24136520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24114871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24043422", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23977684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23941326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23681577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23428344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23256673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23161123", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22821490", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22665294"
      ], 
      "type": "list", 
      "id": "55184d46622b194345000001", 
      "snippets": [
        {
          "offsetInBeginSection": 707, 
          "offsetInEndSection": 803, 
          "text": "DIGE requires the labelling of proteins by fluorochromes prior to their separation on 2DE gels. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24136520", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 91, 
          "text": "Stains-All (ISA) staining method for phosphoproteins in SDS-PAGE was described.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 353, 
          "text": " Pro-Q Diamond stain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24114871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "Quantitative proteome analyses suggest that the well-established stain colloidal Coomassie Blue, when used as an infrared dye, may provide sensitive, post-electrophoretic in-gel protein detection that can rival even Sypro Ruby.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24043422", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "Several new fast staining protocols for the visualization of proteins separated by SDS-PAGE utilizing Coomassie Blue staining (CBS) have been described in literature. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 176, 
          "text": "The CyDye family of fluorescent dyes is currently the overwhelming choice for applications in proteomic analysis, using two-dimensional difference gel electrophoresis (2D-DIGE)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23941326", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 666, 
          "offsetInEndSection": 945, 
          "text": "his enables the co-detection of phosphoproteins as well as total proteins from the same gel and is accomplished by utilizing two different fluorescent stains, the ProQ-Diamond, which stains only phosphorylated proteins, and Sypro Ruby, which stains the entire subset of proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 178, 
          "offsetInEndSection": 449, 
          "text": "Detection of the resulting protein maps relies on staining (i.e. colloidal coomassie blue (CCB) or SYPRO Ruby (SR), in addition to many others). Fluorescent in-gel protein stains are generally preferred for higher sensitivity, reduced background, and wider dynamic range.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23428344", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 486, 
          "text": "Commonly used staining methods with excellent mass spectrometry compatibility are coomassie brilliant blue (CBB) or fluorescent dyes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23256673", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "The typical concentration of protein loaded varies from 0.13 to 1.40 \u03bcg/\u03bcL for a classical silver staining method in 2DE gel", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161123", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Silver staining is widely used to detect protein in polyacrylamide gels when high sensitivity is required.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22821490", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Silver staining is used to detect proteins after electrophoretic separation on polyacrylamide gels", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665294", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the enzymes known as dual specificity phoshpatases (DUSPs)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24311790", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24308939", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24206177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24155099", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23926106", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23190643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22812510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22266315", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21764456", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21300429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21288197"
      ], 
      "type": "summary", 
      "id": "5518e7a7622b194345000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 180, 
          "text": "MAPK activity is negatively regulated by members of the dual specificity phosphatase (Dusp) family, which differ in expression, substrate specificity, and subcellular localization.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311790", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 333, 
          "text": "Dual-specificity phosphatases (DUSPs) dephosphorylate phosphotyrosine and phosphoserine/phosphothreonine residues on target MAPKs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24308939", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 340, 
          "text": " The dual-specificity phosphatases (DUSPs) constitute a heterogeneous group of cysteine-based protein tyrosine phosphatases, whose members exert a pivotal role in cell physiology by dephosphorylation of phosphoserine, phosphothreonine, and phosphotyrosine residues from proteins, as well as other non-proteinaceous substrates. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24206177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "Several dual-specificity phosphatases (DUSPs) that play key roles in the direct or indirect inactivation of different MAP kinases (MAPKs) have been implicated in human cancers over the past decade.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155099", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 247, 
          "text": "Dual-specificity MAP kinase phosphatases (MKPs) provide a complex negative regulatory network that acts to shape the duration, magnitude and spatiotemporal profile of MAP kinase activities in response to both physiological and pathological stimuli", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22812510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 409, 
          "text": "Dual-specificity phosphatases (DUSPs) is an emerging subclass of the protein tyrosine phosphatase gene superfamily, a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. Recently, a series of investigations of DUSPs defined their essential roles in cell proliferation, cancer and the immune response. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190643", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 260, 
          "text": "Mitogen-activated protein kinases (MAPKs) fulfill essential biological functions and are key pharmaceutical targets. Regulation of MAPKs is achieved via a plethora of regulatory proteins including activating MAPKKs and an abundance of deactivating phosphatases", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23926106", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288197", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 310, 
          "text": "Dual-specificity protein phosphatases participate in signal transduction pathways inactivating mitogen-activated protein kinases (MAP kinases). These signaling pathways are of critical importance in the regulation of numerous biological processes, including cell proliferation, differentiation and development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300429", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 106, 
          "text": "Dual specificity phosphatase 1 (DUSP1) dephosphorylates and, hence, regulates the activity of MAP kinases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764456", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 374, 
          "text": "Dual-Specificity Phosphatases (DUSPs) are enzymes that remove phosphate groups from both phospho-tyrosine and phospho-serine/threonine residues. A subgroup of DUSPs specifically targets Mitogen-Activated Protein Kinases (MAPKs) and has been shown to participate in the regulation of differential cellular responses to the large variety of stimuli conveyed by MAPK-pathways. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266315", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which MAP kinase phosphorylates the transcription factor c-jun?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24321566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24321066", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24300195", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24291243", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24285252", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24272171", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24270002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24252081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24144051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24139673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24113186", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15708845", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15637069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15228586"
      ], 
      "type": "factoid", 
      "id": "5518e7da622b194345000004", 
      "snippets": [
        {
          "offsetInBeginSection": 955, 
          "offsetInEndSection": 987, 
          "text": " c-Jun NH2-terminal kinase (JNK)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321566", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 213, 
          "offsetInEndSection": 294, 
          "text": " c-jun N-terminal kinase (JNK) of mitogen-activated protein kinase (MAPK) family ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321066", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 927, 
          "offsetInEndSection": 955, 
          "text": "-Jun N-terminal kinase (JNK)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300195", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 820, 
          "offsetInEndSection": 859, 
          "text": "activated c-Jun N-terminal kinase (JNK)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291243", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 919, 
          "offsetInEndSection": 1006, 
          "text": "-Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) signaling pathways", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285252", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 454, 
          "text": " c-Jun N-terminal kinases (JNK) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24272171", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1075, 
          "offsetInEndSection": 1116, 
          "text": " including c-Jun N-terminal kinase, c-Jun", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24270002", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 118, 
          "text": "The c-Jun N-terminal kinase (JNK) is thought to be involved in inflammation, proliferation and apoptosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252081", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 785, 
          "offsetInEndSection": 828, 
          "text": " c-Jun NH2-terminal protein kinases (JNK), ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144051", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1288, 
          "offsetInEndSection": 1357, 
          "text": " c-Jun N-terminal kinase (JNK) phosphorylation, c-Jun phosphorylation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139673", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1820, 
          "offsetInEndSection": 1893, 
          "text": "JNK phosphorylated recombinant c-Jun at T91/T93 in a T95-dependent manner", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24113186", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 826, 
          "offsetInEndSection": 898, 
          "text": " c-Jun N-terminal kinase (JNK) MAPKs (mitogen-activated protein kinases)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228586", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 170, 
          "text": "c-Jun N-terminal kinases (JNKs) are a group of mitogen-activated protein kinase family members that are important in regulating cell growth, proliferation, and apoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15637069", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 581, 
          "offsetInEndSection": 943, 
          "text": "Jun and Fos transcriptional activities are also regulated by phosphorylation as a result of the activation of intracellular signaling cascades. In this regard, the phosphorylation of c-Jun by UV-induced JNK has been readily documented, whereas a role for Fos proteins in UV-mediated responses and the identification of Fos-activating kinases has remained elusive", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15708845", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the different members/isoforms of the Ras oncogenes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24247240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24194124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23871832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23496764", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23412389", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23103856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22981836", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22648805", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22589270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21924373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21779495", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21779492"
      ], 
      "type": "list", 
      "id": "5518e817622b194345000006", 
      "snippets": [
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 172, 
          "text": "The major Ras isoforms (K, H, and N) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24247240", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Mutations in Ras isoforms such as K-Ras, N-Ras, and H-Ras contribute to roughly 85, 15, and 1% of human cancers, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24194124", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 249, 
          "text": "the Ras isoforms (H, N and K) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871832", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 39, 
          "text": "The mutant forms of KRas, NRas and HRas", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496764", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 149, 
          "offsetInEndSection": 190, 
          "text": " lipidated Ras isoforms (H-Ras and N-Ras)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23412389", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 10, 
          "offsetInEndSection": 134, 
          "text": ": H-Ras, K-Ras, and N-Ras regulate cellular growth and survival and are often activated by somatic mutation in human tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103856", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 263, 
          "offsetInEndSection": 327, 
          "text": "Human tumours frequently express Ras proteins (Ha-, Ki-, N-Ras) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22981836", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 120, 
          "offsetInEndSection": 175, 
          "text": " There are three major ras isoforms: H-, N- and K-Ras. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22648805", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22589270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 80, 
          "offsetInEndSection": 132, 
          "text": "hree closely related isoforms, HRAS, KRAS and NRAS, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21924373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 215, 
          "text": "H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21779495", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 380, 
          "offsetInEndSection": 422, 
          "text": "he 3 Ras isoforms-H-Ras, K-Ras, and N-Ras-", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21779492", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are EDNRB mutations involved in the development of Hirschsprung disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22132166", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21915282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20009762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16618617", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15834508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15294878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12574515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12355085", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11434563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11302967", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8852660"
      ], 
      "type": "yesno", 
      "id": "551910c5622b194345000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "QTL analysis identifies a modifier locus of aganglionosis in the rat model of Hirschsprung disease carrying Ednrb(sl) mutations", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132166", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 256, 
          "offsetInEndSection": 497, 
          "text": "As reported previously, when the same null mutation of the Ednrb gene, Ednrb(sl), was introgressed into the F344 strain, almost 60% of F344-Ednrb(sl/sl) pups did not show any symptoms of aganglionosis, appearing healthy and normally fertile.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132166", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Genetic background strongly modifies the severity of symptoms of Hirschsprung disease, but not hearing loss in rats carrying Ednrb(sl) mutations", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915282", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 325, 
          "offsetInEndSection": 570, 
          "text": "In this study, we found that the null mutation of the Ednrb gene, thought indispensable for enteric neuron development, is insufficient to result in HSCR disease when bred onto a different genetic background in rats carrying Ednrb(sl) mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21915282", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "New roles of EDNRB and EDN3 in the pathogenesis of Hirschsprung disease.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20009762", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 330, 
          "offsetInEndSection": 515, 
          "text": "The aim of this study was to evaluate the implication of the EDN3 and EDNRB genes in a series of patients with Hirschsprung disease from Spain and determinate their mutational spectrum.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20009762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 87, 
          "text": "A De Novo novel mutation of the EDNRB gene in a Taiwanese boy with Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16618617", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 382, 
          "text": "Although mutations in eight different genes (EDNRB, EDN3, ECE1, SOX10, RET, GDNF, NTN, SIP1) have been identified in affected individuals, it is now clear that RET and EDNRB are the primary genes implicated in the etiology of HSCR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16618617", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 408, 
          "text": "Mutations in genes of the RET receptor tyrosine kinase and endothelin receptor B (EDNRB) signaling pathways have been shown to be associated in HSCR patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Interactions between Sox10 and EdnrB modulate penetrance and severity of aganglionosis in the Sox10Dom mouse model of Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294878", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 110, 
          "offsetInEndSection": 319, 
          "text": "Molecular genetic analyses have revealed that interactions between mutations in the genes encoding the RET receptor tyrosine kinase and the endothelin receptor type B (EDNRB) are central to the genesis of HSCR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12574515", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 121, 
          "text": "Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12355085", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 987, 
          "offsetInEndSection": 1101, 
          "text": "Thus, genetic interaction between mutations in RET and EDNRB is an underlying mechanism for this complex disorder.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12355085", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 44, 
          "text": "EDNRB/EDN3 and Hirschsprung disease type II.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11434563", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302967", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 269, 
          "text": "wo susceptibility genes have been recently identified in HSCR, namely the RET proto-oncogene and the endothelin B receptor (EDNRB) gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8852660", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which proteins have been identified as RET ligands?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18970938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17638907", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16294336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12668632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11973622", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11409869", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11324313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11106284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10822229", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10790203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9885824", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9764818", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9700200"
      ], 
      "type": "list", 
      "id": "551910d3622b194345000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Polymorphisms in the genes encoding the 4 RET ligands, GDNF, NTN, ARTN, PSPN, and susceptibility to Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18970938", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 507, 
          "offsetInEndSection": 649, 
          "text": "Given the pivotal role of RET in HSCR, the genes encoding their ligands (GDNF, NRTN, ARTN, and PSPN) are also good candidates for the disease.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18970938", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1179, 
          "offsetInEndSection": 1308, 
          "text": "Indeed, the RET ligands persephin and GDNF robustly stimulated calcitonin mRNA, which was blocked by pretreatment with NVP-AST487", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17638907", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 226, 
          "offsetInEndSection": 301, 
          "text": "The ligands bind RET through GDNF family receptor alpha, termed GFRalpha1-4", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16294336", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 66, 
          "offsetInEndSection": 224, 
          "text": "RET is activated by members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands, which include GDNF, neurturin, artemin, and persephin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16294336", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "GDNF availability determines enteric neuron number by controlling precursor proliferation", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12668632", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 217, 
          "offsetInEndSection": 365, 
          "text": "Five germline mutations in the glial cell-line-derived neurotrophic factor (GDNF) gene, one of the RET ligands, have been detected in HSCR patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11973622", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 199, 
          "text": "The glial-cell-line-derived neurotrophic factor (GDNF) family receptors alpha (GFRalpha) are cell surface bound glycoproteins that mediate interactions of the GDNF ligand family with the RET receptor", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11409869", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 882, 
          "offsetInEndSection": 1035, 
          "text": "In particular, the recent identification of neurotrophic factors acting as RET ligands (GDNF and Neurturin) provide additional candidate genes for HSCR. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11324313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 467, 
          "offsetInEndSection": 663, 
          "text": "Mutations in genes that encode RET ligands (GDNF and NTN); components of another signaling pathway (EDNRB, EDN3, ECE-1); and the transcription factor, SOX10, have been identified in HSCR patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11106284", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10822229", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 214, 
          "offsetInEndSection": 418, 
          "text": "Mutations in the GDNF gene, and encoding one of the RET ligands, either alone or in combination with RET mutations, can also cause HSCR, as can mutations in four other genes (EDN3, EDNRB, ECE1, and SOX10)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 883, 
          "offsetInEndSection": 1036, 
          "text": "In particular, the recent identification of neurotrophic factors acting as RET ligands (GDNF and Neurturin) provide additional candidate genes for HSCR. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885824", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 260, 
          "text": "Ret ligands have been recently identified as the neuron survival factor GDNF (Glial-Derived Neurotrophic Factor) and Neurturin.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9764818", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "Mutation of the RET ligand, neurturin, supports multigenic inheritance in Hirschsprung disease", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9700200", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 300, 
          "offsetInEndSection": 555, 
          "text": "Considering that RET and glial cell line-derived neurotrophic factor (GDNF) mutations have been reported in the disease, we regarded the other RET ligand, neurturin (NTN), as an attractive candidate gene, especially as it shares large homologies with GDNF", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9700200", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is PLK2 involved in alpha-synuclein phosphorylation in Parkinson disease?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23983262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21050448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19004816"
      ], 
      "type": "yesno", 
      "id": "551910fa622b19434500000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "An increase in \u03b1-synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 316, 
          "offsetInEndSection": 540, 
          "text": "Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy-diseased brains, interacts with, phosphorylates and enhances \u03b1-synuclein autophagic degradation in a kinase activity-dependent manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1004, 
          "offsetInEndSection": 1219, 
          "text": "Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of \u03b1-synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983262", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 728, 
          "offsetInEndSection": 845, 
          "text": " \u03b1-Synuclein increased PLK2 levels and GSK-3\u03b2 activity and increased the levels of phosphorylated \u03b1-Synuclein and Tau", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21050448", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 96, 
          "text": "Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 184, 
          "text": "Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of alpha-synuclein phosphorylated at Ser-129 (p-Ser-129)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 293, 
          "offsetInEndSection": 477, 
          "text": "Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to alpha-synuclein phosphorylation at Ser-129 in neurons.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 566, 
          "text": "PLK2 directly phosphorylates alpha-synuclein at Ser-129 in an in vitro biochemical assay", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 975, 
          "text": "These results indicate that PLK2 plays a critical role in alpha-synuclein phosphorylation in central nervous system.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19004816", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23427148", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20621975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18192286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16760737", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10874640", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9571278", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7605558", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1785632", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23984569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23023332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22639450", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21307714", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20301454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17979970", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17303258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16970241", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15884042", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12846610", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9508238", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9130129", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8929375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8563763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7573131", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7573130"
      ], 
      "type": "factoid", 
      "id": "5519110f622b19434500000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Goldberg-Shprintzen syndrome (GOSHS, MIM #609460) is an autosomal recessive disorder of intellectual disability, specific facial gestalt and Hirschsprung's disease (HSCR).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427148", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Goldberg-Shprintzen syndrome (GOSHS) is a rare clinical disorder characterized by central and enteric nervous system defects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1208, 
          "offsetInEndSection": 1400, 
          "text": "Thus, our data indicate that KBP is involved in neuronal differentiation and that the central and enteric nervous system defects seen in GOSHS are likely caused by microtubule-related defects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621975", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Mutations in Kif1-binding protein/KIAA1279 (KBP) cause the devastating neurological disorder Goldberg-Shprintzen syndrome (GSS) in humans.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192286", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "We describe a brother and sister with Hirschsprung disease, hypotonia, and ptosis. Their condition resembles that in 2 sibs reported by Goldberg and Shprintzen.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1785632", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 147, 
          "text": "A 5-year-old girl with Hirschsprung disease, unusual facial appearance, psychomotor retardation, epilepsy, and congenital heart disease is reported", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 352, 
          "offsetInEndSection": 487, 
          "text": "Cranial computed tomography demonstrated abnormal findings that may suggest defective neuronal migration and/or dysgenesis of the brain", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605558", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 194, 
          "text": "In 1981, Goldberg and Shprintzen described siblings with short-segment Hirschsprung disease, cleft palate, microcephaly, mild mental retardation, short stature and distinctive facial appearance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9571278", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "A consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-Shprintzen syndrome)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10874640", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Hirschsprung disease, mental retardation, microcephaly, and specific craniofacial dysmorphism were observed in three children from a large, consanguineous, Moroccan family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10874640", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 283, 
          "offsetInEndSection": 402, 
          "text": "The patient showed dysmorphic facies and weakness of connective tissue, and was scheduled to undergo abdominal surgery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 443, 
          "offsetInEndSection": 558, 
          "text": "Shprintzen-Goldberg syndrome (SGS) has considerable phenotypic overlap with MFS and LDS, including aortic aneurysm.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23023332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 205, 
          "text": "We report on maternal half-sibs born to unaffected, non-consanguineous parents with classical Shprintzen-Goldberg syndrome (SGS) who had in addition intestinal malrotation and an aberrant subclavian artery", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639450", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 56, 
          "offsetInEndSection": 441, 
          "text": "keletal abnormalities common to 3 of them include bowing of long bones (with a variable degree of progression over time), flare of the metaphyses, a large anterior fontanel with persistent patency into the second to fourth years of life, 13 pairs of ribs, distinct vertebral abnormalities which were absent neonatally but evolved by the second year of life, and progressive osteopenia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 132, 
          "text": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573131", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 89, 
          "text": "Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8563763", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 503, 
          "text": "Additional common findings include other craniofacial anomalies, hypotonia, obstructive apnea, foot deformity, and congenital weakness of the abdominal wall", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8563763", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 122, 
          "offsetInEndSection": 372, 
          "text": " The radiological features were characterized by late-onset craniosynostosis, arachnodactyly, undermodeling of short tubular bones, mildly undermodeled and slightly bowed long bones, twisted ribs and tall vertebral bodies with elongated neural arches", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8929375", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Aortic root replacement for annuloaortic ectasia in Shprintzen-Goldberg syndrome: a case report", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9130129", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Annuloaortic ectasia due to Shprintzen-Goldberg syndrome (SGS) is reported", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9130129", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508238", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 195, 
          "text": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 195, 
          "text": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884042", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 768, 
          "offsetInEndSection": 913, 
          "text": "Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884042", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Shprintzen-Goldberg syndrome is a rare connective tissue disorder characterized by marfanoid habitus and additional dysmorphic stigmata.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16970241", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 129, 
          "text": "Overall intelligibility, language, articulation, voice and resonance characteristics in a child with Shprintzen-Goldberg syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303258", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17979970", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 25, 
          "offsetInEndSection": 802, 
          "text": "Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301454", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Surgical treatment for scoliosis in patients with Shprintzen-Goldberg syndrome.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307714", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 106, 
          "text": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307714", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23427518", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21336163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17932455", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16688751", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15908750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15006694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14681759", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11891681"
      ], 
      "type": "factoid", 
      "id": "5519113b622b19434500000f", 
      "snippets": [
        {
          "offsetInBeginSection": 219, 
          "offsetInEndSection": 275, 
          "text": "The cause of MWS is a de novo mutation in the ZEB2 gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427518", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 171, 
          "text": "zfhz1b is the causative gene for Mowat-Wilson syndrome, in which patients demonstrate developmental delay and Hirschsprung disease, as well as other anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21336163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 160, 
          "text": "Intrahepatic biliary anomalies in a patient with Mowat-Wilson syndrome uncover a role for the zinc finger homeobox gene zfhx1b in vertebrate biliary development", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21336163", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 458, 
          "offsetInEndSection": 565, 
          "text": "We used the zebrafish model system to determine whether zfhx1b has a role in vertebrate biliary development", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21336163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 133, 
          "text": "Comprehensive ZEB2 gene analysis for Mowat-Wilson syndrome in a North American cohort: a suggested approach to molecular diagnostics.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "A case of Mowat-Wilson syndrome caused by a truncating mutation within exon 8 of the ZEB2 gene", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427518", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 456, 
          "offsetInEndSection": 602, 
          "text": "All typical cases result from haploinsufficiency of the ZEB2 (also known as ZFHX1B or SIP-1) gene, with over 100 distinct mutations now described.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 603, 
          "offsetInEndSection": 774, 
          "text": "Approximately 80% of patients have a nonsense or frameshift mutation detectable by sequencing, with the rest having gross deletions necessitating a dosage sensitive assay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1039, 
          "offsetInEndSection": 1127, 
          "text": "Six patients had deletions in the ZEB2 gene, including two novel partial gene deletions.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1128, 
          "offsetInEndSection": 1373, 
          "text": "This report, the first such analysis in North American patients, adds to the growing list of both novel pathogenic mutations associated with MWS, as well as other variants in the ZEB2 gene. In addition, we suggest an economical testing strategy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Nonsense mutations of the ZFHX1B gene in two Japanese girls with Mowat-Wilson syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932455", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly-mental retardation complex caused by mutations in the Zinc Finger Homeobox 1 B gene (ZFHX1B)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 790, 
          "offsetInEndSection": 915, 
          "text": "According to the gene analysis using white blood cells, they had nonsense mutations in ZFHX1B, R695X and Q433X, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 916, 
          "offsetInEndSection": 1074, 
          "text": "In conclusion, molecular genetic analysis of ZFHX1B is important for a definite diagnosis of MWS which has a wide phenotypic spectrum of congenital anomalies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17932455", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "A missense mutation in the ZFHX1B gene associated with an atypical Mowat-Wilson syndrome phenotype", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16688751", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 332, 
          "offsetInEndSection": 638, 
          "text": "Mutations leading to haploinsufficiency of the ZFHX1B gene have been described as the underlying cause of this condition. We report on the clinical findings in a 2(1/2)-year-old boy with some aspects out of the MWS-spectrum in addition to unusual anomalies and a novel missense mutation in the ZFHX1B gene.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16688751", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 118, 
          "text": "Genitourinary anomalies in Mowat-Wilson syndrome with deletion/mutation in the zinc finger homeo box 1B gene (ZFHX1B).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15908750", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 422, 
          "offsetInEndSection": 500, 
          "text": "It is caused by mutations in the zinc finger homeo box 1B gene, ZFHX1B (SIP1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15908750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 172, 
          "text": "Pleiotropic and diverse expression of ZFHX1B gene transcripts during mouse and human development supports the various clinical manifestations of the \"Mowat-Wilson\" syndrome", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006694", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 149, 
          "text": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 287, 
          "text": "ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15006694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 119, 
          "text": "Frameshift mutation of the zinc finger homeo box 1 B gene in syndromic corpus callosum agenesis (Mowat-Wilson syndrome)", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681759", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 440, 
          "text": "Mutation analysis of the zinc finger homeo box 1 B (ZFHX1 B) gene revealed a de novo 7 bp deletion (TGGCCCC) at nucleotide 1773 (1773 delTGGCCCC) resulting in a frameshift and leading to a termination codon at amino acid residue 604 (604 X) in exon 8 C", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681759", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 204, 
          "text": "\"Mowat-Wilson\" syndrome with and without Hirschsprung disease is a distinct, recognizable multiple congenital anomalies-mental retardation syndrome caused by mutations in the zinc finger homeo box 1B gene", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891681", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 390, 
          "text": "Recently mutations in the gene ZFHX1B (SIP1) were shown in patients with \"syndromic Hirschsprung disease\" with mental retardation (MR) and multiple congenital anomalies (MCA), but it was unclear if Hirschsprung disease is an obligate symptom of these mutations and if the distinct facial phenotype delineated by Mowat et al. [1998: J Med Genet 35: 617-623] is specific for ZFHX1B mutations.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11891681", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the common feature in congenital central hypoventilation and Mowat-Wilson syndromes?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17397038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16443855"
      ], 
      "type": "summary", 
      "id": "55191149622b194345000010", 
      "snippets": [
        {
          "offsetInBeginSection": 692, 
          "offsetInEndSection": 982, 
          "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 513, 
          "offsetInEndSection": 880, 
          "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1794, 
          "offsetInEndSection": 1884, 
          "text": "These data highlight the pivotal role of the RET gene in both isolated and syndromic HSCR.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 470, 
          "offsetInEndSection": 643, 
          "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 976, 
          "offsetInEndSection": 1078, 
          "text": "RET was shown to act as a modifier gene for the HSCR phenotype in patients with CCHS but not with MWS.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1292, 
          "offsetInEndSection": 1558, 
          "text": "In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which E3 ubiquitin ligase mediates the ubiquitination and degradation of the interferon receptor type 1 (IFNAR1)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21173164", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19948722", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18056411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17873516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16551269", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15337770", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14532120"
      ], 
      "type": "factoid", 
      "id": "55192892622b194345000012", 
      "snippets": [
        {
          "offsetInBeginSection": 409, 
          "offsetInEndSection": 571, 
          "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 514, 
          "offsetInEndSection": 730, 
          "text": "Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948722", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 524, 
          "offsetInEndSection": 696, 
          "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 242, 
          "offsetInEndSection": 480, 
          "text": " Levels of IFNAR1 (regulated via degradation mediated by the betaTrcp E3 ubiquitin ligase) and IFNalpha signaling were reduced in 1205Lu melanoma cell line that harbors activated BRAF and exhibits high levels of betaTrcp ubiquitin ligase.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17873516", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 429, 
          "offsetInEndSection": 641, 
          "text": "IFNalpha promotes the phosphorylation of IFNAR1 on Ser535, followed by recruitment of the E3 ubiquitin ligase, beta-TrCP2 (beta-transducin repeats-containing protein 2), ubiquitination of IFNAR1 and proteolysis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16551269", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 308, 
          "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 289, 
          "offsetInEndSection": 570, 
          "text": "Here we show that IFNAR1 interacts with the Homolog of Slimb (HOS) F-box protein in a phosphorylation-dependent manner, and that this interaction is promoted by interferon alpha (IFNalpha). IFNAR1 is ubiquitinated by the Skp1-Cullin1-HOS-Roc1 (SCF(HOS)) ubiquitin ligase in vitro. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14532120", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which proteins are the different members of the NF-kappaB family of transcription factors?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9950430", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22405852", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21122287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9129142"
      ], 
      "type": "list", 
      "id": "55192f20622b194345000014", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 197, 
          "text": "The transcription factor NF-kappaB is composed of homodimeric and heterodimeric complexes of Rel/NF-kappaB-family polypeptides, which include Rel-A, c-Rel, Rel-B, NF-kappaB/p50 and NF-kappaB2/p52 .", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9950430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 134, 
          "text": "Nuclear factor kappa B (NF\u03baB) is a dimeric transcription factor comprised of five family members RelA (p65), RelB, c-Rel, p50 and p52.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22405852", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 491, 
          "text": "In mammals, the genes rela, relb, crel, nfkappa\u03921, and nfkappaB encode the five NF-kB protein family members RelA (p65), RelB, c-Rel, p50, and p52, respectively, which form homo- and heterodimeric DNA-binding complexes capable of regulating target gene transcription of specific biological responses differentially.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21122287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 682, 
          "offsetInEndSection": 873, 
          "text": "These results suggest that the Rel-homology domain can act as an allosteric effector to promote transcription by p50/NFkappaB1 and that the configuration of p50 is important for its activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9129142", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the most abundant membrane protein on Earth?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24018323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23933017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23298812", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21718685", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19403948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16307124"
      ], 
      "type": "factoid", 
      "id": "5519a7d5622b194345000015", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 227, 
          "text": "LHCII, the largest plant photosynthetic pigment-protein complex of photosystem II, is a most abundant membrane protein in living organisms and comprises approximately half of the pool of chlorophyll molecules in the biosphere. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24018323", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 53, 
          "text": "LHCII is the most abundant membrane protein on earth.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23933017", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. I", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298812", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 179, 
          "text": "Light-harvesting pigment-protein complex of Photosystem II (LHCII) is the largest photosynthetic antenna complex of plants and the most abundant membrane protein in the biosphere.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21718685", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 204, 
          "offsetInEndSection": 462, 
          "text": "still very little is known about protein degradation and its regulation. The degradation of the most abundant membrane protein on Earth, the light-harvesting complex of Photosystem II (LHC II), is highly regulated under different environmental conditions, e.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307124", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which factors are considered in the ABCD2 score?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23871489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23683740", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22237056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23983858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21646462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21554497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21388829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20582954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20421579", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19803400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19556026"
      ], 
      "type": "list", 
      "id": "551adceb622b194345000018", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "The 'accuracy' of age, blood pressure, clinical features, duration and diabetes (ABCD(2)) scoring by non-stroke specialists referring patients to a daily Rapid Access Stroke Prevention (RASP) service is unclear, as is the accuracy of ABCD(2) scoring by trainee residents. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871489", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 448, 
          "offsetInEndSection": 694, 
          "text": " Classification of low risk was based on an age, blood pressure, clinical features, duration of symptoms and diabetes (ABCD2) score <4 and the absence of high risk features, including known carotid disease, crescendo TIA, or atrial fibrillation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683740", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 165, 
          "offsetInEndSection": 669, 
          "text": "Our goal was to compare the very early predictive accuracy of the most relevant clinical scores [age, blood pressure, clinical features and duration of symptoms (ABCD) score, ABCD and diabetes (ABCD2) score, ABCD and brain infarction on imaging score, ABCD2 and brain infarction on imaging score, ABCD and prior TIA within 1 week of the index event (ABCD3) score, California Risk Score, Essen Stroke Risk Score and Stroke Prognosis Instrument II] in consecutive transient ischemic attack (TIA) patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22237056", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 162, 
          "offsetInEndSection": 374, 
          "text": "We examined the association of the age, blood pressure, clinical features, duration of symptoms and diabetes (ABCD2) score, a validated risk prediction model for stroke after TIA, and the presence of ICS or ECS. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983858", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 210, 
          "text": "BACKGROUND: The ABCD2 score (Age, Blood pressure, Clinical features, Duration of symptoms and Diabetes) is used to identify patients having a transient ischemic attack who are at high risk for imminent stroke. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646462", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 216, 
          "text": "BACKGROUND AND PURPOSE: The risk of stroke after a transient ischaemic attack (TIA) can be predicted by scores incorporating age, blood pressure, clinical features, duration (ABCD-score), and diabetes (ABCD2-score). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21554497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 331, 
          "text": "BACKGROUND: Modifications to the age, blood pressure, clinical symptoms, duration of symptoms, and diabetes (ABCD2) score, which incorporate history of hypertension and acute hyperglycemia in addition to acute blood pressure (BP) elevation and history of diabetes, have been proposed to increase the predictive value of the score. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21388829", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 322, 
          "text": "ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score and magnetic resonance imaging abnormalities help to identify patients at high risk of stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20582954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 835, 
          "text": "METHODS: We prospectively calculated the ABCD(2) score (age [> or = 60 years: 1 point]; blood pressure [systolic >140 mm Hg or diastolic >90 mm Hg: 1[; clinical features [unilateral weakness: 2, speech disturbance without weakness: 1, other symptom: 0]; duration of symptoms [ <10 minutes: 0, 10-59 minutes: 1, > or = 60 minutes: 2]; diabetes mellitus [yes: 1]) in consecutive TIA patients hospitalized in 3 tertiary care neurology departments across 2 different racial populations (white and Asian). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20421579", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 669, 
          "offsetInEndSection": 1250, 
          "text": "Early stroke risk is especially high in TIA patients with a high ABCD2 score of 4 or more (A age over 60 years [1 point]: B blood pressure > 140/90 mmHg [1 point]: C Clinical features, including unilateral weakness [2 points] and speech disturbance without weakness [1 point] D2: Diabetes [1 point] and Duration of symptoms [1 point for < 60 min and 2 points for > 60 min]), acute ischemic lesions on diffusion weighted image, > 50% carotid stenosis, severe intracranial artery stenosis, microembolic signals on transcranial Doppler, atrial fibrillation, or hypercoagulable states.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 311, 
          "text": "STUDY OBJECTIVE: We evaluate, in admitted patients with transient ischemic attack, the accuracy of the ABCD(2) (age [A], blood pressure [B], clinical features [weakness/speech disturbance] [C], transient ischemic attack duration [D], and diabetes history [D]) score in predicting ischemic stroke within 7 days. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19556026", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are people with blood group O protected against severe Malaria?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22771625", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23071435", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22818742", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17959777", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15814030"
      ], 
      "type": "yesno", 
      "id": "551ae6c564b14b4618000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 135, 
          "text": "Differential carbonylation of cytoskeletal proteins in blood group O erythrocytes: potential role in protection against severe malaria.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22771625", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1267, 
          "offsetInEndSection": 1460, 
          "text": ". Our findings indicate a possible correlation between the protection against severe malaria in blood group O individuals and a specific pattern of 4-HNE-carbonylation of cytoskeleton proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22771625", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 314, 
          "text": "There is a predominance of blood group O in malaria-endemic regions, and several lines of evidence suggest that ABO blood groups may influence the outcome of P. falciparum infection", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071435", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1304, 
          "offsetInEndSection": 1541, 
          "text": "These data provide the first evidence that ABO blood group antigens influence macrophage clearance of P. falciparum-infected erythrocytes and suggest an additional mechanism by which blood group O may confer resistance to severe malaria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071435", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "Blood group phenotypes A and B are risk factors for cerebral malaria in Odisha, India.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818742", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 519, 
          "offsetInEndSection": 652, 
          "text": "type O is significantly associated with protection against CM, patients with type A and B group had increased risk for developing CM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818742", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 448, 
          "text": "Malaria has been a major selective force on the human population, and several erythrocyte polymorphisms have evolved that confer resistance to severe malaria. Plasmodium falciparum rosetting, a parasite virulence phenotype associated with severe malaria, is reduced in blood group O erythrocytes compared with groups A, B, and AB, but the contribution of the ABO blood group system to protection against severe malaria has received little attention", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 450, 
          "offsetInEndSection": 579, 
          "text": "We hypothesized that blood group O may confer resistance to severe falciparum malaria through the mechanism of reduced rosetting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1008, 
          "offsetInEndSection": 1142, 
          "text": "It appears that individuals who are of blood-group O are relatively resistant to the severe disease caused by P. falciparum infection.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814030", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which is the localization of the RIFIN family of proteins?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23259643", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23166704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22174947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21332983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19826486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17719658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17255224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17148488", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17014697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16679041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15939796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15306707", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15287581", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14668007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19769795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14573641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12438381"
      ], 
      "type": "summary", 
      "id": "551ae73b6b348bb82c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 11, 
          "offsetInEndSection": 245, 
          "text": " The ability of Plasmodium falciparum to undergo antigenic variation, by switching expression among protein variants encoded by multigene families, such as var, rif and stevor, is key to the survival of this parasite in the human host", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259643", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 143, 
          "offsetInEndSection": 377, 
          "text": " The human malaria parasite Plasmodium falciparum possesses a number of multi-copy gene families, including var, rif, stevor and pfmc-2tm, which encode variant antigens believed to be expressed on the surfaces of infected erythrocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1510, 
          "offsetInEndSection": 1642, 
          "text": " Immunofluorescence analyses performed in parallel revealed two stage-dependent localization patterns of RIFIN, STEVOR and PfMC-2TM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 239, 
          "offsetInEndSection": 283, 
          "text": "d variant surface antigens PfEMP1 and RIFIN ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174947", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 277, 
          "text": "RIFIN and STEVOR proteins are variable surface antigens uniquely found in the malaria parasites Plasmodium falciparum and P. reichenowi.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332983", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1604, 
          "offsetInEndSection": 1659, 
          "text": "parasite surface proteins such as PfEMP1, A-type RIFIN ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 577, 
          "offsetInEndSection": 786, 
          "text": "While A-type RIFINs were found to be associated with the parasite and transported to the surface of infected erythrocytes via Maurer's clefts, B-type RIFINs appeared to be mostly retained inside the parasite. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "Variant proteins of the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1232, 
          "offsetInEndSection": 1442, 
          "text": "Interestingly, some RIFIN variants were detected only in intracellular stages and not in merozoites, pointing to differential developmental expression patterns for distinct members of this large protein family.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 596, 
          "offsetInEndSection": 749, 
          "text": "At least three groups of antigens, P. falciparum erythrocyte membrane protein 1 (PfEMP1)/ RIFIN/SURFIN, P. falciparum histidine-rich protein 2 (PfHRP2), ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17255224", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 260, 
          "offsetInEndSection": 579, 
          "text": "This catalog includes large families of predicted 2 transmembrane (2TM) proteins, including the Rifin, Stevor and Pfmc-2TM superfamilies, of which each possesses a region of extensive sequence diversity across paralogs and between isolates that is confined to a proposed surface-exposed loop on the infected erythrocyte", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17148488", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "RIFINs are clonally variant antigens expressed in Plasmodium falciparum. T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17014697", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "RIFIN proteins belong to the largest Plasmodium falciparum multicopy family of variant surface antigens (VSA) expressed by infected erythrocytes", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16679041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 962, 
          "offsetInEndSection": 1046, 
          "text": "SURFIN4.2 not only was found cotransported with PfEMP1 and RIFIN to the IE surface, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15939796", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 140, 
          "text": "Antibodies to rifin: a component of naturally acquired responses to Plasmodium falciparum variant surface antigens on infected erythrocytes.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15306707", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 845, 
          "offsetInEndSection": 906, 
          "text": "In contrast to other known PIESPs, such as PfEMP1 and Rifin, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15287581", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 117, 
          "offsetInEndSection": 292, 
          "text": "We here present data revealing the existence of a unique common pathway for the surface bound traffic of the clonally variant antigens, repeated-interspersed-antigen (RIFINS) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14668007", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 365, 
          "offsetInEndSection": 527, 
          "text": " rifin proteins (RIF proteins), belonging to the largest known family of variable infected erythrocyte surface-expressed proteins, are also naturally immunogenic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12438381", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 314, 
          "text": "Plasmodium falciparum rifin proteins, belonging to the largest known family of variable infected-erythrocyte surface-expressed proteins encoded by rif genes, were recently shown to be capable of inducing a strong immune response in P. falciparum-infected adults living in an area in Gabon where malaria is endemic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14573641", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 109, 
          "offsetInEndSection": 518, 
          "text": "RIFIN products are targets for the human immune response and contribute to the antigenic variability of the parasite. They are transmembrane proteins grouped into two sub-families (RIF_A and RIF_B). Although recent data show that RIF_A and RIF_B have different sub-cellular localisations and possibly different functions, the same structural organisation has been proposed for members of the two sub-families.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19769795", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the function of the MTH1 enzyme in cancer cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24277933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23295485", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22790201", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22757673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22556419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21787772", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21389046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21195604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20542142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20144704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17917452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17425590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17207658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17071637", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16716086", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16607562", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16621731"
      ], 
      "type": "summary", 
      "id": "551af9106b348bb82c000002", 
      "snippets": [
        {
          "offsetInBeginSection": 220, 
          "offsetInEndSection": 268, 
          "text": "the glucose-responsive transcription factor Mth1", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468525", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Human MTH1 (hMTH1) is an enzyme that hydrolyses several oxidized purine nucleoside triphosphates to their corresponding nucleoside monophosphates", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295485", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 428, 
          "text": " We have recently shown that oncogenic RAS-induced DNA damage and attendant premature senescence can be prevented by overexpressing human MutT Homolog 1 (MTH1), the major mammalian detoxifier of the oxidized DNA precursor, 8-oxo-dGTP. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22790201", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 105, 
          "text": "Human Mut T Homolog 1 (MTH1): a roadblock for the tumor-suppressive effects of oncogenic RAS-induced ROS.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22790201", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 602, 
          "offsetInEndSection": 667, 
          "text": "MutT homolog 1 (oxidized purine nucleoside triphosphatase, MTH1),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22757673", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 780, 
          "offsetInEndSection": 803, 
          "text": "MTH1 cleaves 8-oxo-dGTP", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22556419", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 109, 
          "text": "MTH1 hydrolyzes oxidized nucleotide triphosphates, thereby preventing them from being incorporated into DNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21787772", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "MutT-related proteins, including Escherichia coli MutT and the human MTH1 (NUDT1), degrade 8-oxo-7, 8-dihydrodeoxyguanosine triphosphate (8-oxo-dGTP) to 8-oxo-dGMP and thereby prevent mutations caused by the misincorporation of 8-oxoguanine into DNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21389046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 221, 
          "offsetInEndSection": 325, 
          "text": "MTH1 (or NUDT1) are also involved in the repair of 7,8-dihydro-8-oxoguanine (8-oxo-G), previous studies,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21195604", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 399, 
          "offsetInEndSection": 645, 
          "text": "To counteract such deleterious effects of nucleotide pool damage, mammalian cells possess MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase and related enzymes, thus minimizing the accumulation of oxidized bases in cellular DNA", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 780, 
          "offsetInEndSection": 928, 
          "text": "These results indicate that all three of the human MTH1, MTH2, and NUDT5 proteins act as a defense against the mutagenesis induced by oxidized dGTP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20144704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Human MTH1, an oxidized purine nucleoside triphosphatase, hydrolyzes 8-oxo-dGTP thereby preventing its misincorporation into DNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17917452", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 722, 
          "offsetInEndSection": 922, 
          "text": "MTH1 is a mammalian ortholog of Escherichia coli MutT, which hydrolyzes 8-oxo-dGTP to its monophosphate form in nucleotide pools, thereby preventing incorporation of the mutagenic substrate into DNA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17425590", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 419, 
          "text": "Several pathways are involved in the repair of DNA lesions caused by oxidative stress, such as the base excision repair system (BER), which repairs mutation involving 8-oxoguanine and comprises the MUTYH, OGG1 and MTH1 genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17207658", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 281, 
          "text": "The MTH1 protein catalyzes hydrolysis of oxidatively damaged purine nucleotides including 8-hydroxy-dGTP to the monophosphates. The MTH1 protein seems to act as an important defense system against mutagenesis, carcinogenesis, and cell death induced by oxidized purine nucleotides. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17071637", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 466, 
          "offsetInEndSection": 756, 
          "text": "In mammalian cells, MTH1 and NUDT5 proteins degrade 8-oxoGTP and 8-oxoGDP to 8-oxoGMP, which is an unusable form for RNA synthesis. In a search for proteins functioning at the RNA level, polynucleotide phosphorylase (PNP) protein has been suggested to be a good candidate for such a role. T", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16716086", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "Human MTH1 protein hydrolyzes oxidized purine nucleotides 8-oxo-2'-deoxyguanosine triphosphate (8-oxo-dGTP), 2-OH-dATP or their ribo-forms to their monophosphates, thus minimizing replicational and transcriptional errors both in the nuclei and mitochondria.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16607562", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 321, 
          "text": "In human and rodent cells, MTH1, an oxidized purine nucleoside triphosphatase, efficiently hydrolyzes oxidized dGTP, GTP, dATP and ATP such as 2'-deoxy-8-oxoguanosine triphosphate (8-oxo-dGTP) and 2'-deoxy-2-hydroxyadenosine triphosphate (2-OH-dATP) in nucleotide pools, thus avoiding their incorporation into DNA or RNA.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16621731", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24078436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23652674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23633209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23310926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23286415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22915287", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22584704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22527616", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22291433", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21498161", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21454441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20669561", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20616502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20616498", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20570174"
      ], 
      "type": "factoid", 
      "id": "551c23bc6b348bb82c00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 162, 
          "text": "The cause of familial isolated pituitary adenomas (FIPA) remains unknown in a high percentage of cases, but the AIP gene plays an important role in the etiology. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 107, 
          "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 883, 
          "offsetInEndSection": 1014, 
          "text": "We report a Spanish family with FIPA in whom a mutation in the AIP gene previously unreported in a familiar context was identified.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 785, 
          "offsetInEndSection": 1068, 
          "text": "FIPA, an autosomal-dominant disease with variable penetrance, is explained in 20% of patients by germline mutations in the tumor suppressor aryl hydrocarbon receptor interacting protein(AIP), while no gene abnormality has been identified to date in the majority of the FIPA families.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1308, 
          "offsetInEndSection": 1486, 
          "text": "Understanding the tumorigenic process in AIP-positive and AIP-negative FIPA patients could result in better diagnostic and treatment options for both familial and sporadic cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 93, 
          "offsetInEndSection": 230, 
          "text": "The aryl hydrocarbon receptor interacting protein (AIP) gene has a major role in the pathogenesis of familial isolated pituitary adenoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633209", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 581, 
          "text": " The discovery of heterozygous, loss-of-function germline mutations in the gene encoding the aryl hydrocarbon receptor interacting protein (AIP) in 2006 has subsequently enabled the identification of a mutation in this gene in 20% of FIPA families and 20% of childhood-onset simplex soma- totroph adenomas.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23310926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 860, 
          "offsetInEndSection": 977, 
          "text": " This review aims to summarize currently available clinical data on AIP mutation-positive and negative FIPA patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23310926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 94, 
          "text": "[Aryl hydrocarbon receptor interacting protein gene and familial isolated pituitary adenomas].", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286415", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 337, 
          "offsetInEndSection": 424, 
          "text": "Many heterozygous mutations have been discovered in AIP in about 20% of FIPA families. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 306, 
          "text": "Germline mutations of aryl-hydrocarbon-receptor interacting protein (AIP) are associated with pituitary adenoma predisposition. They occur in 20\u00a0% of familial isolated pituitary adenoma (FIPA) and in about 3-5\u00a0% of sporadic pituitary adenomas, especially in early onset somatotropinomas and prolactinomas. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22915287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1046, 
          "offsetInEndSection": 1188, 
          "text": "We report a FIPA family harbouring an AIP R16H change, supporting the hypothesis that the latter represents a variant of unknown significance.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22915287", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 659, 
          "offsetInEndSection": 805, 
          "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 214, 
          "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 305, 
          "offsetInEndSection": 633, 
          "text": "About 20 % of the families with FIPA harbor inactivating mutation in aryl hydrocarbon receptor-interacting protein gene (AIP) associated with loss of heterozygosity of the same genetic locus (11q13) in the tumor. Rarely different types of extra-pituitary tumors have been described in the setting of AIP mutation-positive FIPA. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 138, 
          "offsetInEndSection": 197, 
          "text": "Mutations in AIP account only for 15-25% of FIPA families. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291433", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 340, 
          "offsetInEndSection": 559, 
          "text": "In 20-40% of families with this syndrome, mutations have been identified in the aryl hydrocarbon receptor interacting protein gene while in the rest of the families the causative gene or genes have not been identified. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498161", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 261, 
          "text": "Germline mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to young-onset pituitary tumours, most often to GH- or prolactin-secreting adenomas, and most of these patients belong to familial isolated pituitary adenoma families.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21454441", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1299, 
          "offsetInEndSection": 1628, 
          "text": "We also briefly describe the genetic basis of three other inherited states predisposing individuals to endocrine tumors, namely Carney's syndrome, hyperparathyroidism type 2 (HRPT2) and familial isolated pituitary adenoma (FIPA), which are related to inactivating mutations in the PRKAR1-alpha, HRPT2 and AIP genes, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20669561", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 425, 
          "offsetInEndSection": 655, 
          "text": "Several studies and reviews have assessed the genetic and clinical features of AIP-mutated FIPA patients, which range from a complete lack of symptoms in adult/elderly individuals to large, aggressive early-onset pituitary tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 353, 
          "offsetInEndSection": 538, 
          "text": "In 20% of FIPA families, heterozygous mutations have been described in the aryl hydrocarbon receptor interacting (AIP) gene, whereas in other families the causative gene(s) are unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20570174", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Does ghrelin play a role in ischemic stroke?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23576609", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22190447", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22167137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20720512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19352052", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15613277"
      ], 
      "type": "yesno", 
      "id": "551c2c276b348bb82c00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 96, 
          "offsetInEndSection": 213, 
          "text": "Recent evidence suggests that ghrelin may also be neuroprotective after injury in animal models of cerebral ischemia.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1573, 
          "offsetInEndSection": 1840, 
          "text": "Overall, these experiments point to a neurodegenerative but antiapoptotic effect of endogenous ghrelin in this model of global ischemia, highlighting that further research is essential before we can apply ghrelin treatments to neurodegenerative insults in the clinic.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23576609", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 981, 
          "offsetInEndSection": 1084, 
          "text": " The serum ghrelin level was higher in the MCAO group when compared with the control group (P < 0.05). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190447", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1435, 
          "offsetInEndSection": 1587, 
          "text": "Our results showed that higher level of serum ghrelin decreased gastrointestinal motility and damage to the intestinal mucosa existed in rats with MCAO.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190447", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22167137", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 597, 
          "offsetInEndSection": 723, 
          "text": "RESULTS: Significantly higher levels of leptin and lower levels of adiponectin and ghrelin were confirmed in the stroke group.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22167137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 873, 
          "offsetInEndSection": 983, 
          "text": "Ghrelin levels correlated mildly with triglyceride levels, and were dominant in men with cardioembolic stroke.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22167137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1133, 
          "offsetInEndSection": 1291, 
          "text": "CONCLUSIONS: Adipokines and ghrelin play an important role in ischemic stroke, but their function in stroke subtypes seems to be different and sex influenced.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22167137", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720512", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 851, 
          "offsetInEndSection": 1026, 
          "text": "Compared with vehicle treatment, human ghrelin treatment in vagus nerve-intact rats after MCAO showed marked reduction in neurological deficit by 57% and infarct size by 25%. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1213, 
          "offsetInEndSection": 1498, 
          "text": "Human ghrelin treatment in vagus nerve-intact rats significantly decreased the above measurements. Human ghrelin treatment also improved 7-day survival and significantly decreased neurological deficit over the entire 7 days after MCAO in vagus nerve-intact rats compared with vehicle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1671, 
          "offsetInEndSection": 1825, 
          "text": "Human ghrelin is thus a neuroprotective agent that inhibits inflammation, nNOS activity, and apoptosis in focal cerebral ischemia through a vagal pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 117, 
          "text": "Ghrelin is known to promote neuronal defense and survival against ischemic injury by inhibiting apoptotic processes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19352052", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 902, 
          "offsetInEndSection": 1104, 
          "text": "Our data indicate that des-acyl ghrelin, as well as ghrelin, protect cortical neurons against ischemic injury through the inhibition of Par-4 expression and apoptotic molecules in mitochondrial pathway.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19352052", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 958, 
          "offsetInEndSection": 1083, 
          "text": "In conclusion, it is considered that ghrelin as well as S-100B can be a useful marker for the prediction of stoke after CPB. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15613277", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is TNNI3K a cardiac-specific protein?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24132636", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23472207", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23369981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23085512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21314842", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20018082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19925440", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18552163", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18021318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17660584", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12721663"
      ], 
      "type": "yesno", 
      "id": "551c4ffc6b348bb82c000010", 
      "snippets": [
        {
          "offsetInBeginSection": 18, 
          "offsetInEndSection": 55, 
          "text": "cardiomyocyte-specific kinase TNNI3K ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24132636", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 382, 
          "offsetInEndSection": 477, 
          "text": "We report that cardiac troponin I-interacting kinase (TNNI3K), a cardiomyocyte-specific kinase,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24132636", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 35, 
          "text": "TNNI3K, a cardiac-specific kinase, ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472207", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 106, 
          "offsetInEndSection": 236, 
          "text": " The cardiac troponin I-interacting kinase (TNNI3K), a novel cardiac specific kinase, is associated with cardiomyocyte hypertrophy", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23472207", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 135, 
          "offsetInEndSection": 286, 
          "text": "Human cardiac troponin I-interacting kinase (TNNI3K) is a novel cardiac-specific functional kinase that can bind to cTnI in a yeast two-hybrid screen. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23369981", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 80, 
          "text": "Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunctio", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085512", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 125, 
          "text": "Cardiac troponin I-interacting kinase (TNNI3K) is a cardiac-specific kinase whose biological function remains largely unknown", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085512", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2, 
          "offsetInEndSection": 89, 
          "text": " Cardiac troponin I-interacting kinase (TNNI3K) is a novel cardiac-specific kinase gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21314842", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 826, 
          "offsetInEndSection": 873, 
          "text": " a novel cardiac-specific kinase gene (TNNI3K),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018082", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 430, 
          "offsetInEndSection": 547, 
          "text": " TNNI3K is a novel cardiac troponin I-interacting kinase gene and its overexpression may promote cardiac myogenesis, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19925440", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "TNNI3K is a new cardiac-specific MAP kinase whose gene is localized to 1p31.1 and that belongs to a tyrosine kinase-like branch in the kinase tree of the human genome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18552163", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 161, 
          "text": "The cardiac ankyrin repeat kinase (CARK) gene, also named TNNI3K for its interaction with cardiac troponin I, is both a unique expression and heart-enriched gene", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18021318", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Molecular cloning of cardiac troponin I-interacting kinase (TNNI3K), a novel cardiac-specific protein kinase containing seven N-terminal ankyrin (ANK) repeats followed by a protein kinase domain and a C-terminal Ser-rich domain, has previously been reported.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17660584", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 374, 
          "offsetInEndSection": 546, 
          "text": " TNNI3K is highly expressed in heart, but is undetectable in other tissues. Immunohistochemical analysis predominantly localized TNNI3K in the nucleus of cardiac myocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12721663", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Where is the angiogenin binding element  located?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24122807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12515546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9413551", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7875314", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2813401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/3289612"
      ], 
      "type": "summary", 
      "id": "551d8b3a6b348bb82c000011", 
      "snippets": [
        {
          "offsetInBeginSection": 362, 
          "offsetInEndSection": 542, 
          "text": "ANG binds at the upstream control element (UCE) of the promoter and enhances promoter occupancy of RNA Pol I as well as the selectivity factor SL1 components TAFI 48 and TAFI 110. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24122807", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 598, 
          "offsetInEndSection": 852, 
          "text": " Here we report that angiogenin binds to CT repeats that are abundant in the nontranscribed region of the ribosomal RNA gene. An angiogenin-binding DNA sequence (CTCTCTCTCTCTCTCTCCCTC) has been identified and designated angiogenin-binding element (ABE). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12515546", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "ROSIER scale is used for which disorder?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22919191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22014183", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21402744", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16239179"
      ], 
      "type": "factoid", 
      "id": "551fd9c06b348bb82c000012", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 78, 
          "text": "Validation of the use of the ROSIER scale in prehospital assessment of stroke.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22919191", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 390, 
          "text": "MATERIALS AND METHODS: Compared with the Cincinnati Prehospital Stroke Scale (CPSS), emergency physicians prospectively used the ROSIER as a stroke recognition tool on suspected patients in the prehospital setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22919191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1679, 
          "offsetInEndSection": 1831, 
          "text": "CONCLUSIONS: The ROSIER is a sensitive and specific stroke recognition tool for health providers' use among Chinese patients in the prehospital setting.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22919191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Can the FAST and ROSIER adult stroke recognition tools be applied to confirmed childhood arterial ischemic stroke?", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014183", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 648, 
          "offsetInEndSection": 853, 
          "text": " Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014183", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 255, 
          "offsetInEndSection": 487, 
          "text": " DIAGNOSTIC SCALES: The results of an assessment with the Recognition of Stroke in the Emergency Room (ROSIER) scale, the Face Arm Speech Test (FAST) scale and the diagnosis of definite or probable stroke by an emergency department.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21402744", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1302, 
          "offsetInEndSection": 1471, 
          "text": "CONCLUSIONS: The simpler FAST scale could replace the more complex ROSIER for the initial assessment of patients with suspected acute stroke in the emergency department.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21402744", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16239179", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 348, 
          "text": "We designed and validated a stroke recognition tool-the Recognition of Stroke in the Emergency Room (ROSIER) scale-for use by ER physicians.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16239179", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 2020, 
          "offsetInEndSection": 2143, 
          "text": "INTERPRETATION: The ROSIER scale was effective in the initial differentiation of acute stroke from stroke mimics in the ER.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16239179", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is there evidence to suggest that triiodothyronine has neuroprotective properties in traumatic brain injury?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23601250", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23313345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12445968", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11719005", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9681483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7804793", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6798220", 
        "http://www.ncbi.nlm.nih.gov/pubmed/839237"
      ], 
      "type": "yesno", 
      "id": "552010076b348bb82c000015", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 97, 
          "text": "Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 604, 
          "offsetInEndSection": 797, 
          "text": "Treatment with T3 (1.2\u03bcg/100g body weight, i.p.) 1h after TBI resulted in a significant improvement in motor and cognitive recovery after CCI, as well as in marked reduction of lesion volumes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 958, 
          "offsetInEndSection": 1433, 
          "text": "Western blot analysis revealed the ability of T3 to reduce brain trauma through modulation of cytoplasmic-nuclear shuttling of nuclear factor-\u03baB (NF-\u03baB). Twenty-four hours after brain trauma, T3-treated mice also showed significantly lower number of TUNEL(+) apoptotic neurons and curtailed induction of Bax, compared to vehicle control. In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1692, 
          "offsetInEndSection": 1798, 
          "text": "The stimulating effect of T3 on peripheral nerve regeneration may have considerable therapeutic potential.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445968", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1651, 
          "offsetInEndSection": 1864, 
          "text": "The present study provides evidence that the peripheral nervous system has its own system responsible for the local production of 3,5,3'-triiodothyronine, which may play a key role during the regeneration process.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11719005", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 411, 
          "offsetInEndSection": 554, 
          "text": "Although it has been hypothesized that T3 may facilitate neuronal regeneration after CNS injury, the 5'-D2 response to brain injury is unknown.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9681483", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 907, 
          "offsetInEndSection": 1097, 
          "text": "The outcome after brain injury is closely correlated with the intensity of these changes, particularly with catecholamine plasma levels and the severity of the low triiodothyronine syndrome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7804793", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 142, 
          "text": "The thyroid hormones triiodothyronine (T3) and L-thyroxine appear to enhance regeneration in the peripheral and central nervous system (CNS). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 836, 
          "offsetInEndSection": 946, 
          "text": "T3 treatment influenced the general levels of incorporation of all treated groups over all days postoperation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1347, 
          "offsetInEndSection": 1459, 
          "text": "T3 effects appear to involve an increased sensitivity of the cells of the injured nervous system to the hormone.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 421, 
          "offsetInEndSection": 791, 
          "text": "T3, when administered over an 8 week period, stimulated axonal regeneration in the dorsal cortex and corpus callosum and promoted healing of the wound in the corpus callosum. The results of this investigation suggest that the use of T3 in the clinical treatment of injury to the central nervous system may be of less value than the work of earlier authors had indicated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/839237", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is a mitochondrial nucleoid?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23721879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23637282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23220174", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20577028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19704786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19703654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15126284"
      ], 
      "type": "summary", 
      "id": "552016a36b348bb82c000018", 
      "snippets": [
        {
          "offsetInBeginSection": 208, 
          "offsetInEndSection": 373, 
          "text": "A naked mtDNA molecule is longer than a typical mitochondrion and is therefore compacted in vivo to form a nucleoprotein complex, denoted the mitochondrial nucleoid.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 136, 
          "text": "The packaging of mitochondrial DNA (mtDNA) into DNA-protein assemblies called nucleoids provides an efficient segregating unit of mtDNA,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637282", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 148, 
          "text": "Mitochondrial DNA (mtDNA) is organized in nucleoids in complex with accessory proteins, proteins of mtDNA replication and gene expression machinery.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220174", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 99, 
          "text": "The independent mitochondrial genetic information is organized in so-called mitochondrial nucleoids", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20577028", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 32, 
          "offsetInEndSection": 179, 
          "text": " packaging of mitochondrial DNA (mtDNA) into protein-DNA assemblies called nucleoids confers higher-order organization to the mitochondrial genome.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704786", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 264, 
          "offsetInEndSection": 420, 
          "text": "mitochondrial DNA is packaged into macromolecular assemblies called nucleoids, composed of one or more copies of mitochondrial DNA and associated proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19703654", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 71, 
          "offsetInEndSection": 178, 
          "text": "human mitochondrial DNA (mtDNA) had long been believed to be rather naked because mitochondria lack histone", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15126284", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the sedimentation coefficient of the mammalian mitoribosome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11943462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11402041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/6284743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19567276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15966747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14757048"
      ], 
      "type": "factoid", 
      "id": "55201a316b348bb82c000019", 
      "snippets": [
        {
          "offsetInBeginSection": 75, 
          "offsetInEndSection": 119, 
          "text": " The mammalian mitochondrial ribosomes (55S)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11943462", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S, consisting of 39 S large and 28 S small subunits.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11402041", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "The 55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6284743", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 751, 
          "offsetInEndSection": 860, 
          "text": "59 of 78 proteins of the 55S mitoribosome, several TIM and TOM proteins and cell death proteins were present.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19567276", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 275, 
          "offsetInEndSection": 344, 
          "text": "The sedimentation coefficient of the intact monosome was about 55 S. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 874, 
          "offsetInEndSection": 1024, 
          "text": "Though the nematode mitoribosome has a larger size than the bacterial ribosome, it does not differ significantly in size from mammalian mitoribosomes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966747", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 128, 
          "text": "The mammalian mitochondrial (mt) ribosome (mitoribosome) is a bacterial-type ribosome but has a highly protein-rich composition.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14757048", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What species is associated with Tetrodotoxin?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24295175", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24279996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22690139", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22688023", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22069694", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22163191", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22028709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21734837", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21549050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23724281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20637221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20479966", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20161971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20411115"
      ], 
      "type": "summary", 
      "id": "552033206b348bb82c00001b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 139, 
          "text": "The selling and importing of puffer fish species and their products was banned in Thailand in 2002, because of possible neurotoxic effects.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295175", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 72, 
          "text": "Efficiency of a rapid test for detection of tetrodotoxin in puffer fish.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295175", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 76, 
          "text": "Marine pufferfish contain tetrodotoxin (TTX), an extremely potent neurotoxin", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24279996", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 255, 
          "text": "Tetrodotoxin is a potent low weight marine toxin found in warm waters, especially of the Indian and Pacific Oceans. Intoxications are usually linked to the consumption of the puffer fish, although TTX was already detected in several different edible taxa.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22690139", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 183, 
          "text": "Food poisoning due to ingestion of a puffer fish occurred in Nagasaki Prefecture, Japan, in October 2008, causing neurotoxic symptoms similar to those of tetrodotoxin (TTX) poisoning.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22688023", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1156, 
          "offsetInEndSection": 1366, 
          "text": " Our findings raised a concern for people, not only Thais but also inhabitants of other countries situated on the Andaman coast; consuming puffers of the Andaman seas is risky due to potential TTX intoxication.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069694", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 74, 
          "text": "Toxic marine puffer fish in Thailand seas and tetrodotoxin they contained.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069694", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 321, 
          "text": "Puffer fish, Takifugu niphobles, collected from the Hong Kong coastal waters were screened for tetrodotoxin-producing bacteria. A Gram-negative, non-acid-fast, non-sporing and rod shaped bacterial strain (designated as gutB01) was isolated from the intestine of the puffer fish and was shown to produce tetrodotoxin (TTX)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22163191", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Isolation and identification of a new tetrodotoxin-producing bacterial species, Raoultella terrigena, from Hong Kong marine puffer fish Takifugu niphobles.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22163191", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Green toadfish Lagocephalus lunaris inhabits tropical and subtropical seas and contains high tetrodotoxin (TTX) levels in the muscle as well as liver and gonad", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22028709", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 145, 
          "text": "Tetrodotoxin (TTX) is a highly potent neurotoxin that blocks the action potential by selectively binding to voltage-gated sodium channels (Na(v))", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734837", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 102, 
          "text": "Suspected tetrodotoxin (TTX) poisoning was associated with eating unknown fish in April 2009 in Taiwan", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549050", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 171, 
          "text": "Marine pufferfish generally contain a large amount of tetrodotoxin (TTX) in their skin and viscera, and have caused many incidences of food poisoning, especially in Japan.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23724281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 371, 
          "offsetInEndSection": 504, 
          "text": " TTX is originally produced by marine bacteria, and pufferfish are intoxicated through the food chain that starts with the bacteria. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23724281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 661, 
          "offsetInEndSection": 759, 
          "text": ", TTX poisoning due to marine snails has recently spread through Japan, China, Taiwan, and Europe.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23724281", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "The inhibitory effects of toxin extracted from muscle or liver of five different puffer fishes (hereafter referred as puffer(s)) captured on the Japanese sea coast ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20637221", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 236, 
          "text": "LC/MS analysis of tetrodotoxin and its deoxy analogs in the marine puffer fish Fugu niphobles from the southern coast of Korea, and in the brackishwater puffer fishes Tetraodon nigroviridis and Tetraodon biocellatus from Southeast Asia.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20479966", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 200, 
          "offsetInEndSection": 446, 
          "text": "Toxins such as saxitoxins, tetrodotoxin, palytoxin, nodularin, okadaic acid, domoic acid, may be produced in large amounts by dinoflagellates, cyanobacteria, bacteria and diatoms and accumulate in vectors that transfer the toxin along food chains", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20161971", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 137, 
          "text": "Tetrodotoxin (TTX) is a low molecular weight (approximately 319 Da) neurotoxin found in a number of animal species, including pufferfish.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20411115", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "In which condition was protein S100A7 originally identified?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22189627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21501383", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21551409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21148126", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20596736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19167844"
      ], 
      "type": "factoid", 
      "id": "55203ae78e534a4535000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 124, 
          "text": "Psoriasin (S100A7), originally identified in psoriasis, is a calcium-binding protein belonging to the multigenic S100 family", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22189627", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 113, 
          "text": "Psoriasin (S100 A7) was discovered two decades ago as a protein abundantly expressed in psoriatic keratinocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501383", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 8, 
          "offsetInEndSection": 213, 
          "text": " Psoriasin, originally isolated from psoriasis as an overexpressed molecule of unknown function, has recently been identified as a principal Escherichia coli-killing antimicrobial peptide of healthy skin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21551409", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 650, 
          "text": "Inflammation-prone psoriatic skin constitutively expresses elevated concentrations of S100A7 (psoriasin)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148126", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "S100A7 (psoriasin) and S100A15 (koebnerisin) were first identified in inflamed psoriatic skin. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20596736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 175, 
          "text": "Human psoriasin (S100A7) has originally been described as a member of the family of S100 calcium-binding proteins which is overexpressed in patients suffering from psoriasis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19167844", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are Notch mutations related to T-cell Acute Lymphoblastic Leukemia (T-ALL)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20967796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18184405", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24252593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24140475", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24068942", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23730497", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23022380"
      ], 
      "type": "yesno", 
      "id": "5522fadb7b523f2123000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 467, 
          "text": "Notch receptors participate in a highly conserved signalling pathway that regulates normal development and tissue homeostasis in a context- and dose-dependent manner. Deregulated Notch signalling has been implicated in many diseases, but the clearest example of a pathogenic role is found in T-cell lymphoblastic leukaemia/lymphoma (T-LL), in which the majority of human and murine tumours have acquired mutations that lead to aberrant increases in Notch1 signalling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967796", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 351, 
          "text": "NOTCH proteins (NOTCH1, NOTCH2, NOTCH3 and NOTCH4) play crucial roles in embryonic development. Also, mounting evidence indicates that NOTCH contributes to the pathogenesis of hematopoietic and solid malignancies. Recent studies reported a high incidence of gain-of-function mutations of the NOTCH1 gene in T-cell acute lymphoblastic leukemias (ALL). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1126, 
          "offsetInEndSection": 1300, 
          "text": "Our data indicate that NOTCH1 is mutated in T-ALL, but not in other common human cancers, and that NOTCH2, NOTCH3 and NOTH4 genes are rarely mutated in common human cancers. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 602, 
          "text": "The Notch signaling pathway plays a critical role in maintaining the balance between cell proliferation, differentiation and apoptosis, and is a highly conserved signaling pathway that regulates normal development in a context- and dose-dependent manner. Dysregulation of Notch signaling has been suggested to be key events in a variety of hematological malignancies. Notch1 signaling appears to be the central oncogenic trigger in T cell acute lymphoblastic leukemia (T-ALL), in which the majority of human malignancies have acquired mutations that lead to constitutive activation of Notch1 signaling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252593", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 521, 
          "text": "T-cell acute lymphoblastic leukemia (T-ALL) is characterized as a high-risk stratified disease associated with frequent relapse, chemotherapy resistance, and a poorer prognostic outlook than B-precursor ALL. Many of the challenges in treating T-ALL reflect the lack of prognostic cytogenetic or molecular abnormalities on which to base therapy, including targeted therapy. Notch1 activating mutations were identified in more than 50% of T-ALL cases and can be therapeutically targeted with \u03b3-secretase inhibitors (GSIs). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140475", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 180, 
          "offsetInEndSection": 296, 
          "text": "Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068942", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 364, 
          "text": "T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is characterized by aberrant activation of NOTCH1 in over 60% of T-ALL cases. The high prevalence of activating NOTCH1 mutations highlights the critical role of NOTCH signaling in the pathogenesis of this disease and has prompted the development of therapeutic approaches targeting the NOTCH signaling pathway. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730497", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 153, 
          "text": "Activating mutations in NOTCH1, an essential regulator of T cell development, are frequently found in human T cell acute lymphoblastic leukemia (T-ALL). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022380", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "For what is Protein A from Staphylococcus aureus used in biochemistry?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24291195", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24184233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24033345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23776704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23770556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22136061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22621885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12472184"
      ], 
      "type": "summary", 
      "id": "5523dc8c7b523f2123000002", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 155, 
          "text": "Staphylococcal protein A (SpA) binds Fc\u03b3 and VH3 clan Fab domains of human and animal immunoglobulin (Ig) with each of its five Ig binding domains (IgBDs),", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291195", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Protein A from Staphylococcus aureus plays one key role as an immobilized affinity ligand for the purification of antibodies. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24184233", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 94, 
          "offsetInEndSection": 215, 
          "text": "The recombinant SpA is also widely used in biotechnology to purify polyclonal and monoclonal immunoglobulin G antibodies.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24033345", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 103, 
          "text": "Staphylococcus aureus protein A (SpA) is the most popular affinity ligand for immunoglobulin G1 (IgG1).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776704", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "Staphylococcal Protein A (SPA), a cell wall protein of Staphylococcus aureus, is in high demand because of its ability to bind immunoglobulins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 144, 
          "text": "Protein A from the bacterium Staphylococcus aureus (SpA) has been widely used as an affinity ligand for purification of immunoglobulin G (IgG). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136061", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 196, 
          "text": "Affinity chromatography with protein A from Staphylococcus aureus (SpA) is the most widespread and accepted methodology for antibody capture during the downstream process of antibody manufacturing", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22621885", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 167, 
          "text": "Affinity chromatography using protein A from Staphylococcus aureus as the ligand has been widely used for the isolation of immunoglobulin G (IgG) from various species.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12472184", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "List fluorescent reporter proteins.", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24128932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23822504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23741385", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23347004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20601526", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20532610", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20471991", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20429918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18592415", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18566430", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18556507", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18501461", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18473954", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17646710", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17553146", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17407539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16468989", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15258449", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14579736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12771211"
      ], 
      "type": "list", 
      "id": "5523e47f7b523f2123000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 164, 
          "text": "Fluorescent Timer, or DsRed1-E5, is a mutant of the red fluorescent protein, dsRed, in which fluorescence shifts over time from green to red as the protein matures.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24128932", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 776, 
          "offsetInEndSection": 807, 
          "text": "green fluorescent protein (Gfp)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23822504", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 98, 
          "text": "Characterization of flavin-based fluorescent proteins: an emerging class of fluorescent reporters.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741385", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 215, 
          "offsetInEndSection": 256, 
          "text": "Flavin-based fluorescent proteins (FbFPs)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741385", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 286, 
          "offsetInEndSection": 329, 
          "text": "mCherry was employed as a reporter protein ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23347004", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 723, 
          "offsetInEndSection": 749, 
          "text": "yellow fluorescent protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20601526", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 249, 
          "offsetInEndSection": 295, 
          "text": "red cytoplasmic fluorescent reporter protein. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 478, 
          "offsetInEndSection": 510, 
          "text": "red fluorescent reporter protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532610", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 623, 
          "offsetInEndSection": 667, 
          "text": " enhanced green fluorescent reporter protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20471991", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 146, 
          "text": "Fluorescent and luminescent reporter genes have become popular tools for the real-time monitoring of gene expression in living cells. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20429918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 641, 
          "offsetInEndSection": 715, 
          "text": " fluorescent reporter protein [green fluorescent protein (GFP) and DsRed2]", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592415", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 187, 
          "offsetInEndSection": 222, 
          "text": "coral fluorescent reporter protein ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566430", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 402, 
          "offsetInEndSection": 487, 
          "text": "driving a cassette for the enhanced green \"live\" fluorescent reporter protein (eGFP) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18556507", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 253, 
          "offsetInEndSection": 290, 
          "text": "GFP as a fluorescent reporter protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18501461", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 146, 
          "offsetInEndSection": 154, 
          "text": " protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18473954", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 311, 
          "offsetInEndSection": 356, 
          "text": "red fluorescent reporter protein (RFP) gene. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17646710", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 35, 
          "text": "The red fluorescent protein eqFP611", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17553146", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 748, 
          "offsetInEndSection": 792, 
          "text": "the green fluorescent reporter protein gene ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17407539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 414, 
          "offsetInEndSection": 447, 
          "text": " red fluorescent reporter protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468989", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 534, 
          "offsetInEndSection": 603, 
          "text": "beta-phycoerythrin, a fluorescent reporter protein derived from algae", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15258449", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 458, 
          "offsetInEndSection": 504, 
          "text": " live-cell fluorescent reporter protein, Timer", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14579736", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1172, 
          "offsetInEndSection": 1204, 
          "text": "red fluorescent reporter protein", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12771211", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is Trypan blue used for?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23354080", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24320727", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24316855", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24312318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24304568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24300339", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24296136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24289578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24279639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24256980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24244400", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24238300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24236478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24231574", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24228750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24228508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24212220", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24195509", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24190701", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160177", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24140394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24139500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24129092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24127887", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24123008"
      ], 
      "type": "factoid", 
      "id": "5523e7837b523f2123000006", 
      "snippets": [
        {
          "offsetInBeginSection": 300, 
          "offsetInEndSection": 342, 
          "text": " cell death by trypan blue exclusion assay", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23354080", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1107, 
          "offsetInEndSection": 1277, 
          "text": "Examination of cell viability in UCP2-transfected cells with Trypan Blue and Annexin-V staining revealed that UCP2 transfection led to significantly increased cell death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320727", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 435, 
          "offsetInEndSection": 495, 
          "text": "assessed for their viability by vital staining (Trypan blue)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24316855", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 913, 
          "offsetInEndSection": 961, 
          "text": "the trypan blue exclusion test of cell viability", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312318", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 452, 
          "offsetInEndSection": 543, 
          "text": " Cell viability was determined by MTT, neutral red uptake and trypan blue exclusion assays.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24304568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 493, 
          "offsetInEndSection": 637, 
          "text": "Cytotoxicity, apoptosis, and necrosis were investigated by trypan blue exclusion, MTT assay, and annexin V/propidium iodide assay, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300339", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 441, 
          "offsetInEndSection": 586, 
          "text": "Cytotoxicity was measured using the Trypan Blue Dye Exclusion assay and genotoxicity using the Comet Assay (alkaline single-cell electrophoresis)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24296136", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 476, 
          "offsetInEndSection": 555, 
          "text": "Apoptosis of MCF-7 cells was evidenced by investigating trypan blue exclusion, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289578", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 405, 
          "offsetInEndSection": 502, 
          "text": "cell viability was measured using an MTT assay and the trypan blue exclusion method, respectively", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24279639", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 696, 
          "offsetInEndSection": 775, 
          "text": "Cell viability and apoptosis assay using MTT analysis and trypan blue staining,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24256980", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1008, 
          "offsetInEndSection": 1055, 
          "text": "cell death was assayed by trypan blue exclusion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244400", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1279, 
          "offsetInEndSection": 1307, 
          "text": "cell viability (Trypan Blue)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 818, 
          "offsetInEndSection": 869, 
          "text": "cell viability using both Trypan Blue dye exclusion", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24238300", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 440, 
          "offsetInEndSection": 482, 
          "text": " cell-viability analysis with trypan blue ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24236478", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 801, 
          "offsetInEndSection": 911, 
          "text": " Specimens were examined for keratinocyte survival at 7, 14, 21, 28, and 35 days using the trypan blue assay. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24231574", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 492, 
          "offsetInEndSection": 653, 
          "text": "For cytotoxicity testing, relative growth activity, trypan blue exclusion, (3)H-thymidine incorporation and cytokinesis-block proliferation index were assessed. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228750", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1000, 
          "offsetInEndSection": 1046, 
          "text": "trypan blue was used to detect cell viability.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228508", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 351, 
          "offsetInEndSection": 415, 
          "text": "Cell viability was measured by a trypan blue dye exclusion test.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212220", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 606, 
          "offsetInEndSection": 675, 
          "text": " Cell viability was determined using the trypan blue exclusion assay.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24195509", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 387, 
          "offsetInEndSection": 459, 
          "text": "Cell death was analyzed by MTT viability assay and trypan blue staining.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24190701", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 654, 
          "offsetInEndSection": 711, 
          "text": " cell viability was determined by trypan blue exclusion. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160177", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1665, 
          "offsetInEndSection": 1705, 
          "text": " the cell viability (trypan blue method)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140394", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 265, 
          "offsetInEndSection": 328, 
          "text": "trypan blue staining to test the viability of cancer cell lines", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139500", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 607, 
          "offsetInEndSection": 749, 
          "text": " Cell viability and survival were assessed using 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide and trypan blue exclusion assays.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129092", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 303, 
          "offsetInEndSection": 412, 
          "text": " Viability and proliferation of immobilized DPSCs were determined by trypan blue and MTT assay, respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127887", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 318, 
          "offsetInEndSection": 476, 
          "text": " Cell proliferation and viability were assessed using trypan blue and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay respectively.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24123008", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Has the protein GFP been used in transgenesis for live protein imaging?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24312079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24297703", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23480392", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22700411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22551423", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22497513", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22493255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22173943", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21708138", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21490567", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21406720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21316751", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21248708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20378924", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20226563", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20085825", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19688097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19549299", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19087237"
      ], 
      "type": "yesno", 
      "id": "5523e8cc7b523f2123000007", 
      "snippets": [
        {
          "offsetInBeginSection": 423, 
          "offsetInEndSection": 638, 
          "text": "we review recent advancement in the functional studies of the three different GnRH neuron systems, mainly focusing on the electrophysiological analysis of the GnRH-green fluorescent protein (GFP) transgenic animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312079", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 636, 
          "offsetInEndSection": 681, 
          "text": "founders were found to be transgenic for GFP.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297703", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 845, 
          "offsetInEndSection": 906, 
          "text": "GFP expression was detected in a wide range of murine tissues", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24297703", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 77, 
          "text": "Transgenic Xenopus laevis for live imaging in cell and developmental biology.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23480392", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 264, 
          "text": "The stable transgenesis of genes encoding functional or spatially localized proteins, fused to fluorescent proteins such as green fluorescent protein (GFP) or red fluorescent protein (RFP), is an extremely important research tool in cell and developmental biology.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23480392", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 68, 
          "text": "GFP-transgenic animals for in vivo imaging: rats, rabbits, and pigs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22700411", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 482, 
          "offsetInEndSection": 627, 
          "text": "We have further extended the techniques of genetic engineering to rats, rabbits, and pigs, and have created corresponding GFP-transgenic animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22700411", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1473, 
          "offsetInEndSection": 1661, 
          "text": "The results revealed that the 3.6-GFP transgenic animals provide a unique model for direct analysis of cellular and molecular mechanisms of pulp repair and tertiary dentinogenesis in vivo.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22551423", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 71, 
          "text": "Long-term effects of PERV-specific RNA interference in transgenic pigs.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22497513", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1204, 
          "offsetInEndSection": 1319, 
          "text": "green fluorescent protein (GFP) as reporter of the vector system were consistently expressed in transgenic animals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22497513", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 187, 
          "text": "The ability to specify the expression levels of exogenous genes inserted in the genomes of transgenic animals is critical for the success of a wide variety of experimental manipulations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22493255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 81, 
          "text": "Welfare assessment in transgenic pigs expressing green fluorescent protein (GFP).", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22173943", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 552, 
          "offsetInEndSection": 654, 
          "text": "transgenic animals expressing GFP with wildtype animals along various stages of post natal development", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22173943", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 79, 
          "text": "Production of transgenic chickens expressing a tetracycline-inducible GFP gene.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21708138", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 1021, 
          "offsetInEndSection": 1116, 
          "text": "transgenic animals can be readily created to express fluorescently tagged proteins or reporters", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21490567", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1342, 
          "offsetInEndSection": 1487, 
          "text": "These findings suggest that mhc2dab:GFP and cd45:DsRed transgenic lines will be instrumental in elucidating the immune response in the zebrafish.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21406720", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 912, 
          "offsetInEndSection": 996, 
          "text": "f 33 mice born, 28 (81%) carried the transgene DNA and 15 (55.5%) were GFP-positive.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21316751", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 159, 
          "text": "Lentiviral vectors containing the green fluorescent protein gene have been successfully used to select transgenic embryos before transfer to a surrogate mother", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21316751", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 306, 
          "offsetInEndSection": 476, 
          "text": "Typically transgenes are generated by placing a promoter upstream of a GFP reporter gene or cDNA of interest, and this often produces a representative expression pattern.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 127, 
          "text": "Survival and immunogenicity of mesenchymal stem cells from the green fluorescent protein transgenic rat in the adult rat brain.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378924", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 309, 
          "text": "This problem has been lessened by the availability of transgenic animals that express \"reporter\" genes, such as green fluorescent protein (GFP)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378924", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 133, 
          "offsetInEndSection": 203, 
          "text": " full-length GFP fusion proteins was examined, in transgenic animals, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20226563", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 664, 
          "offsetInEndSection": 734, 
          "text": "Two stable transgenic lines express GFP prior to hair-bundle formation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20085825", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 429, 
          "offsetInEndSection": 579, 
          "text": "we generated two transgenic pigs by somatic cell nuclear transfer (SCNT) that express green fluorescent protein (GFP) driven by cytomegalovirus (CMV).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19688097", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 140, 
          "text": "Fluorescent proteins such as the green fluorescent protein (GFP) have widely been used in transgenic animals as reporter genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19549299", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 137, 
          "text": "Green Fluorescent Protein (GFP) is used extensively as a reporter for transgene expression in Drosophila and other organisms.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19087237", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which mutations of phopspholamban have been found in patients with cardiomyopathy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23871674", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23568436", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22707725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21332051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21282613", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12639993", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12610310"
      ], 
      "type": "list", 
      "id": "5523f1a62c8b63434a000002", 
      "snippets": [
        {
          "offsetInBeginSection": 741, 
          "offsetInEndSection": 1147, 
          "text": " In 19 of 142 patients (13%), the PLN founder mutation c.40_42delAGA (p.Arg14del) was identified. PLN mutation carriers more often had low-voltage electrocardiograms (p\u00a0= 0.004), inverted T waves in leads V4 to V6 (p <0.001), and additional structural (p\u00a0= 0.007) or functional (p\u00a0= 0.017) left ventricular impairment, whereas desmosomal mutation carriers had more solitary right ventricular abnormalities.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23871674", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 217, 
          "text": "Recently, we showed that the c.40_42delAGA (p.Arg14del) mutation in the phospholamban (PLN) gene can be identified in 10-15\u00a0% of Dutch patients with dilated cardiomyopathy or arrhythmogenic cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568436", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 357, 
          "offsetInEndSection": 450, 
          "text": "PLN mutation R14del was identified in 12 (12 %) ARVC patients and in 39 (15 %) DCM patients. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1344, 
          "offsetInEndSection": 1656, 
          "text": "The PLN R14del founder mutation is present in a substantial number of patients clinically diagnosed with DCM or ARVC. R14del+ patients diagnosed with DCM showed an arrhythmogenic phenotype, and SCD at young age can be the presenting symptom. These findings support the concept of 'arrhythmogenic cardiomyopathy'.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820313", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 300, 
          "offsetInEndSection": 1328, 
          "text": "Herein we reveal mechanistic insight into how four hereditary mutants of phospholamban, Arg(9) to Cys, Arg(9) to Leu, Arg(9) to His, and Arg(14) deletion, alter regulation of SERCA. Deletion of Arg(14) disrupts the protein kinase A recognition motif, which abrogates phospholamban phosphorylation and results in constitutive SERCA inhibition. Mutation of Arg(9) causes more complex changes in function, where hydrophobic substitutions such as cysteine and leucine eliminate both SERCA inhibition and phospholamban phosphorylation, whereas an aromatic substitution such as histidine selectively disrupts phosphorylation. We demonstrate that the role of Arg(9) in phospholamban function is multifaceted: it is important for inhibition of SERCA, it increases the efficiency of phosphorylation, and it is critical for protein kinase A recognition in the context of the phospholamban pentamer. Given the synergistic consequences on contractility, it is not surprising that the mutants cause lethal, hereditary dilated cardiomyopathy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22707725", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 155, 
          "offsetInEndSection": 443, 
          "text": "Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 568, 
          "offsetInEndSection": 682, 
          "text": "To assess the function of this mutant PLN, we introduced the PLN-R14Del in cardiac myocytes of the PLN null mouse.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1801, 
          "offsetInEndSection": 1945, 
          "text": "Thus, human PLN-R14Del is misrouted to the sarcolemma, in the absence of endogenous PLN, and alters NKA activity, leading to cardiac remodeling.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 157, 
          "offsetInEndSection": 337, 
          "text": "Mutations in the gene encoding PLN have been associated with idiopathic dilated cardiomyopathy; however, no systematic search for PLN mutations in heart failure has been conducted.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 767, 
          "offsetInEndSection": 892, 
          "text": "Two patients presented a G-T missense mutation at the G26 nucleotide, which encodes an Arg-Leu substitution at codon 9 (R9L).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 893, 
          "offsetInEndSection": 1158, 
          "text": "One patient presented a G-A missense mutation at the same nucleotide, which encodes an Arg-His substitution at codon 9 (R9H). The fourth affected patient presented a T-G nonsense mutation at the nucleotide 116, substituting a termination codon for Leu-39 (L39stop).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22137083", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 546, 
          "offsetInEndSection": 867, 
          "text": "The genetic analysis was focused on R9C mutation with the ability to block PLN phosphorylation leading to chronic inhibition of SERCA2a activity. Another analysed mutation causing the alteration of PLN level in cells was related to the substitution of a leucine residue at position 39 with a premature stop codon (L39X). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332051", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 172, 
          "offsetInEndSection": 295, 
          "text": "A missense mutation in PLN cytoplasmic domain (R9C) triggers dilated cardiomyopathy in humans, leading to premature death. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 595, 
          "offsetInEndSection": 746, 
          "text": "These effects are enhanced under oxidizing conditions, suggesting that oxidative stress may exacerbate the cardiotoxic effects of the PLN(R9C) mutant. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282613", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 640, 
          "offsetInEndSection": 950, 
          "text": "We identified 1 family with a deletion of arginine 14 in the PLN. Interestingly, unlike other individuals reported with the identical PLN mutation, these individuals were not diagnosed with dilated cardiomyopathy until their seventh decade when they were only mildly symptomatic with congestive heart failure. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 90, 
          "text": "Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17010801", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 223, 
          "offsetInEndSection": 689, 
          "text": "Through genetic screening of dilated cardiomyopathy patients, we identified a previously uncharacterized deletion of arginine 14 (PLN-R14Del) in the coding region of the phospholamban (PLN) gene in a large family with hereditary heart failure. No homozygous individuals were identified. By middle age, heterozygous individuals developed left ventricular dilation, contractile dysfunction, and episodic ventricular arrhythmias, with overt heart failure in some cases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 847, 
          "text": "Transgenic mice overexpressing the mutant PLN-R14Del recapitulated human cardiomyopathy exhibiting similar histopathologic abnormalities and premature death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 111, 
          "text": "A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16432188", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 370, 
          "offsetInEndSection": 769, 
          "text": "Here, a T116G point mutation, substituting a termination codon for Leu-39 (L39stop), was identified in two families with hereditary heart failure. The heterozygous individuals exhibited hypertrophy without diminished contractile performance. Strikingly, both individuals homozygous for L39stop developed dilated cardiomyopathy and heart failure, requiring cardiac transplantation at ages 16 and 27. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12639993", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 188, 
          "offsetInEndSection": 878, 
          "text": "Here we report that an inherited human dilated cardiomyopathy with refractory congestive heart failure is caused by a dominant Arg --> Cys missense mutation at residue 9 (R9C) in phospholamban (PLN), a transmembrane phosphoprotein that inhibits the cardiac sarcoplasmic reticular Ca2+-adenosine triphosphatase (SERCA2a) pump. Transgenic PLN(R9C) mice recapitulated human heart failure with premature death. Cellular and biochemical studies revealed that, unlike wild-type PLN, PLN(R9C) did not directly inhibit SERCA2a. Rather, PLN(R9C) trapped protein kinase A (PKA), which blocked PKA-mediated phosphorylation of wild-type PLN and in turn delayed decay of calcium transients in myocytes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610310", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What kind of enzyme is encoded by the proto-oncogene ABL1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23842646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21435002", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20841568", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19794087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19290927", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18796434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18528425", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12796783"
      ], 
      "type": "factoid", 
      "id": "55241f9e2c8b63434a000004", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 336, 
          "text": "The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces diverse extracellular signals to protein networks that control proliferation, survival, migration and invasion. ABL1 was first identified as an oncogene required for the development of leukaemias initiated by retroviruses or chromosome translocations. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23842646", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 613, 
          "text": "Chromosomal rearrangements involving the ABL1 gene, leading to a BCR-ABL1 fusion gene, have been mainly associated with chronic myeloid leukemia and B-cell acute lymphoblastic leukemia (ALL). At present, six other genes have been shown to fuse to ABL1. The kinase domain of ABL1 is retained in all chimeric proteins that are also composed of the N-terminal part of the partner protein that often includes a coiled-coil or a helix-loop-helix domain. These latter domains allow oligomerization of the protein that is required for tyrosine kinase activation, cytoskeletal localization, and neoplastic transformation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435002", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 543, 
          "text": "ABL-family proteins comprise one of the best conserved branches of the tyrosine kinases. Each ABL protein contains an SH3-SH2-TK (Src homology 3-Src homology 2-tyrosine kinase) domain cassette, which confers autoregulated kinase activity and is common among nonreceptor tyrosine kinases. This cassette is coupled to an actin-binding and -bundling domain, which makes ABL proteins capable of connecting phosphoregulation with actin-filament reorganization. Two vertebrate paralogs, ABL1 and ABL2, have evolved to perform specialized functions. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20841568", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 857, 
          "text": "Protein tyrosine kinases form a large family of signaling proteins implicated in both normal and malignant cell signaling. The aim of this study was to identify protein tyro-sine kinases that can transform hematopoietic cells to growth factor independent proliferation when constitutively activated by homodimerization. We used a modified retroviral insertion mutagenesis screen with a retroviral vector containing the homodimerization domain of ETV6 followed by an artificial splice donor site. Integration of this retroviral vector within a gene of the host genome would generate a fusion transcript containing the dimerization domain and part of the disrupted gene. Using this strategy with the IL3 dependent Ba/F3 cell line, we identified 8 different protein tyrosine kinases (Abl1, Fgfr1, Hck, Jak2, Lck, Mertk, Mst1r, Tnk1) that transformed the cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19794087", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 341, 
          "offsetInEndSection": 952, 
          "text": "Three families of tyrosine kinases have long been recognized to play critical roles in TCR-dependent signaling. They are the Src, zeta-associated protein of 70 kDa, and Tec families of kinases. More recently, the Abelson (Abl) tyrosine kinases have been shown to be activated by TCR engagement and to be required for maximal TCR signaling. Using T-cell conditional knockout mice deficient for Abl family kinases, Abl (Abl1) and Abl-related gene (Arg) (Abl2), it was recently shown that loss of Abl kinases results in defective T-cell development and a partial block in the transition to the CD4(+)CD8(+) stage. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19290927", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 332, 
          "text": "ABL family tyrosine kinases are tightly regulated by autoinhibition and phosphorylation mechanisms. These kinases maintain an inactive conformation through intramolecular interactions involving SH3 and SH2 domains. RIN1, a downstream effector of RAS, binds to the ABL SH3 and SH2 domains and stimulates ABL tyrosine kinase activity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18796434", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 333, 
          "offsetInEndSection": 471, 
          "text": "RIN1 binding to the ABL2 kinase resulted in a large decrease in Km and a small increase in Vmax toward an ABL consensus substrate peptide.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18796434", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 859, 
          "offsetInEndSection": 1036, 
          "text": "RIN1 increased the kinase activity of both ABL1 and ABL2, and this occurred in the presence or absence of ABL regulatory domains outside the SH3-SH2-tyrosine kinase domain core.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18796434", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 383, 
          "text": "Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18528425", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 334, 
          "offsetInEndSection": 639, 
          "text": "Abl1 (previously known as Abl) and the Abl1-related gene product Abl2 (previously known as Arg) define a family of tyrosine kinases that regulate actin structure and presynaptic axon guidance. Here we show that the Abl kinases are critical mediators of postsynaptic assembly downstream of agrin and MuSK. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12796783", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is the enzymatic activity of the breast cancer associated gene BRCA1?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24278741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20681793", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19088202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17420471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16710298", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16479151", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15254397"
      ], 
      "type": "factoid", 
      "id": "552421082c8b63434a000005", 
      "snippets": [
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 478, 
          "text": "E3-ubiquitin ligase activity is the only known enzymatic activity of BRCA1, which is mediated by the N-terminal RING finger domain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20681793", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 647, 
          "offsetInEndSection": 852, 
          "text": "BRCA1 nuclear transport and ubiquitin E3 ligase enzymatic activity are tightly regulated by the BRCA1 dimeric binding partner BARD1 and further modulated by cancer mutations and diverse signaling pathways.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278741", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088202", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 291, 
          "offsetInEndSection": 609, 
          "text": "The protein encoded by BRCA1 interacts in vivo with the related BARD1 protein to form a heterodimeric complex that acts as a ubiquitin E3 ligase. Because the enzymatic activity of the BRCA1/BARD1 heterodimer is conserved over a broad phylogenetic range, it is thought to be critical for the central functions of BRCA1.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19088202", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 86, 
          "text": "A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420471", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 508, 
          "offsetInEndSection": 772, 
          "text": "In this study, we identified an ubiquitin-dependent mechanism by which BRCA1 inhibits transcription. BRCA1 ubiquitinates the transcriptional preinitiation complex, preventing stable association of TFIIE and TFIIH, and thus blocks the initiation of mRNA synthesis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 726, 
          "offsetInEndSection": 937, 
          "text": "In the structure the arrangement of the Ring-domains is similar to another H2A E3 ligase, the BRCA1/BARD1 complex, but complex formation depends on an N-terminal arm of Ring1b that embraces the Bmi1 Ring-domain.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16710298", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 429, 
          "text": "Discovering the precise function of the breast and ovarian specific tumor suppressor, BRCA1, has proven to be quite complicated. It has been determined that BRCA1, together with BARD1, comprise an E3 ubiquitin ligase. Since it is now known that BRCA1 is an enzyme, the challenge for BRCA1 research is to learn how this enzymatic activity functions in normal breast and ovarian cells in order to suppress cancerous transformation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16479151", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 306, 
          "text": "The BRCA1 tumor suppressor gene is expressed in all mammalian cells. Within these cells, the BRCA1 protein product interacts with several seemingly distinct nuclear complexes. Proteins within these complexes are potential targets for the E3-ubiquitin ligase activity associated with BRCA1:BARD1 complexes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15254397", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 443, 
          "offsetInEndSection": 765, 
          "text": "During both DNA replication and DNA repair, BRCA1 appears to serve both adaptor and enzymatic functions. Roles include transient physical recruitment of NBS1, gammaH2AX, FANCD2 and other proteins in specific repair associated complexes, and enzymatic activity as an E3-ubiquitin ligase against a subset of these proteins. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15254397", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which genes/proteins have been found to inhibit cyclin dependent kinase 4 (CDK4)?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19147556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17881001", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11790141", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10454538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9827724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9194486", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7652577", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7630635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7630199", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7936665"
      ], 
      "type": "list", 
      "id": "552435602c8b63434a000009", 
      "snippets": [
        {
          "offsetInBeginSection": 1068, 
          "offsetInEndSection": 1289, 
          "text": "Interestingly, the Cdk inhibitor p18(Ink4c) was induced in the transgenic pineal glands independently of p53, and transgenic mice that lacked Ink4c developed invasive PNET, although at an older age than those lacking p53.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1446, 
          "offsetInEndSection": 1713, 
          "text": "Our finding that the Cdk4 inhibitor p18(Ink4c) is a tumor suppressor in cyclin D1-driven PNET suggests that pharmacologic interventions to inhibit Cdk4 activity may be a useful chemoprevention or therapeutic strategy in cancer driven by primary RB pathway disruption.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19147556", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 501, 
          "offsetInEndSection": 704, 
          "text": "Our previous studies showed that while both specific CDK4 inhibitor p16INK4A (P16) and gankyrin bind to cyclin-dependent kinase 4 (CDK4) in similar fashion, only P16 inhibits the kinase activity of CDK4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17881001", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 176, 
          "offsetInEndSection": 316, 
          "text": "Recent biological studies of Cyclin D1/Cdk4 have proposed that p21 C-terminal domain (p21(CT)) plays a key role as a potent Cdk4 inhibitor. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790141", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 892, 
          "offsetInEndSection": 1107, 
          "text": "Especially, our data suggests that the D(149)FYHSKRR(156) region of p21 is critical for Cdk4 binding, indicating that the major driving force for complex originates from hydrophobic interaction between p21 and Cdk4.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790141", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 466, 
          "offsetInEndSection": 592, 
          "text": "We show that c-Myc prevents induction of the cdk4 inhibitor p15(Ink4b) and the subsequent inhibition of G(1) cdks by TGF-beta.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10454538", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 152, 
          "offsetInEndSection": 430, 
          "text": "CDK activity is modulated by inhibitors such as p15INK4b and p16INK4a. Loss of function of p15INK4b and p16INK4a (multiple tumor suppressor-I and CDK4 inhibitor) determines impairment in the control of the cell cycle and contributes to the transformation of several cell types. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9827724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 151, 
          "text": "D-type cyclins, in association with the cyclin-dependent kinases CDK4 and CDK6, promote progression through the G1 phase of the cell cycle.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9827724", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 250, 
          "text": "In the present study, we analyzed human ovarian carcinoma cell lines for abnormalities in the tumor suppressor gene Rb (retinoblastoma) and in cyclin-dependent kinase 4 (CDK4) inhibitor genes (p16INK4 and p15INK4B) using molecular biology techniques.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9194486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1607, 
          "offsetInEndSection": 1744, 
          "text": "These data suggest that abnormalities of Rb and CDK4 inhibitor genes (p16INK4, p15INK4B) may be involved in human ovarian carcinogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9194486", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 319, 
          "offsetInEndSection": 513, 
          "text": "The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16INK4a, but not of p21 or of p27KIP1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7652577", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 143, 
          "text": "The p15 and p16 CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in malignant mesothelioma and other cancers.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7630635", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 257, 
          "text": "The cyclin-dependent kinase 4 (cdk4) inhibitor (p16INK4/MTS1/CDKN2) gene has been recently identified as a putative tumor suppressor gene because of the high frequency of homozygous deletion observed in numerous human tumor cell lines, including leukemias. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7630199", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 193, 
          "offsetInEndSection": 369, 
          "text": "The identification of a cdk4 inhibitor, p16INK4, as a target for mutations in cultured tumor lines and primary tumors suggested that RB activity may be affected in these cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7936665", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Are ACTA1 (alpha actin) and NEB (nebulin) genes related to nemaline myopathy?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22407809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22358459", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20012312", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19648653", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16945536", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15564032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15495263", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11257471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11166164"
      ], 
      "type": "yesno", 
      "id": "552440452c8b63434a00000b", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 262, 
          "text": "Nemaline myopathy (NM) is a group of congenital myopathies, characterized by the presence of distinct rod-like inclusions \"nemaline bodies\" in the sarcoplasm of skeletal muscle fibers. To date, ACTA1, NEB, TPM3, TPM2, TNNT1, and CFL2 have been found to cause NM.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22407809", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 356, 
          "text": "Nemaline myopathy (NM) is the most common congenital myopathy and is caused by mutations in various genes including NEB (nebulin), TPM2 (beta-tropomyosin), TPM3 (gamma-tropomyosin), and ACTA1 (skeletal alpha-actin). 20-25% of NM cases carry ACTA1 defects and these particular mutations usually induce substitutions of single residues in the actin protein. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22358459", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 487, 
          "text": "Nemaline myopathy (NM) is a genetically and clinically heterogenous muscle disorder, which is myopathologically characterized by nemaline bodies. Mutations in six genes have been reported to cause NM: Nebulin (NEB Pelin 1999), alpha-skeletal muscle actin (ACTA1 Nowak 1999), alpha-slow tropomyosin (TPM3 Laing 1995), beta-tropomyosin (TPM2 Donner 2002), slow troponin T (TNNT1 Johnston 2000) and cofilin 2 (CFL2 Agrawal 2007). The majority of cases are due to mutation in NEB and ACTA1. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20012312", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 635, 
          "text": "Nemaline myopathy is a heterogenous form of congenital myopathy characterised by a variable spectrum of clinical features, predominated in the severe form by profound muscle hypotonia and weakness accompanied by respiratory insufficiency. The clinical variability, with differing age of onset and severity of symptoms makes the diagnosis of nemaline myopathy difficult in some cases. Severe forms of nemaline myopathy may be caused by mutation of a number of different genes: skeletal muscle actin (ACTA1), nebulin (NEB) and alpha-tropomyosin (TPM3), all of which encode components of the sarcomeric thin filaments of skeletal muscle. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19648653", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 114, 
          "text": "Most nemaline myopathy patients have mutations in the nebulin (NEB) or skeletal muscle alpha-actin (ACTA1) genes. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945536", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "We report muscle MRI findings of 10 patients from 8 families with nemaline myopathy. Patients with involvement of the nebulin (NEB) gene showed a consistent pattern of selective muscle involvement corresponding to clinical severity.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15564032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 522, 
          "offsetInEndSection": 719, 
          "text": "Patients with nemaline myopathy secondary to mutations in the skeletal muscle alpha-actin (ACTA1) gene showed diffuse involvement of thigh and leg muscles with relative sparing of the gastrocnemii.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15564032", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 584, 
          "text": "Congenital myopathies are clinical and genetic heterogeneous disorders characterized by skeletal muscle weakness ranging in severity. Three major forms have been identified: actin myopathy, intranuclear rod myopathy, and nemaline myopathy. Nemaline myopathy is the most common of these myopathies and is further subdivided into seven groups according to severity, progressiveness, and age of onset. At present, five genes have been linked to congenital myopathies. These include alpha-actin (ACTA1), alpha- and beta-tropomyosin (TPM3 and TPM2), troponin T (TNNT1), and nebulin (NEB). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15495263", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 360, 
          "text": "Nemaline myopathy is a structural congenital myopathy which may show both autosomal dominant and autosomal recessive inheritance patterns. Mutations in three different genes have been identified as the cause of nemaline myopathy: the gene for slow alpha-tropomyosin 3 (TPM3) at 1q22-23, the nebulin gene (NEB) at 2q21.1-q22, and the actin gene (ACTA1) at 1q42.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11257471", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 426, 
          "text": "Nemaline myopathy is a clinically and genetically heterogeneous condition. The clinical spectrum ranges from severe cases with antenatal or neonatal onset and early death to late onset cases with only slow progression. Three genes are known to cause nemaline myopathy: the genes for nebulin (NEB) on chromosome 2q22, slow alpha-tropomyosin (TPM3) on chromosome 1q21 and skeletal muscle alpha-actin (ACTA1) on chromosome 1q42. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11166164", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "What is known as Von Hippel\u2013Lindau disease or syndrome?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24292403", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24138046", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23843833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23652669", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23384228", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22659535", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22461457", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22265326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21955200", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21362373", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20833332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20687511", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20231120", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18751708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18434768", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18203931"
      ], 
      "type": "summary", 
      "id": "552446612c8b63434a00000c", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 443, 
          "text": "Von Hippel-Lindau syndrome is an autosomal dominant inherited phacomatosis with a predisposition for the central nervous system and retina. There is variable expression with hemangioblastomas in the brain, medulla oblongata, spinal chord, renal carcinoma, pheochromocytoma, pancreatic cysts and islet cell tumors as well as tumors of the endolymphatic sac of the inner ear. Clinical symptoms occur first after an age of approximately 30\u00a0years.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292403", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 195, 
          "text": "Von Hippel-Lindau Disease (VHL) is an autosomal dominant inherited systemic cancer syndrome that gives rise to cystic and highly vascularized tumors in many organs, including the eye.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24138046", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 410, 
          "text": "Von Hippel-Lindau (VHL) disease is a hereditary, autosomal dominant syndrome which is manifested by a range of different benign and malignant tumors. This disease can present with different clinical presentations such as; retinal angioma (RA), hemangioblastoma (HB) of the central nervous system (CNS), pheochromocytoma (Pheo), and epididymal cystadenoma. Tumors are usually accompanied with cysts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843833", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 1115, 
          "text": "von Hippel-Lindau (VHL) disease is an autosomal-dominant familial cancer syndrome associated with mutations of the VHL tumor suppressor gene (3p25-26). Its estimated incidence ranges from 1 in 36,000 to 1 in 53,000 with a penetrance of up to 95% by age 60. Genotype-phenotype correlation divides VHL into two broad clinical subtypes. Type 1 VHL is predominantly associated with large deletion or truncation mutations which result in an encoded protein with very little or no activity. It is associated with retinal and CNS hemangioblastoma and renal cell carcinoma but not pheochromocytoma. Type 2 is usually associated with missense mutations encoding a protein with limited activity and includes pheochromocytoma. It is further classified into three other subtypes (2A, 2B, 2C) based on the presence of hemangioblastoma and renal cell carcinoma. Visceral cysts in the kidney, pancreas and epididymis, nonfunctioning pancreatic neuroendocrine tumors which often show distinctive clear cell cytology, endolymphatic sac tumors and head and neck paragangliomas are well recognized but less common presenting features.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652669", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 302, 
          "text": "von Hippel-Lindau (VHL) disease is an inheritable multisystem tumor syndrome characterized by multiple benign and malignant tumors affecting multiple organs. VHL is the result of a germline mutation in the VHL tumor suppressor gene. Molecular genomic analysis routinely confirms the clinical diagnosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23384228", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 436, 
          "text": "Von Hippel-Lindau (VHL) disease is a rare autosomal dominant syndrome (1/36,000 live births) with highly penetrance that predispose to the development of a panel of highly vascularized tumors (model of tumoral angiogenesis). Main manifestations include central nervous system (CNS) and retinal haemangioblastomas, endolymphatic sac tumors, clear-cell renal cell carcinomas (RCC), phaeochromocytomas and pancreatic neuroendocrine tumors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22659535", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 9, 
          "offsetInEndSection": 221, 
          "text": "Von Hippel-Lindau (VHL) disease is an inherited syndrome caused by germline mutations in the VHL tumor suppressor gene, predisposing to a variety of neoplasms including pancreatic neuroendocrine tumors (PanNET). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461457", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 255, 
          "text": "Von Hippel-Lindau disease is an autosomal dominant disorder involving the development of specific tumours in multiple organs, both benign and malignant. In the CNS, the syndrome is characterized by haemangioblastomas of the retina, spinal cord and brain. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22265326", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 288, 
          "text": "Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21955200", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 171, 
          "text": "Von Hippel-Lindau (VHL) syndrome is an autosomal dominant familial cancer syndrome predisposing the affected individuals to multiple tumours in various organs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21362373", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 405, 
          "text": "von Hippel-Lindau disease (VHL) disease increases susceptibility to several malignancies, including renal cell carcinoma, haemangioblastomas of the central nervous system or retina and phaeochromocytomas. The VHL tumour suppressor gene, responsible for the disease, encodes for a major regulator of the hypoxic response by targeting the transcription factor hypoxia inducible factor (HIF) for degradation.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20833332", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 358, 
          "text": "Von Hippel-Lindau syndrome (VHLS) is an autosomal dominant familial cancer syndrome arising from germ-line inactivation of the VHL gene on the short arm of chromosome 3. VHLS manifests in a myriad of hyper-vascular tumors of both benign and malignant nature. Incidence of VHLS is roughly 1 in 36,000 live births and has over 90% penetrance by the age of 65. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20687511", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 490, 
          "text": "Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene is responsible for the development of renal carcinomas, pheochromocytomas and tumours in other organs. The gene product (pVHL) is a central component in the oxygen-sensing pathway through its role in the regulation of the hypoxia-inducible factor (HIF). Loss of pVHL leads to activation of the HIF pathway in normoxia with the concomitant increase in tumour vascularisation due to the up-regulation of pro-angiogenic genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20231120", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 375, 
          "text": "Germ line inactivation of the von-Hippel-Lindau (VHL) tumor suppressor gene causes von Hippel-Lindau hereditary cancer syndrome, and somatic mutations of this gene have been linked to the development of sporadic hemangioblastomas and clear cell renal carcinomas. The protein encoded by VHL, pVHL, has no known enzymatic activities but interacts with various partner proteins.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18751708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 432, 
          "offsetInEndSection": 873, 
          "text": "pVHL acts as a multi-purpose adaptor protein that controls different gene expression programs. Through its oxygen-dependent regulation of hypoxia-inducible factor alpha (HIFalpha), pVHL plays a central role in the oxygen-sensing pathway. In addition, many HIFalpha-independent functions of pVHL have recently been identified. These include microtubule-based processes, extracellular matrix assembly and suppression of kidney cyst formation. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18751708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 225, 
          "text": "von Hippel-Lindau (VHL) disease is an inherited multisystem familial cancer syndrome caused by mutations of the VHL gene on chromosome 3p25. A wide variety of neoplastic processes are known to be associated with VHL disease. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434768", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 572, 
          "text": "von Hippel-Lindau (VHL) disease is a rare, autosomal dominantly inherited multisystem disorder characterized by development of a variety of benign and malignant tumors. The spectrum of clinical manifestations of the disease is broad and includes retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. The most common causes of death in VHL disease patients are renal cell carcinoma and neurologic complications from cerebellar hemangioblastomas. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18203931", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which are the different homologs or family members of the hedgehog proteins in mammals?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20519495", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11044404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22391297", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21167467", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18612197", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15645142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12967338"
      ], 
      "type": "list", 
      "id": "5524562387ecba3764000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 272, 
          "text": "Hedgehog (Hh) signaling proteins stimulate cell proliferation, differentiation, and tissue patterning at multiple points in animal development. A single Hh homolog is present in Drosophila, but three Hh homologs, Sonic Hh, Indian Hh, and Desert Hh, are present in mammals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519495", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1103, 
          "offsetInEndSection": 1261, 
          "text": " We report here biochemical and x-ray structural studies of Sonic, Indian, and Desert Hh proteins both alone and complexed with active domains of CDO and BOC.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20519495", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 151, 
          "offsetInEndSection": 580, 
          "text": "Previous work has shown that activin, a TGF(beta+) signaling molecule, permits pancreas development by repressing expression of Sonic hedgehog (Shh), a member of the hedgehog family of signaling molecules that antagonize pancreas development. Here we show that Indian hedgehog (Ihh), another hedgehog family member, and Patched 1 (Ptc1), a receptor and negative regulator of hedgehog activity, are expressed in pancreatic tissue.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11044404", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 299, 
          "text": "The original hedgehog (hh) gene was found in Drosophila and named for the appearance of a mutant phenotype which causes an embryo to be covered with pointy denticles, thus resembling a hedgehog. The hedgehog family consists of sonic hedgehog (Shh), desert hedgehog (Dhh), and Indian hedgehog (Ihh). ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22391297", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 213, 
          "text": "Indian hedgehog (IHH) is a secreted signaling molecule of the hedgehog family known to play important roles in the regulation of chondrocyte differentiation, cortical bone formation, and the development of joints.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21167467", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 233, 
          "text": "Hedgehog (Hh) plays a pivotal role in various tissues during embryonic development, tissue homeostasis and tumorigenesis. In mammals, Hh exists in three homologs: Desert hedgehog (Dhh), Indian hedgehog (Ihh) and Sonic hedgehog (Shh).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18612197", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 321, 
          "text": "Sonic hedgehog (SHH), Desert hedgehog (DHH) and Indian hedgehog (IHH) bind to Patched family receptors (PTCH1 and PTCH2) to transduce signals to GLI1, GLI2 and GLI3. GLI family transcription factors then activate transcription of Hedgehog target genes, such as FOXE1 and FOXM1 encoding Forkhead-box transcription factors.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15645142", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 220, 
          "text": "Indian hedgehog (IHH) and its receptors patched (PTC) and smoothened (SMO) belong to the hedgehog family of signaling molecules, which are essential for a variety of patterning events during mammalian tIssue development.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12967338", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which type of cell death is known as anoikis?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23357260", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23830918", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22505926", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21953325", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21352421", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21114588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20577896", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20153362", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20031162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19828453", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18719379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18579285", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18045538", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15302871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14702756", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14551156"
      ], 
      "type": "summary", 
      "id": "5525317687ecba3764000007", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 223, 
          "text": "As a barrier to metastasis of cancer, cells that lost contact with the neighbouring cells or extracellular matrix(Extracellular matrix, ECM) will be subjected to apoptosis. This cell death process has been termed \"anoikis\".", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 224, 
          "offsetInEndSection": 417, 
          "text": "When normal epithelial cells or solid tumor cells without metastatic potential detach from the primary site, and then enter into the circulatory system, the anoikis mechanism will be activated.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 418, 
          "offsetInEndSection": 539, 
          "text": "The significance of anoikis is to prevent the shedding cells from growing and implanting into other inappropriate sites. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 258, 
          "text": "Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonizing of distant organs. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830918", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 170, 
          "offsetInEndSection": 357, 
          "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 377, 
          "text": "Anoikis is a programmed cell death occurring upon cell detachment from the correct extracellular matrix, thus disrupting integrin ligation. It is a critical mechanism in preventing dysplastic cell growth or attachment to an inappropriate matrix. Anoikis prevents detached epithelial cells from colonizing elsewhere and is thus essential for tissue homeostasis and development. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953325", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 226, 
          "text": "Detachment from the extracellular matrix induces a form of programmed cell death termed anoikis. Resistance to anoikis permits cancer cells to survive in systemic circulation and facilitates their metastasis to distant organs.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21352421", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 154, 
          "text": "Anoikis - apoptotic cell death triggered by loss of extracellular matrix (ECM) contacts - is dysregulated in many chronic debilitating and fatal diseases.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21114588", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 287, 
          "text": "The extracellular matrix (ECM) plays a key role in cell-cell communication and signaling, and the signals it propagates are important for tissue remodeling and survival. However, signals from disease-altered ECM may lead to anoikis-apoptotic cell death triggered by loss of ECM contacts.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20577896", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 157, 
          "text": "Anoikis is a mode of apoptotic cell death, consequential to insufficient cell-matrix interactions and a critical player in tumor angiogenesis and metastasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153362", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 953, 
          "offsetInEndSection": 1258, 
          "text": "Anoikis is also a physiologic process in normal cells used to maintain homeostasis, in which cell death is induced in response to loss of extracellular membrane (ECM) attachment. Cancer cells are notoriously resistant to anoikis, enabling metastasis and new tumor growth beyond their original environment.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20031162", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 141, 
          "offsetInEndSection": 245, 
          "text": "Anoikis is a subtype of apoptosis induced by detachment of adherent cells from the extracellular matrix.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828453", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 411, 
          "text": "Developed organs display strict spatial organization of differentiated cells which is required for proper organ function. One important device that prevents tissue disorganization is the death of cells that lose anchorage to their native matrix, a signal that indicates potential loss of proper tissue context. Termed anoikis (Greek for Homelessness), this form of cell death is a specialized form of apoptosis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18719379", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 416, 
          "text": "As a barrier to metastases, cells normally undergo apoptosis after they lose contact with their extra cellular matrix or their neighbouring cells. This cell death process has been termed \"anoikis\". Tumour cells that acquire malignant potential have developed mechanisms to resist anoikis and thereby survive after detachment from their primary site and while travelling through the lymphatic and circulatory systems.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18579285", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 126, 
          "text": "Epithelial cells require attachment to extracellular matrix (ECM) to suppress an apoptotic cell death program termed anoikis. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045538", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 207, 
          "text": "Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis. Integrin stimulation protects cells from anoikis, but the responsible mechanisms are not well known.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15302871", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 203, 
          "offsetInEndSection": 536, 
          "text": "Apoptosis triggered by cell detachment from the extracellular matrix, which occurs during hepatocyte isolation, is a phenomenon termed \"anoikis\". It's importance in the normal physiologic development of the human body, as well as in disease states, has been described. Cancer cells harbor anoikis resistance allowing spread to occur.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702756", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 335, 
          "text": "Ano\u00efkis is defined as programmed cell death induced by the loss of cell/matrix interactions. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells in the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts, and cardiac myocytes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551156", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 336, 
          "offsetInEndSection": 739, 
          "text": "Adhesion is also a key factor for the differentiation of mesenchymal stem cells. In particular, fibronectin is considered a factor of survival and differentiation for many adherent cells. Adhesion generates cell tensional integrity (tensegrity) and repression of apoptotic signals, whereas detachment has the opposite effect. Ano\u00efkis plays a physiological role by regulating cell homeostasis in tissues.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551156", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Which phenomenon is described as oncogene addiction?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23637683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23532334", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22860051", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22647359", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22312254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22235994", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21974937", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21969595", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21828272", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21575270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20173739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18451131", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18451130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16869776", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16857816"
      ], 
      "type": "summary", 
      "id": "55253d7087ecba3764000008", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 216, 
          "text": "Tumor cell growth and survival can often be impaired by inactivating a single oncogen- a phenomenon that has been called as \"oncogene addiction.\" It is in such scenarios that molecular targeted therapies may succeed.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637683", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 190, 
          "text": "The clinical efficacy of tyrosine kinase inhibitors supports the dependence of distinct subsets of cancers on specific driver mutations for survival, a phenomenon called \"oncogene addiction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23532334", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 12, 
          "offsetInEndSection": 335, 
          "text": "A given tumor is usually dependent on the oncogene that is activated in the respective tumor entity. This phenomenon called oncogene addiction provides the rationale for attempts to target oncogene products in a therapeutic manner, be it by small molecules, by small interfering RNAs (siRNA) or by antigen-specific T cells.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22860051", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 290, 
          "text": "It has long been established that cancers can become addicted to particular oncogenes. Despite the genetic complexity that governs tumorigenesis, certain cancers can exhibit a critical dependency on the expression of a single oncogene, which when removed leads to death of the cancer cell. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647359", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 744, 
          "offsetInEndSection": 1279, 
          "text": "We now know that oncogenes are dysfunctional proto-oncogenes and that dysfunctional tumor suppressor genes contribute to the cancer process. Furthermore, Weinstein and others have hypothesized the phenomenon of oncogene addiction as a distinct characteristic of the malignant cell. It can be assumed that cancer cells, indeed, become dependent on such vital oncogenes. The products of these vital oncogenes, such as c-myc, may well be the Achilles heel by which targeted molecular therapy may lead to truly personalized cancer therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22312254", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 524, 
          "text": "Despite complex genomic and epigenetic abnormalities, many cancers are irrevocably dependent on an initiating oncogenic lesion whose restoration to a normal physiological activation can elicit a dramatic and sudden reversal of their neoplastic properties. This phenomenon of the reversal of tumorigenesis has been described as oncogene addiction. Oncogene addiction had been thought to occur largely through tumour cell-autonomous mechanisms such as proliferative arrest, apoptosis, differentiation and cellular senescence. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22235994", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 421, 
          "text": "Cancers can exhibit marked tumor regression after oncogene inhibition through a phenomenon called \"oncogene addiction.\" The ability to predict when a tumor will exhibit oncogene addiction would be useful in the development of targeted therapeutics. Oncogene addiction is likely the consequence of many cellular programs. However, we reasoned that many of these inputs may converge on aggregate survival and death signals.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21974937", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 229, 
          "text": "The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969595", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 470, 
          "text": "Although human cancers have complex genotypes and are genomically unstable, they often remain dependent on the continued presence of single-driver mutations-a phenomenon dubbed \"oncogene addiction.\" Such dependencies have been demonstrated in mouse models, where conditional expression systems have revealed that oncogenes able to initiate cancer are often required for tumor maintenance and progression, thus validating the pathways they control as therapeutic targets.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21828272", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 240, 
          "text": "Oncogene addiction is a phenomenon that the survival of cancer cells depends on an activated oncogene or inactivation of tumor suppressor gene, and is regarded as the 'Achilles heel' of the successful molecular targeted therapies in cancer.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21575270", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 232, 
          "text": "Inhibition of an initiating oncogene often leads to extensive tumour cell death, a phenomenon known as oncogene addiction. This has led to the search for compounds that specifically target and inhibit oncogenes as anticancer agents.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20173739", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 761, 
          "text": "Cancer is a multistep process whereby genetic events that result in the activation of proto-oncogenes or the inactivation of tumor suppressor genes usurp physiologic programs mandating relentless proliferation and growth. Experimental evidence surprisingly illustrates that the inactivation of even a single oncogene can be sufficient to induce sustained tumor regression. These observations suggest the hypothesis that tumors become irrevocably addicted to the oncogenes that initiated tumorigenesis. The proposed explanation for this phenomenon is that activated oncogenes result in a signaling state in which the sudden abatement of oncogene activity balances towards proliferative arrest and apoptosis. Indeed, substantial evidence supports this hypothesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451131", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 281, 
          "text": "Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called \"oncogene addiction,\" provides a rationale for molecular targeted therapy.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451130", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 429, 
          "text": "Does an activated oncogene that initiates tumor growth need to remain activated to maintain the cancer phenotype? This question has been answered affirmatively by experiments in which doxycycline-regulated oncogene activation induces growth of large tumors that regress completely upon oncogene inactivation--a phenomenon called oncogene addiction. We assemble here the evidence that oncogene addiction is angiogenesis-dependent.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16869776", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 738, 
          "text": "\"Oncogene addiction\" describes the curious acquired dependence of tumor cells on an activated oncogene for their survival and/or proliferation, a phenomenon that has important implications for the success of targeted cancer therapies. However, the mechanisms explaining oncogene addiction remain elusive. We propose that \"addiction\" may be an illusion generated as a consequence of differential attenuation rates of prosurvival and proapoptotic signals emanating from an oncoprotein acutely following its inactivation. According to this model, which we call \"oncogenic shock,\" prosurvival signals dissipate quickly on oncoprotein inactivation whereas proapoptotic signals linger sufficiently long to commit the cell to an apoptotic death.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16857816", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is RANKL secreted from the cells?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24267510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24265865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23835909", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23827649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23632157", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22948539", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22901753", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22867712", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21618594"
      ], 
      "type": "yesno", 
      "id": "55262a9787ecba3764000009", 
      "snippets": [
        {
          "offsetInBeginSection": 114, 
          "offsetInEndSection": 242, 
          "text": "Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-\u03baB ligand (RANKL) ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24267510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 266, 
          "text": "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily. It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL).", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24265865", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1110, 
          "offsetInEndSection": 1247, 
          "text": "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835909", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 228, 
          "text": "Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23827649", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 324, 
          "offsetInEndSection": 439, 
          "text": "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 95, 
          "text": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL.", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23698708", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 471, 
          "offsetInEndSection": 621, 
          "text": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23632157", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 486, 
          "text": "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22948539", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 690, 
          "offsetInEndSection": 1005, 
          "text": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22901753", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 468, 
          "offsetInEndSection": 758, 
          "text": " osteoclastogenesis and bone destruction in autoimmune arthritis. We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22867712", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 269, 
          "offsetInEndSection": 478, 
          "text": "Osteoprotegerin (OPG) and receptor activator of nuclear factor \u03baB ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21618594", 
          "endSection": "abstract"
        }
      ]
    }, 
    {
      "body": "Is  farnesoid X receptor (FXR) a nuclear receptor?", 
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24291500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24261510", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24211198", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24177031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24091600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24089008", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24068255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24064762", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24041925", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24037988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24004079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23982684", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23824184", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23861371", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23811326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23784309", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23772048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23720266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23688559", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23680185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23651738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23609136"
      ], 
      "type": "yesno", 
      "id": "55263a1898daae017c000001", 
      "snippets": [
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 245, 
          "text": "Farnesoid X receptor (FXR) belongs to the ligand-activated nuclear receptor superfamily, and functions as a transcription factor regulating the transcription of numerous genes involved in bile acid homeostasis, lipoprotein and glucose metabolism", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291500", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 13, 
          "offsetInEndSection": 210, 
          "text": " Farnesoid X receptor (FXR) is an ascending target for metabolic and inflammatory diseases. As a nuclear receptor, FXR exhibits many physiological effects in transcription control of several genes.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261510", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 171, 
          "offsetInEndSection": 269, 
          "text": " FXR is a member of the nuclear receptor superfamily which is also highly expressed in the liver. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24211198", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 166, 
          "text": "Farnesoid X receptor (FXR) is a bile acid nuclear receptor described through mouse knockout studies as a tumor suppressor for the development of colon adenocarcinomas", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24177031", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 123, 
          "text": "Farnesoid X receptor (FXR, Nr1h4) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24091600", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1403, 
          "offsetInEndSection": 1445, 
          "text": "the nuclear receptor farnesoid X receptor ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089008", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 704, 
          "offsetInEndSection": 784, 
          "text": " farnesoid X receptor (FXR), a nuclear receptor activated by bile acid ligands. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068255", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 270, 
          "offsetInEndSection": 339, 
          "text": "T-\u03b2-MCA is an farnesoid X receptor (FXR) nuclear receptor antagonist,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064762", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 228, 
          "offsetInEndSection": 356, 
          "text": " Farnesoid X receptor (FXR), a nuclear receptor (NR) and originally considered as a bile acid-activated transcriptional factor, ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24041925", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 124, 
          "offsetInEndSection": 234, 
          "text": " The nuclear receptor farnesoid X receptor (FXR) plays a major role in the enterohepatic cycling of bile acids", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24037988", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 130, 
          "text": "Liver X receptors, LXRs, are ligand-activated transcription factors that belong to the group H nuclear receptor (NR) superfamily. ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24004079", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 198, 
          "text": "The intracellular nuclear receptor farnesoid X receptor and the transmembrane G protein-coupled receptor TGR5 respond to bile acids by activating transcriptional networks and/or signalling cascades.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23982684", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 168, 
          "offsetInEndSection": 243, 
          "text": "ncluding those of nuclear receptors, primarily farnesoid X receptor (FXR), ", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23824184", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1333, 
          "offsetInEndSection": 1383, 
          "text": "ile acids and their cognate nuclear receptor, FXR,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23861371", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 138, 
          "text": "Farnesoid X receptor (FXR, Nr1h4) and small heterodimer partner (SHP, Nr0b2) are nuclear receptors that are critical to liver homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23811326", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 347, 
          "offsetInEndSection": 412, 
          "text": "he activation of the nuclear receptor farnesoid X receptor (FXR\u03b1)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23784309", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 259, 
          "offsetInEndSection": 322, 
          "text": "bile acid-activated nuclear receptor farnesoid X receptor (FXR)", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23772048", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 1518, 
          "offsetInEndSection": 1587, 
          "text": " nuclear receptor signaling, notably by the farnesoid X receptor (FXR", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720266", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 115, 
          "text": "FXR (farnesoid X receptor, NRIH4), a nuclear receptor, plays a major role in the control of cholesterol metabolism.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688559", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 166, 
          "offsetInEndSection": 214, 
          "text": "The role of the nuclear receptor FXR is unclear.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680185", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 18, 
          "offsetInEndSection": 39, 
          "text": "nuclear receptor FXR ", 
          "beginSection": "title", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680185", 
          "endSection": "title"
        }, 
        {
          "offsetInBeginSection": 27, 
          "offsetInEndSection": 114, 
          "text": "a member of the nuclear receptor superfamily of ligand-activated transcription factors,", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23651738", 
          "endSection": "abstract"
        }, 
        {
          "offsetInBeginSection": 0, 
          "offsetInEndSection": 120, 
          "text": "Farnesoid X receptor (FXR) is a nuclear receptor that functions as a bile acid sensor controlling bile acid homeostasis.", 
          "beginSection": "abstract", 
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23609136", 
          "endSection": "abstract"
        }
      ]
    }
  ]
}